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prediction of intestinal absorp-
tion during the drug development 
process. However, because of the 
complexity of the factors affecting 
permeation through the intestinal 
epithelia there still are gaps in our 
capabilities of translating the in vitro 
observed permeation characteristics 
to the in vivo situation. This thesis 
provides further insights into the 
dynamics of the drug disposition 
kinetics in epithelial permeation as 
well as on the confounding factors 
involved in in vitro experimental 
settings.
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ABSTRACT
Permeation through the intestinal epithelia is a major barrier for oral drug delivery,
which is the most often utilized administration route. Therefore, there is considerable
interest in developing ways to reliably predict epithelial permeation early on in the
drug discovery - development process. Consequently, several in vitro assays are
utilized to gain insight into the mechanisms involved in permeation as well as to screen
the compounds for their transport characteristics. However, the predictive value of
these in vitro methods relies to a great extent on the appropriate interpretation and
thorough understanding of the in vitro data.
In vitro permeation experiments with cultured cell monolayers have been applied
successfully for the prediction of the extent of intestinal absorption of compounds
which are primarily transported via the passive transcellular route. However, simple
extrapolation from the apparent in vitro permeability to the in vivo intestinal absorption
is less reliable when paracellular permeation or active transporters are significantly
involved in permeation through the epithelia. A key characteristic of active transport is
its saturability, especially in the intestine where the drug concentrations are high. Thus,
successful prediction of the active transport must account for the concentration
dependency. Simple membrane based assays as well as cell monolayer permeation
experiments have been applied for studies of concentration dependent transporter
function. However, the reported in vitro determined kinetic parameters describing the
transporter saturation are inconsistent. Consequently, the extrapolation to the in vivo
setting remains challenging.
The  main  focus  of  the  present  study  was  the  interplay  of  active  and  passive  drug
disposition in in vitro cellular permeation models. The effects of the experimental
conditions on the apparent permeability and active transport were examined.
Furthermore, drawbacks of the data analysis approaches traditionally applied in
permeation experiments were investigated. Additionally, the pH and the protein
concentration were shown to alter the observed P-glycoprotein ATPase activation
kinetics in a membrane based assay. These results provide further insights into the
dynamics  of  the  drug  disposition  kinetics  in  epithelial  permeation  as  well  as  on  the
confounding factors involved in in vitro experimental settings. Moreover, the
compartmental model based analysis applied for the in vitro permeation data seems to
be a promising approach for determining transporter kinetics.
National Library of Medicine Classification: QV 38, WB 350, WI 400, WI 402, QS
532.5.E7, QU 120
Medical Subject Headings: Pharmaceutical Preparations; Pharmacokinetics;
Administration, Oral; Intestinal Absorption; Epithelium; Epithelial Cells; Intestinal
Mucosa; Permeability; Biological Transport; Cells, Cultured; Cell Membrane;
Hydrogen-Ion Concentration; Proteins; P-Glycoprotein; Adenosine Triphosphatases;
Research Design; In vitro
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julkaisuja. Terveystieteiden tiedekunnan väitöskirjat, 15. 2010. 105 p.
TIIVISTELMÄ
Lääkeaineen kyky kulkeutua ruoansulatuskanavan epiteelisolukon läpi on eräs
merkittävimmistä suun kautta annosteltujen lääkeaineiden imeytymistä rajoittavista
tekijöistä. Tämän vuoksi useita in vitro menetelmiä käytetään jo lääkekehityksen
alkuvaiheessa lääkeaineiden läpäisykyvyn ennustamiseksi ja sopivien
lääkeainekandidaattien seulomiseksi. Näiden menetelmien ennustearvo kuitenkin
perustuu merkittävässä määrin saatujen tulosten oikeaan tulkintaan ja perinpohjaiseen
ymmärtämiseen.
Soluviljelmissä kasvatetuilla epiteelisoluilla tehtäviä lääkeaineiden läpäisykokeita on
onnistuneesti käytetty ennustamaan lääkeaineiden imeytymistä
ruoansulatuskanavasta, kun pääasiallinen imeytymismekanismi on passiiviseen
diffuusioon perustuva kulkeutuminen solukalvojen läpi. Toisaalta in vitro havaitun
läpäisyn kyky ennustaa kliinistä lääkeaineiden imeytymistä on osoittautunut
heikommaksi, kun lääkeaineen kulkeutuminen soluvälitilan kautta tai aktiiviset
kuljetusprosessit vaikuttavat merkittävästi lääkeaineen imeytymiseen. Eräs aktiivisen
kuljetuksen tärkeimmistä ominaisuuksista on saturoituvuus eli riippuvuus
lääkeainepitoisuudesta, joka tulisi ottaa huomioon ennustettaessa aktiivisesti
kuljetettavien lääkeaineiden imeytymistä. Aktiivisten kuljetusprosessien
pitoisuusriippuvuuden tutkimiseen on sovellettu sekä eristetyillä solukalvoilla että
elävillä soluilla suoritettavia in vitro kokeita. Kirjallisuudessa raportoiduissa
pitoisuusriippuvuutta kuvaavissa parametreissa on kuitenkin suurta vaihtelua ja
näiden in vitro tulosten hyväksikäyttäminen kliinisen lääkeaineiden imeytymisen
ennustamisessa on osoittautunut erittäin haastavaksi.
Tässä väitöskirjatyössä keskityttiin pääasiassa passiivisen kulkeutumisen ja aktiivisen
kuljetuksen yhteistoimintaan in vitro soluläpäisykokeiden aikana. Tutkimuksessa
selvitettiin koeolosuhteiden vaikutuksia havaittuun läpäisykykyyn ja aktiiviseen
kuljetukseen. Lisäksi pH:n ja proteiinipitoisuuden osoitettiin vaikuttavan havaittuun P-
glykoproteiinin ATPaasi -aktivaatiokinetiikkaan eristetyillä solukalvoilla suoritetuissa
kuljetusproteiinin aktiivisuuskokeissa. Nämä tulokset antavat lisätietoa passiivisen ja
aktiivisen kulkeutumisen dynamiikasta sekä useista häiritsevistä tekijöistä
koeasetteluissa. Lisäksi tämän väitöskirjatyön tulokset osoittavat matemaattisiin
monitilamalleihin perustuvan tulosanalyysin olevan lupaava lähestymistapa
aktiivisten kuljetusproteiinien toiminnan tutkimuksessa.
Yleinen suomalainen asiasanasto: lääkeaineet; lääkkeet; kulkeutuminen; imeytyminen;
farmakokinetiikka; ruoansulatuselimet; suolisto; solut; solukalvot; epiteeli; läpäisevyys;
pH; proteiinit
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It would be so much better if we called most of them models rather than
theories.  Then  we  would  not  have  to  defend  their  truth  but  only  their
usefulness. Most of us need models in order to think.
G. Scatchard, Discuss. Faraday Soc., 1956, 21, 27
x
xi
Acknowledgements
The present study was carried out in the Department of Pharmaceutics, University of
Kuopio during the years 2005-2009 and finalised in the School of Pharmacy, Faculty of
Health Sciences, University of Eastern Finland in 2010.
This  research  has  been  funded  by  the  Finnish  Foundation  for  Technology  and
Innovation (TEKES) and the Graduate School for Pharmaceutical Research (GSPR).
Additionally, University of Kuopio, The Finnish Pharmacists' Association and The
Finnish Pharmaceutical Society have provided financial support for my PhD studies.
I thank Professor Jukka Mönkkönen, my principle supervisor, Dean of the Faculty of
Health Sciences, for believing in me and my research during the whole course of my
PhD work. You gave me plenty of freedom to take my research in the direction I found
most  interesting,  but  still  guided my work when I  did not  know where  to  proceed or
which track to choose. I also thank Professor Arto Urtti, my second supervisor during
the very early  days  of  this  work,  whose original  ideas  contributed significantly  at  the
starting point of present study and for the general direction these studies have taken.
Unfortunately, the practical issues with schedules prevented me from taking the full
advantage of his expertise. I am also greatful to Timo Korjamo, PhD, who replaced
Professor  Urtti  as  my  second  supervisor  a  couple  of  years  ago.  You  have  given  me
many useful comments and much guidance during the days you have been officially
my supervisor. However, especially I would like to thank you for the invaluable
practical  and scientific  guidance you provided during the  early  days,  when you were
not  officially  my supervisor  and were  still  preparing your  own thesis.  However  busy
you  were  with  your  own  work,  you  had  always  time  for  my  not-always-very-
intelligent speculations. I hope also you received something back from me during those
debates. Moreover, I have to admit that a significant part of the ideas underlying my
studies probably came originally from your mind.
I am honoured to have Associate Professor Anna-Lena Ungell as my opponent and
Professor  Olavi  Pelkonen  and  Sibylle  Neuhoff,  PhD,  as  the  reviewers  of  my  thesis.
Thank you for your expert contributions.
The Master's thesis work of Varpu Lepikkö contributed significantly to paper IV. I
thank  you  for  your  input.  My  other  Master's  thesis  student,  Outi  Kolju,  is  also
acknowledged for her work. Your thesis has served as an excellent source of references
for me. I  also thank and bow to Mr Markku Taskinen, without your skilful assistance
these experiments may never have been completed and one should not overlook your
invaluable work in fine tuning the methodologies and keeping the lab running. I also
highly appreciate the way you questioned ways of doing things when needed. My little
brother Olli Heikkinen, BSc, I owe thanks for the mind broadening discussions during
the early phase of the model development for the paper II and, more importantly,
listening  to  (or  at  least  convincingly  pretending  to)  my  sometimes  never  ending
xii
babbling about almost anything. I also thank Ewen MacDonald, PhD, for his efforts to
improve the English in my text.
Additionally, I have had the privilege to collaborate with many bright scientists during
the years. Eva del Amo, MSc, thanks for bringing an international breeze into our
group and especially for the most inspiring collaboration with the P-gp review. Sanna
Siissalo, PhD, Jussi Malkki, MSc, and all the other individuals involved with the IVIVC
and IVIVRe projects are also acknowledged. Without all you people working for these
projects  my PhD studies  may never  have even started.  Kirsi  Myöhänen,  PhD,  I  thank
you for the introducing me to the interesting world of placental perfusion. I  must not
neglect the impact of Professor Per Artursson, Gunilla Englund, PhD, and Pär Matsson,
PhD. I was privileged to conduct lab work for my Master's thesis under your guidance
in Uppsala during the fall 2004. Your reassuring words during those days encouraged
me to proceed to my PhD.
Marjukka Suhonen, PhD, Jenni Hakkarainen, MSc, and Heidi Kemiläinen, MSc, I thank
you for taking me into your coffee group in the early days and all the scientific and
non-scientific discussions we had. Additionally, I am grateful to Heidi for making the
crucial decision which opened the doors for me. I also thank ‘the researchers of an
alternative reality’ Doctors Riikka Laitinen and Jari Pajander for sharing with me their
ever so positive thoughts of life, science and everything while I have been sipping my
coffee in regular Terapiatuoli sessions during the last year or so. Also all the guys in the
floorball teams I have played over the years have to be acknowledged for helping me
to  hold  on  both  my  mental  and  physical  health.  Moreover,  to The Apes, i.e. Anssi,
Kimmo,  Paavo,  Tero,  Timo,  Toni,  Vesa  and  Ville,  I  owe  a  huge  thanks  for  the  good
times spent during the past decade and especially for helping me to keep ‘fit’ by
arranging annual ‘sports’ events.
I also want to thank____________________________(add your name here iff applicable)
for being interested enough in my thesis to read it through.
Furthermore, I thank my parents Paula & Matti and my siblings, Esa, Sanna & Olli (him
again). Without you, I wouldn’t be me.
Last and foremost, I want to express my deepest gratitude to my beloved wife Henna
and  my  son  Topi  simply  for  just  being  there.  Words  are  not  enough  to  express  how
much you mean to me.
Kuopio, May 2010
Aki Heikkinen
xiii
List of original publications
This doctoral thesis is based on the following original publications:
I Heikkinen A.T., Mönkkönen J.: Protein concentration and pH affect the
apparent P-glycoprotein ATPase activation kinetics, Int J Pharm 346: 169-172,
2008.
© 2007 Elsevier B.V. All rights reserved.
II Heikkinen A.T., Mönkkönen J., Korjamo T.: Kinetics of cellular retention
during Caco-2 permeation experiments: Role of lysosomal sequestration and
impact on permeability estimates, J Pharmacol Exp Ther 328:882-892, 2009.
© 2009 the American Society for Pharmacology and Experimental
Therapeutics. All rights reserved.
III Heikkinen A.T., Mönkkönen J., Korjamo T.: Determination of permeation
resistance distribution in in vitro cell monolayer permeation experiments. Eur
J Pharm Sci 40: 132-142, 2010.
© 2010 Elsevier B.V. All rights reserved.
IV Heikkinen A.T., Korjamo T., Lepikkö V., Mönkkönen J.: Effects of
experimental setup on the apparent concentration dependency of active efflux
transport in in vitro cell permeation experiments. Mol Pharmaceutics 7: 605-
617, 2010.
© 2010 the American Chemical Society. All rights reserved.
Additionally, some parts of the literature review in this thesis are adapted with
permission from a previously published review article:
Heikkinen A.T., Korjamo T., Mönkkönen J.: Modeling the drug disposition
kinetics in in vitro intestinal absorption cell models. Basic Clin Pharmacol
Toxicol 106:180-188, 2010.
© 2009 The Authors. All rights reserved.
Journal compilation © 2009 Nordic Pharmacological Society.
All the publications were adapted with the permission of copyright owners.
xiv
Contents
1 INTRODUCTION .................................................................................................. 1
2 BACKGROUND OF THE STUDY ...................................................................... 2
2.1 Gut wall permeation ..................................................................................................... 2
2.2 Barriers and transfer routes involved in epithelial permeation ................................ 4
2.2.1 Unstirred water layer/Aqueous boundary layer .......................................................... 4
2.2.2 Passive cellular permeation ........................................................................................ 7
2.2.3 Active transport ......................................................................................................... 8
2.2.4 Gut wall metabolism .................................................................................................. 8
2.3 P-glycoprotein................................................................................................................ 9
2.3.1 Experimental in vitro methods to study the drug - P-glycoprotein interaction ...........10
2.3.2 ATPase assay ............................................................................................................12
2.3.3 Vesicular transport assay ..........................................................................................13
2.3.4 Modulation of cellular uptake assays .........................................................................14
2.4 In vitro cell permeation experiments ...........................................................................15
2.5 Mathematical models of drug disposition kinetics in cell permeation experiments
 .............................................................................................................................................16
2.5.1 Single barrier models .................................................................................................16
2.5.1.1 Unidirectional single barrier models ....................................................................18
2.5.1.2 Bidirectional single barrier models .......................................................................19
2.5.1.3 Applications of the single barrier models .............................................................20
2.5.2 Compartmental models ..............................................................................................23
2.5.2.1 Applications of compartmental models ................................................................24
2.6 Physiologically based models of in vivo intestinal absorption .................................25
3 AIMS OF THE STUDY ........................................................................................ 27
4 GENERAL EXPERIMENTAL PROCEDURES ................................................ 28
4.1 Chemicals ......................................................................................................................28
4.2 Cell culture ....................................................................................................................28
4.3 Sample analysis ............................................................................................................29
4.4 Compartmental models ...............................................................................................29
4.4.1 Model 1a: Three-compartment model .........................................................................29
4.4.2 Model 1b: Four-compartment model ..........................................................................31
4.4.3 Model 2: Five-compartment model ............................................................................31
xv
5 PROTEIN CONCENTRATION AND PH AFFECT THE APPARENT
P-GLYCOPROTEIN ATPASE ACTIVATION KINETICS .............................. 34
5.1 Introduction ..................................................................................................................35
5.2 Materials and methods ................................................................................................35
5.3 Results and discussion .................................................................................................36
5.4 Conclusions ...................................................................................................................38
6 KINETICS OF CELLULAR RETENTION DURING PERMEATION
EXPERIMENTS ........................................................................................................ 39
6.1 Introduction ..................................................................................................................40
6.2 Methods .........................................................................................................................41
6.2.1 Permeability and cellular retention experiments. .......................................................41
6.2.2 Kinetic modelling. .....................................................................................................42
6.2.2.1 Model 1a: Modeling the permeation and rapid cellular binding ...........................42
6.2.2.2 Model 1b: Modeling the lysosomal sequestration kinetics ....................................43
6.2.2.3 Simulations. ........................................................................................................43
6.2.3 Estimation of permeability coefficients. ......................................................................43
6.3 Results ...........................................................................................................................44
6.3.1 Cellular retention during permeation experiments. ...................................................44
6.3.2 Kinetic modelling of the solute transfer and cellular retention. ..................................47
6.3.3 Estimation of permeability coefficients. ......................................................................50
6.4 Discussion .....................................................................................................................52
7 DISTRIBUTION OF PERMEATION RESISTANCE IN IN VITRO CELL
PERMEATION EXPERIMENTS ........................................................................... 56
7.1 Introduction ..................................................................................................................57
7.2 Materials and methods ................................................................................................59
7.2.1 Experimental data .....................................................................................................59
7.2.2 Kinetic modeling .......................................................................................................59
7.2.3 Simulations and estimation of model parameters .......................................................60
7.3 Results ...........................................................................................................................61
7.3.1 Estimation of the cell membrane permeabilities, cellular distribution and the effects of
agitation on the ABL thickness ...........................................................................................61
7.3.2 Effects of extracellular pH and shaking rate on the free cellular and cell surface
concentrations during the cell permeation experiments ......................................................63
7.4 Discussion .....................................................................................................................65
7.5 Appendix: Approximation of the proportion of cytosol in the permeation
resistance of cell monolayer ..............................................................................................69
xvi
7.5.1 Calculation of Rcell from experimental data ................................................................70
7.5.2 Calculation of Rcyto from theoretical considerations ....................................................72
7.5.3 Calculation of Rcyto% .................................................................................................73
8 CONCENTRATION DEPENDENCY OF ACTIVE EFFLUX TRANSPORT
IN IN VITRO CELL PERMEATION EXPERIMENTS ...................................... 75
8.1 Introduction ..................................................................................................................76
8.2 Experimental section ....................................................................................................78
8.2.1 Permeation experiments and sample analysis ............................................................78
8.2.2 Selection of compounds .............................................................................................78
8.2.3 Determination of the apparent permeability and apparent P-gp function ...................79
8.2.4 Parameter estimation.................................................................................................80
8.3 Results ...........................................................................................................................81
8.3.1 Effects of passive permeability on the apparent P-gp mediated transport....................81
8.3.2 Effects of lysosomal sequestration on the apparent P-gp mediated transport ..............84
8.3.3 Effects of P-gp expression level on the apparent P-gp mediated transport ..................85
8.3.4 Compartmental modeling and determination of Km and Vmax of P-gp mediated
transport in situ .................................................................................................................86
8.4 Discussion .....................................................................................................................87
9 SUMMARY AND FUTURE PERSPECTIVES ................................................. 94
10 CONCLUSIONS ................................................................................................. 96
11 REFERENCES ...................................................................................................... 97
xvii
Abbreviations
A Area of the cell monolayer
ABC ATP binding cassette, a family of transporter proteins
ABL Aqueous boundary layer, consists of barriers formed by porous support
filter (when applicable) and the unstirred water layer (UWL)
APgp P-gp-ATPase activity
APgp,0 Baseline of the P-gp-ATPase activity
APgp,max Maximum achievable P-gp-ATPase activity with a given activator
BCRP Breast Cancer Resistance Protein, an ABC transporter encoded by ABCG2
gene
Caco-2 Human colon adenocarcinoma cell line
CABL Average concentration within ABL
Capi Concentration in the apical compartment
Cbaso Concentration in the basal compartment
Cbulk Concentration in the bulk phase
Ccell Total cellular concentration
Ccell,free Free cellular concentration
Cd0 Concentration in the donor compartment at the beginning of the
experiment
Cr Concentration in the receiver compartment
Csurf Concentration at the cell surface
<C> Average system concentration
CYP Cytochrome P450, a family of enzymes involved in drug metabolism
Daq Aqueous diffusion coefficient
DMSO Dimethylsulfoxide
EC50,K The intracellular concentration resulting the cellular distribution
coefficient (K) to be the average of maximum and minimum values
EC50,Pgp The concentration resulting in half maximum activation of P-gp-ATPase
activity
FA Fraction absorbed
iP Inorganic phosphate, released in ATP hydrolysis
IVIVE In vitro – In vivo extrapolation
K Apparent cellular distribution cefficient, ratio of total and free cellular
concentration
Km The intracellular free concentration resulting in 50% of the maximum P-
gp mediated transport rate
Km,app The initial donor concentration (Cd0) resulting in 50% of the maximum
effective P-gp mediated transport rate (Vmax,app) in permeation
experiments
Kmax Apparent maximum of K, approached asymptotically at low
concentrations
Kmin Apparent  minimum  of  K,  approached  asymptotically  at  high
concentrations
LLC-PK1 Porcine kidney cell line
M Amount
xviii
MDCK Madine Darby canine kidney cell line, strains I and II
MDCKII-MDR1 Transfected MDCK (strain II) cell line constitutively expressing human P-
glycoprotein
MRP2 Multidrug resistance-associated protein 2, an ABC transporter encoded by
the ABCC2 gene
P Permeability
PABL Permeability through an aqueous boundary layer
Papi Composite  permeability  through  the  cell  membrane  and  ABL  at  apical
side
Papp Apparent permeability
Papp,Palm Apparent permeability determined using Equation 2.4. Accounts for the
loss of sink conditions. 100% recovery assumed.
Papp,sink Apparent permeability determined using Equation 2.3. Receiver sink
conditions and 100% recovery assumed.
Papp,Tran Apparent permeability determined using Equation 2.5. Accounts for the
loss  of  sink  conditions.  Accounts  for  the  changes  in  recovery  as  a  first
order process.
Pbaso Composite permeability through the cell membrane and ABL at basal side
Pi Permeability  of  ionized  species  of  the  compound  through  a  cell
membrane
Pu Permeability of unionized species of the compound through a cell
membrane
PBPK Physiologically based pharmacokinetics
P-gp P-glycoprotein, an ABC transporter encoded by ABCB1 gene
Q12 and Q21 First order cellular distribution rate coefficients from cytosolic to
lysosomal and lysosomal to cytosolic compartment, respectively
SLC Solute carriers, a family of transporter proteins
TEER Transepithelial electrical resistance
UGT Uridine  diphosphate  glucuronosyltransferase,  a  family  of  enzymes
involved in drug metabolism
UWL Unstirred water layer
Vmax Maximum P-gp mediated transport rate
Vmax,app Apparent maximum effective P-gp mediated transport rate in permeation
experiments
1 Introduction
There is a constant need for new drugs. The inexorable development of bacterial
resistance to current antibiotics creates a never-ending need for novel antibiotics
(Walsh, 2003). In addition, treatments for several diseases, such as HIV and different
types of cancer, would greatly benefit from new, more efficacious, drugs. However, the
development of new drugs is expensive and time consuming (DiMasi et al., 2003), and
these costs are translated at least in part into the price that society has to pay for the
drug therapy. Therefore, efficacious tools to lower the costs and expedite the drug
development process are of profound importance. The costs of drug development
increase dramatically during the clinical phases of development. Therefore, although in
vitro studies are not likely to ever obviate in vivo animal and clinical studies in drug
development, the ability to produce reliable predictions of the in vivo behavior of drugs
as early as possible during the drug discovery - development process would save time
and resources needed to bring new drug molecules to the market.
The oral route is a convenient and the most often applied route for drug
administration. However, the oral bioavailability of drugs may be limited by several
factors, including inadequate solubility, slow dissolution and inappropriate stability of
the  drug  within  the  intestine,  poor  ability  to  penetrate  the  gut  wall  and  extensive
metabolism within the gut wall and/or in the liver before reaching the systemic
circulation (Dressman et al., 1998). Thus, one important prerequisite for an orally
administered drug to reach the target site within the body is the ability to be
transported  in  an  intact  form  across  the  gut  wall  from  the  intestinal  lumen  to  the
mesenteric circulation. In addition, in order to reach the target site within the body, the
drug often has to penetrate also other barrier tissues, such as the blood brain barrier
when the drug target lies in the central nervous system. Therefore, the disposition
characteristics of a molecule through the epithelial and endothelial barriers define to a
great extent the suitability of the molecule as a drug.
Various in vitro approaches  have  been  used  to  screen  and  predict  the  disposition  of
drugs  through  the  epithelial  and  endothelial  barriers  of  the  body  as  well  as  to  gain
insights  into  the  mechanisms  involved.  In  this  thesis,  the  passive  and  active  drug
disposition in in vitro models of drug absorption and disposition were explored with
the emphasis on understanding the underlying mechanistic interplay. The discussion
stems mainly from the viewpoint of intestinal absorption and permeation through the
gut wall. However, majority of the results may also have implications to the drug
disposition in other epithelial and endothelial barriers of the body.
22 Background of the study
2.1 GUT WALL PERMEATION
The gut wall permeation from intestinal lumen into circulation involves passage
through series of barriers. The unstirred water and mucous layers on top of the
epithelial cells may serve as rate limiting permeation barriers if the permeability
through the epithelial cells is very high (Loftsson and Brewster, 2008). Furthermore, the
rate of blood flow flushing the intestinal epithelia may serve as a rate limiting step for
high permeability compounds (Cong et al., 2000). However, generally the above
mentioned  barriers  are  considered  to  play  only  a  minor  role in vivo,  and  for  the
majority of compounds the epithelial cells lining the gut wall are considered to be the
primary barrier for gut wall permeation (Lennernäs, 2007).
The epithelial cells along the intestine, as well as along the crypt-villus axis, differ in
several characteristics relevant for drug permeation (Figure 2.1), such as paracellular
space (Fihn et al., 2000; Hollander, 1992) and expression levels of several transporters
and drug metabolizing enzymes (Berggren et al., 2007; Englund et al., 2006).
Furthermore, the site of absorption within the intestine and the epithelia involved may
differ between drugs. Rapidly absorbed molecules are likely to use only the proximal
part of the intestine whereas slowly absorbed molecules (whether the slow absorption
is attributable to slow dissolution, slow release from the formulation or low
permeability) are likely to be absorbed also from the distal parts of the intestine. In
addition, only the villi tips are considered to contribute to the effective area for
absorption of high permeability compounds whereas low permeability compounds are
believed  to  diffuse  further  down  along  the  crypt-villus  axis  and  exploit  larger
absorptive surface area (Artursson et al., 2001; Strocchi and Levitt, 1993). However, this
suggestion stems mainly from experimental results on anesthetized animals and, in
contrast, a very recent analysis of literature data has casted some doubt on the validity
of this hypothesis in awake human beings by suggesting that the whole surface area of
epithelia would be available also for high permeability compounds (Avdeef and Tam,
2010). Due to the complexity of the mechanisms involved in the drug permeation
through the  gut  wall,  a  single in vitro model can never fully appreciate all the factors
involved. Therefore, rigorous prediction of intestinal absorption requires a thorough
understanding of the underlying mechanisms both in vivo and in vitro (Ungell, 2004).
3Figure 2.1. The spatial variation of factors affecting the gut wall permeation. The general trends
of expression levels of selected transporters and metabolic enzymes are shown. The enterocytes
migrate from the crypt area to the villi tips during maturation. Thus, the expression levels vary
also along the crypt-villus axis. The paracellular space is tighter at the villi tips compared to
crypt region and tighter in colon than in small intestine, whereas the data available suggests
only minor differences in paracellular space between different segments of the small intestine
(Markov et al., 2010). Only villi tips are considered to be available for absorption of high
permeability compounds, whereas low permeability compounds have time to diffuse further
down between the villi  and exploit  the larger surface area for absorption. The microclimate pH
near the epithelial surface has been reported to vary between different segments of the intestine.
Furthermore, microclimate pH varies also along the crypt-villus axis, the profile shown
represents experimental data from rat jejunum (Daniel et al., 1985). Compiled from (Avdeef,
2003; Berggren et al., 2007; Chan et al., 2004; Dahan et al., 2009; Daniel et al., 1985;
Englund et al., 2006; Fihn et al., 2000; Hollander, 1992; Matsson, 2007; Mouly and Paine,
2003; Neuhoff, 2005; Paine et al., 1997)
42.2 BARRIERS AND TRANSFER ROUTES INVOLVED IN EPITHELIAL
PERMEATION
Barriers and transfer routes involved in epithelial permeation both in vitro and in vivo
are summarized in Figure 2.2.
Figure 2.2. Schematic representation of the barriers and transfer routes in in vivo intestinal
epithelia (A,C) and in in vitro cell monolayer permeation experiments (B,C). (A) In addition to
the epithelial cell layer, the permeation barrier consists of the unstirred water and mucus layer
at the luminal side in vivo. Additionally, the rate of blood flow flushing the basal side of the
enterocytes may serve as the rate limiting step of the in vivo absorption of high permeability
compounds. (B) The cell monolayer, the unstirred water layer on  both sides as well as the
porous filter support at the basal side form the permeation barrier in in vitro permeation
experiments. (C) The transfer through epithelial cell layer may involve: (1) paracellular
diffusion; (2) lateral diffusion via cell membrane; (3) transcellular diffusion through the cell
membranes and the cytosol; (4,6) active efflux and (5,7) uptake through apical and basal cell
membranes, respectively; (8) specific and unspecific binding/sequestration to the cellular
structures and (9) intracellular metabolism.
2.2.1 Unstirred water layer/Aqueous boundary layer
Even when the bulk solution of a vessel is well stirred, there usually is a stagnant layer
adjacent to the membrane surface. Consequently, when a drug permeates through the
membrane, a concentration gradient can be formed to the vicinity of the surface (Barry
and Diamond, 1984). This additional diffusion barrier is known as the unstirred water
layer (UWL). UWL is not a clearly defined boundary; the concentration changes
5gradually from the surface value to the bulk value (Pohl et al., 1998). However, for
operational purposes the situation is often modeled as a completely unstirred region
adjacent to the membrane followed by the bulk phase with a uniform concentration
(Figure 2.3). The operational UWL thickness is defined by
Equation 2.1
dC/dx is the concentration gradient adjacent to the membrane surface and is modeled
as constant throughout the operational UWL thickness h. Cbulk and  Csurf refer  to  the
concentrations in the bulk phase and at the surface of the membrane, respectively.
The UWL thickness in the human intestine has been estimated to be approximately 100
µm under physiological conditions and is attributed mainly to the mucous layer
covering the epithelia (Lennernäs, 2007). However, this estimate does not take into
account the folded structure of intestinal epithelia and it has been suggested that if one
considers the folded structure, the thickness of UWL would be approximately 300 µm
(Sugano, 2009a).
Figure 2.3. Schematic representation of the concept of unstirred layers as a permeation barrier.
Solid curve represents a hypothetical concentration profile during steady state permeation; Cbulk
and Csurf refer to the concentrations in the bulk phases and at the surfaces of the membrane (gray
box), respectively. Dashed curve is the operational concentration profile and h1 and  h2 are  the
operational  thicknesses  of  the  unstirred  layer  on  both  sides  of  the  membrane.  Compiled  from
(Barry and Diamond, 1984; Korjamo et al., 2009; Pohl et al., 1998).
The role of UWL as an intestinal absorption barrier in vivo is somewhat controversial in
the recent literature. The estimated human in vivo jejunal effective permeability of two
high-permeability compounds, D-glucose and antipyrine was not significantly affected
by a fourfold change in single-pass perfusion rates (Fagerholm and Lennernäs, 1995).
Consequently, it was concluded that UWL is not a significant absorption barrier in vivo
h
C-C
dx
dC surfbulk?
6but, rather, the permeation rate of both high and low permeability compounds is
controlled by the epithelial cell layer (Fagerholm and Lennernäs, 1995; Lennernäs,
2007). On the other hand, simulation studies aiming for explaining the observed
enhancement of solubility limited intestinal absorption by bile micelle solubilisation,
dose strength increase and particle size reduction have pointed to a clinically
significant role of UWL as an absorption barrier for high permeability compounds in
vivo (Sugano, 2009a; Sugano, 2010). Furthermore, the role of UWL as an in vivo
absorption barrier has also been supported by kinetic modeling of the absorption of a
P-glycoprotein substrate digoxin in the rat intestinal perfusion studies (Liu et al., 2006).
This discrepancy could be explained by the superimposition of UWL and the intestinal
mucuous layer. If the mucous layer would be sufficiently robust not to be significantly
distracted by the flow of the perfusion media in intestinal perfusion experiments, the
above mentioned observation by Fagerholm and Lennernäs would lead only to the
conclusion that the putative unstirred layer above the mucous layer is not playing any
role in the permeation barrier, but would not reveal anything about the role of the
UWL caused by the undisturbed mucous layer. However, there is no experimental data
available about the behavior of mucous layer in these kinds of experiments.
Nonetheless, it is generally accepted that the contribution of UWL is significant in vitro
(Adson et al., 1995; Avdeef et al., 2005; Korjamo et al., 2009; Yu and Sinko, 1997) and
should thus not be neglected. UWL complicates the experimental determination of
actual permeability through the biological permeation barrier of interest, especially of
high permeability compounds, and thus makes the comparison of permeation data
from different laboratories difficult.  Moreover, UWL may hinder the determination of
mechanisms involved in the permeation of the biological barrier as well as the
elucidation of structure permeability relationships during drug discovery
(Balakrishnan et al., 2007; Korjamo et al., 2009; Youdim et al., 2003).
In the current literature, the aqueous boundary layer (ABL) is sometimes used as a
synonym  for  UWL.  However,  in in vitro cell monolayer permeation setting, also the
support filter on which in vitro cell monolayers are cultured forms a permeation
barrier. The disposition of a molecule through the support filter is attributed to the
aqueous diffusion within the pores of the filter. Thus, the filter can be considered as an
aqueous boundary for permeation, similarly to UWL. Consequently, in this thesis,  the
terminology of Balakrishnan and coworkers (2007) is adapted: the ABL consists of the
UWL and also the porous support filter when applicable (i.e. at the basal side when cell
monolayers are grown on support filters).
72.2.2 Passive cellular permeation
The epithelial permeation of rapidly absorbed compounds is considered to primarily
occur passively via the transcellular route, whereas also other permeation routes and
mechanisms may play an important role in the permeation of slowly absorbed
compounds (Artursson et al., 2001). Passive transcellular permeation involves
penetration across the apical cell membrane followed by diffusion through the cell
cytosol and, finally, permeation across the basal cell membrane. Furthermore, very
lipophilic compounds distribute exceedingly into the cell membranes and, thus, the
involvement of diffusion via lateral cell membrane has also been hypothesized (Raub et
al., 1993). Although several processes are involved, the permeation through the apical
cell membrane is generally considered to be the rate limiting step of passive
transcellular permeation in vivo (Lennernäs, 2007).
The majority of drug molecules are weak acids or bases. Thus, under physiological
conditions, the drug molecules often exist in both ionized and neutral forms. Ionized
and neutral forms have their own distinct characteristics in terms of distribution
between lipid and aqueous phases and behavior in electrochemical gradients.
Consequently, the neutral form is generally considered to be able to passively permeate
through lipid membranes, whereas the passive permeability of ionized form is
considered insignificant or even non-existent; a concept commonly known as the pH
partition hypothesis (Shore et al., 1957). Therefore, the pH conditions at the surface of
the intestinal epithelium may play a significant role in the permeation of the drugs
through the gut wall. There is a considerable variation in the pH conditions within the
intestine and consequently, the proportion of ionized and neutral forms may vary
markedly between different locations. However, it is generally considered that the
slightly acidic microclimate pH (Figure 2.1) at the surface of the intestinal epithelia is
not directly regulated by the luminal pH (Avdeef, 2003; Legen and Kristl, 2003; Shiau et
al., 1985).
In addition to the transcellular route, drugs may permeate the intestinal epithelia by
diffusing via the paracellular space. However, the paracellular space is restricted by the
tight junctions between the cells. Consequently, paracellular permeation is limited by
the paracellular pore size, porosity and the paracellular path length (Avdeef, 2010). The
paracellular permeation route is accessible for both ionized and neutral compounds.
However, because of the negative charge of the cell surface, it has been suggested that
paracellular permeability of neutral compounds would be lower than that of cations
and higher than that of anions of same size (Adson et al., 1995; Karlsson et al., 1999;
Linnankoski et al., 2009; Pade and Stavchansky, 1997). The paracellular pores have
been estimated to have a radius of ?10 Å and comprise only a fraction of about 10-5 of
8the surface area of the epithelium of human small intestine (Linnankoski et al., 2009).
On the other hand, the characteristics of paracellular route in vitro may vary
significantly between cell lines and laboratories (Avdeef, 2010). Nonetheless, this
permeation route is considered to play a significant role in the epithelial permeation
only for relatively small hydrophilic compounds with poor cell membrane
permeability (Artursson et al., 2001).
2.2.3 Active transport
Although the passive transfer through the cell membranes is a major determinant of
the epithelial permeability, the involvement of active transporters in drug transport
through the cell membranes has been recognized during recent decades (Al-Awqati,
1999). The solute carriers (SLC) and ATP binding cassette (ABC) transporters are the
two major gene families among the cell membrane transporters involved in drug
transport (Giacomini et al., 2010). The eukaryote ABC transporters are solely efflux
transporters  that  utilize  the  energy  of  ATP  to  transport  the  drugs  out  of  the  cells
independent of the direction of the substrate concentration gradient (Chang, 2003). On
the contrary, the SLC family includes transporters which facilitate the transport of the
substrates along the concentration gradient as well as secondary active transporters
which exploit ion gradients for concentrative transport (Steffansen et al., 2004). Thus,
depending on the location and transport direction of the transporter involved,
transporters may regulate the intestinal absorption by either enhancing or inhibiting
the gut wall permeation. However, SLC transporters are generally considered to
facilitate intestinal absorption (Steffansen et al., 2004) whereas the majority of drug
transporting ABC transporters, such as P-glycoprotien (P-gp), breast cancer resistance
protein (BCRP) and multidrug resistance associated protein 2 (MRP2) impair intestinal
absorption (Chan et al., 2004). The passive diffusion rate is linear with respect to drug
concentration gradient, whereas the active transport is saturable. Consequently, the
involvement of active transporter may result in nonlinearity in the intestinal absorption
kinetics. At low doses, the transporter significantly contributes to (either increases or
decreases) the absorption, whereas at high doses the absorption is primarily dictated
by passive permeation. Furthermore, the inhibition or induction of drug transporters
may result in drug-drug and food-drug interactions (Balayssac et al., 2005; Steffansen et
al., 2004; Zhang et al., 2009).
2.2.4 Gut wall metabolism
In addition to the barriers for drug transfer, the permeation of a drug from the
intestinal lumen into the mesenteric circulation may be restricted by metabolism within
the enterocytes, mediated primarily by cytochrome P450 (CYP) and uridine
diphosphate (UDP) glucuronosyl transferase (UGT) enzymes. Although the liver is the
9primary site of drug metabolism, metabolism in the enterocytes has been shown to
significantly contribute to the first pass metabolism of some drugs, such as the short-
acting benzodiazepine midazolam (Paine et al., 1996; Thummel et al., 1996). Moreover,
there is a significant overlap in the substrate specificities of the transporters and
metabolic enzymes resulting in a complex interplay of active transport and metabolism
during the permeation through the gut wall (Pang, 2003; Siissalo et al., 2010). Probably
the best recognized of these is the interplay of P-gp with CYP3A4 (Knight et al., 2006).
Figure 2.4. Schematic of the putative structure and translocation cycle of P-gp. The two
transmembrane domains form together a funnel shaped binding pocket through the cell
membrane. The transported substrate (D) reaches the ON-binding site located within the cell
membrane presumably via the inner leaflet of the membrane. P-gp utilizes the energy from ATP
hydrolysis to translocate the substrate to the low affinity OFF-site from where the substrate is
released into the extracellular space. Compiled from (Ambudkar et al., 2006; Omote and Al-
Shawi, 2006).
2.3 P-GLYCOPROTEIN
P-glycoprotein (P-gp), an efflux transporter, is a transmembrane protein containing
two  consecutive  units  which  are  composed  of  one  ATP  binding  domain  and  a
transmembrane domain containing six transmembrane helices. In the current literature,
the  name  P-glycoprotein  is  generally  used  for  this  protein  and  the  encoding  gene  is
referred to as MDR1 (multidrug resistance), or as ABCB1 as proposed by The Human
Gene  Nomenclature  Committee.  The  two  transmembrane  domains  form  together  a
binding pocket for transported substrates within the cell membrane (Figure 2.4).
Putatively, the transported substrates bind to the ON-site of the binding pocket located
within the inner lipid leaflet of the cell membrane. Subsequently, the ATP binding sites
bind and hydrolyze ATP, releasing inorganic phosphate (iP) and ADP, which provides
the energy for translocation of the transported substrate from the ON-site of the
binding pocket to the OFF-site of the binding pocket located at the outer lipid leaflet of
the cell membrane from where the transported substrate is released to the extracellular
space (Figure 2.4). However, the exact mechanism of P-gp action, i.e. the molecular
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details of how ATP hydrolysis is coupled to transport, are still under debate. The recent
insights to the molecular mechanism of action of P-gp have been reviewed in detail by
Ambudkar et al (2006).
P-gp is often overexpressed in cancer tissues and is one of the mechanisms responsible
for the cancer multidrug resistance by extruding several chemotherapeutic agents out
from the cancer cells (Polgar and Bates, 2005). P-gp is also highly expressed in several
healthy epithelial and endothelial tissues of the body, such as in the apical membrane
of the enterocytes, canalicular membrane of the hepatocytes, brush border of proximal
tubules of kidney and the apical membrane of the microcapillary endothelia
constituting the blood brain barrier (Cordon-Cardo et al., 1989; Thiebaut et al., 1987).
The transported substrates of P-gp include a variety of structurally unrelated
xenobiotics,  including several  clinically  important  drugs,  such as  digoxin (Englund et
al., 2004), some HIV protease inhibitors (Owen et al., 2005) and some anticancer agents
(Schellens et al., 2000). Typically, P-gp substrates are relatively hydrophobic
compounds that can form hydrogen bonds. Furthermore, the presence of tertiary
amino groups and planar aromatic domains is promoting for an interaction with P-gp
(Seelig and Landwojtowicz, 2000). However, within these broad criteria, there seems to
be no further general structural similarities between P-gp substrates and the detailed
molecular  mechanism of  substrate  recognition of  P-gp remains  unknown (Omote  and
Al-Shawi, 2006). Because of the wide substrate specificity and the localization at several
barrier  tissues  of  the  body,  a  physiological  task  of  P-gp  is  considered  to  be  the
regulation of entry of potentially toxic xenobiotics into vulnerable tissues of the body
(Cordon-Cardo et al., 1989). P-gp has been shown to inhibit the intestinal absorption
and access into the central nervous system as well as enhancing the hepatic and renal
elimination of P-gp substrates (Balayssac et al., 2005; Fromm, 2003). Furthermore, P-gp
mediated transport has been suggested to contribute to the regulation of the substrate
concentration at the metabolic sites in the hepatocytes (Lau et al., 2004) and enterocytes
(Knight et al., 2006). Thus, P-gp may affect the pharmacokinetics of a wide range of
compounds at several levels. In this respect, it is important to consider the contribution
of P-gp when predicting the in vivo pharmacokinetics.
2.3.1 Experimental in vitro methods to study the drug - P-glycoprotein
interaction
Due to of the evident role of P-gp in pharmacotherapy, the drug molecules are studied
for their interaction with P-gp already in the early drug development phase (Balimane
et al., 2006; Polli et al., 2001). A number of experimental approaches, including
membrane based ATPase and vesicular transport assays as well as cell based cellular
uptake and transcellular transport assays, have been established to identify and study
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the functional interaction between drug molecules and P-gp. The information obtained
from these assays as well as the time and other resources needed to perform the
experiments vary with the different experimental approaches. Understanding the
strengths and limitations of each methodology is essential for rational use of these
assays and for appropriate interpretation of the results. However, although several
methods are available, the U.S. Food and Drug Administration states in their draft
guidance concerning drug interaction studies that “the transcellular transport assay
should be used as a definitive method for identifying P-gp substrates and inhibitors”
(FDA, 2006). Some characteristics of the different methods used to assess transporter
interactions are summarized in Table 2.1. The membrane based ATPase and vesicular
transport assays as well as cell based cellular uptake assays are briefly described below,
whereas transcellular transport, i.e. cell monolayer permeation experiments are
covered more comprehensively in Chapters 2.4 and 2.5. Similar experimental
approaches are available also for studying other ABC transporters in addition to P-gp.
Furthermore, vesicular transport, cellular uptake and transcellular transport assays can
be modified for studying also other types of transporter proteins (Xia et al., 2007).
Table 2.1. Summary of the characteristics of different in vitro methods to study drug – P-gp
interactions
ATPase Vesicular
transport
Modulation of
cellular uptake
Transcellular
transport
Throughput ++++ +++ ++ +
Membrane or cell
based
Membrane Membrane Cell Differentiated cell
monolayer
Detection of
inhibitors and
substrates
Activators and
inhibitors can be
detected in
separate
experiments
Risk of false
positives and
false negatives
Substrates and
inhibitors can be
detected in
separate
experiments
Detects, but does
not distinguish,
substrates and
inhibitors
simultaneously
Substrates and
inhibitors can be
detected in
separate
experiments
Detection method
required
Independent of
the compounds
used
Fast colorimetric
measurement
Dependent on the
compound traced
Dependent on the
probe compound
used, direct
fluorometric
detection often
applied
Dependent on the
compound traced
Detection of
transport
No Yes No Yes
Optimal drug
concentration
Intermediate
Dependent on the
compound used
Low for
substrates
High for inhibitors
High Low for
substrates
High for inhibitors
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2.3.2 ATPase assay
P-gp is an ATP hydrolyzing protein and the energy provided is utilized for extrusion of
the transported substrates out of the cell. In the absence of exogenous substrates, P-gp
maintains a baseline level ATPase activity, possibly due to putative endogenous
substrate(s) present in the lipid membrane (Borgnia et al., 1996). Usually, the presence
of transported substrates markedly activates the ATPase activity of P-gp. This
characteristic can be used to pinpoint the P-gp substrates by measuring the ATP
hydrolysis rate. In addition, inhibitors of substrate activated P-gp-ATPase activity can
be detected. In practice, the experiments are performed using the cell membrane
fraction from P-gp expressing cells (Sarkadi et al., 1992; Xia et al., 2007) or with P-gp
reconstituted into artificial lipid membranes (Borgnia et al., 1996). Cell membranes
from transfected insect cells expressing human P-gp are often exploited in these
studies. P-gp is incubated in the presence of ATP and the P-gp-ATPase activity is
quantified by measuring the rate of iP release. P-gp must be in orientation exposing the
ATP binding domains to the incubation medium in order to ATP to be accessible to P-
gp. However, it is usually not known in detail in which proportion the lipid bilayer is
oriented as right-side-out vesicles with ATP binding domain of P-gp located inside the
vesicles (not accessible to ATP), or as inside-out vesicles or open lamellae with the ATP
binding domain exposed to the incubation medium (Glavinas et al., 2008). Therefore,
the exact amount of active P-gp in the assay is often not known and, thus, the ATPase
activity per amount of P-gp cannot always be quantified accurately.
An additional characteristic hampering the use of ATPase activation studies in
quantitative prediction of transport is the fact that these predictions must be based on
an assumption of constant and substrate independent stoichiometry between ATPase
activity and the transport rate. Indeed, results with a limited number of compounds
support the correlation between ATPase activity and transport rate. However, the
reported coupling ratios (molecules of ATP hydrolyzed per molecule transported) vary
significantly for different substrates (Ambudkar et al., 1997; Ambudkar et al., 1999;
Omote and Al-Shawi, 2002; Shapiro and Ling, 1998). However, the exact determination
of the transport rate is challenging, especially of high permeability compounds. Thus, it
can be speculated that variations in reported coupling ratios may reflect the variation
in the experimental errors in the estimation of transport rates rather than a true
substrate dependency of the coupling ratio. Consequently, the validity of the
assumption of substrate independent stoichiometry remains to be clarified.
Although the above mentioned drawbacks in the use of P-gp-ATPase rate as a
surrogate for transport of rate of substrates, this methodology has been successfully
used to shed light into functional polymorphism (Sakurai et al., 2007) and species
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differences of P-gp function (Xia et al., 2006). The ATPase assay has also been exploited
to study the concentration dependency of the interaction between P-gp and substrates
(Adachi et al., 2001; Xia et al., 2006). One postulated advantage of ATPase assay in such
studies is the knowledge of the substrate concentration at the close vicinity of the
binding site. The incubation medium in the ATPase experiments mimics the aqueous
cytosol and, thus, the observed concentration dependency of ATPase activation is
assumed not to be confounded by transmembrane movement rate of the substrate
(Glavinas et al., 2008). Additionally, the straightforwardness of the assay, the
possibility for use in the high throughput mode and the possibility to characterize the
function of one specific transporter have made the ATPase assay an attractive and
widely used screening method for P-gp interactions in the pharmaceutical industry
(Feng et al., 2008; Glavinas et al., 2008; Polli et al., 2001; Xia et al., 2007). The goal of
screening is to detect compounds susceptible either to P-gp mediated transport or to P-
gp mediated interactions as P-gp inhibitors. Therefore, one needs to take into account
that both false negatives and false positives with respect to experimentally detectable
transport of the substrate are possible when using P-gp-ATPase measurements (Polli et
al., 2001; Xia et al., 2007). Some of the highly P-gp-ATPase activating compounds are
not detectably transported by P-gp whereas some compounds that are evidently
transported by P-gp, such as cyclosporin A, do not exhibit any detectable activation of
P-gp-ATPase. High ATPase activation without detectable P-gp mediated transport is
associated with compounds with high lipid membrane permeability. The compounds
may be transported by P-gp per se, but the passive diffusion is much faster than the P-
gp mediated transport rate. Consequently, for these compounds the P-gp mediated
transport can be difficult or impossible to detect experimentally. However, these types
of compounds may act as competitive inhibitors of P-gp mediated transport in living
cells (Polli et al., 2001). The evident P-gp mediated transport without P-gp-ATPase
activation has been speculated to be due to their slow P-gp mediated translocation rate
resulting in such a slow rate of ATP hydrolysis that it does not result in any detectable
activation of the baseline level P-gp-ATPase activity (Glavinas et al., 2008).
2.3.3 Vesicular transport assay
Vesicular transport assays can be used either to trace the P-gp mediated transport of
the compound of interest or to explore the modulation (inhibition) of P-gp mediated
transport of a known P-gp substrate (Glavinas et al., 2008). Similar vesicular
preparations to those utilized in P-gp-ATPase experiments can also be used for
vesicular transport experiments. In these experiments, the accumulation of the
experimental compound into the vesicles is measured and the difference in the
accumulation rates in the absence and presence of ATP is attributed to P-gp mediated
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transport.  Similarly  to  the  ATPase  assay,  the  lipid  bilayer  in  the  preparation  used
should  primarily  be  in  the  inside-out  vesicle  conformation  because  the  P-gp  in  the
right-side-out vesicles and open lamellae does not contribute to compound
accumulation. Although the presence of these undesirable conformations in the
membrane usually does not compromise the ability to detect transporter function, they
may complicate the data analysis if a quantitative analysis is being performed
(Glavinas et al., 2008). The advantage of this method compared to the ATPase assay is
the fact that with this method, the actual P-gp mediated transport of the substrate is
being determined. Furthermore, similarly to ATPase experiments, the drug
concentration  in  the  aqueous  phase  in  close  vicinity  to  P-gp  is  assumed  not  to  be
confounded by transmembrane disposition, thus simplifying the interpretation of the
concentration dependency of the observed interaction (Glavinas et al., 2008). On the
other hand, this method requires an individual detection method for each substrate,
making the experiments more laborious and expensive. Furthermore, rigorous
measurement of the P-gp mediated transport rate of high passive permeability
substrates may be experimentally challenging, because the active transport is likely to
be masked by the passive disposition (Xia et al., 2007). Consequently, vesicular
transport assay is often applied as a screening tool for transporter inhibitors (Glavinas
et al., 2008; Pedersen et al., 2008).
2.3.4 Modulation of cellular uptake assays
The  modulation  of  uptake  of  known  P-gp  substrates  into  living  cells  can  be  used  to
study interactions between P-gp and drug molecules. The acetomethyl ester of calcein
(calcein-AM) is a lipophilic P-gp substrate with high passive permeability through the
cell membranes. The intracellular esterases rapidly cleave the ester bond inside the cell
converting non-fluorescent calcein-AM into highly fluorescent calcein which is not able
to permeate through the cell membranes. The P-gp mediated transport inhibits the
influx of calcein-AM. Consequently, P-gp inhibition increases the cellular calcein-AM
concentration leading to an increase in accumulation of calcein which can be readily
detected. In addition to the calcein-AM assay, which is widely used as a screening tool
for P-gp inhibitors (Feng et al., 2008; Polli et al., 2001), also other highly fluorescent
probe P-gp substrates, such as daunorubicin  and rhodamine 123, have been employed
(Litman et al., 2003; Schwab et al., 2003).
The advantages of the cellular uptake assay include easy and fast experimental setup
once the setup is optimized and the cells needed have been cultivated reproducibly.
The assay potentially detects both substrates and inhibitors simultaneously, which can
be regarded as an advantage in the screening setting. However, the downside of this
methodology is the fact that the results do not provide information of the transfer of
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the compound studied and, thus, it is impossible to differentiate substrates from
inhibitors. In comparison with the membrane based ATPase and vesicular transport
assays, the time and resources needed to cultivate the cells for the experiments
represent further drawback to using cellular uptake assays in screening. Furthermore,
the studied inhibitor has to permeate through the cell membrane in order to reach the
intracellular binding site of P-gp. This may seriously complicate the data interpretation
in  concentration  dependency  studies  (Litman  et  al.,  2003).  It  should  also  be  borne  in
mind that the specificity of the cellular uptake assay, alike any other cell culture assay,
for a particular transporter is dependent on the expression levels of transporters in the
cells used, as well as on the specificity of the probe substrate.
2.4 IN VITRO CELL PERMEATION EXPERIMENTS
In vitro cell permeation experiments are routinely used during drug development
process for screening the intestinal absorption potential of compounds as well as for
more detailed predictions of intestinal absorption (Artursson et al., 2001; Badhan et al.,
2009; Balimane and Chong, 2005). Furthermore, these experiments are used for
screening the transporter interactions that might complicate the pharmacokinetic
behavior of the compound and also for a more thorough exploration of the
mechanisms involved in drug disposition (Artursson et al., 2001; Balimane and Chong,
2005; Polli et al., 2001).
Several in vitro cell models, such as Caco-2 (a human colonic adenocarcinoma cell line),
canine kidney derived MDCK (both strains I and II) and porcine kidney derived LLC-
PK1 have been used in in vitro cell permeation studies (Artursson et al., 2001; Balimane
and Chong, 2005; Braun et al., 2000; Matsson et al., 2005). Although all the transfer
routes relevant to intestinal absorption may, in principle, be present in in vitro cell
models, the relative contribution of different routes tends to differ from the in vivo
situation.  Thus,  none  of  the  cell  models  established  truly  fully  resembles  the in vivo
intestinal absorption barrier. The features of differentiated Caco-2 monolayer cultured
on porous support filters mimic some of the characteristics of human intestinal
epithelia. The cell membrane composition is assumed to be similar (Hidalgo, 2001;
Ungell, 2004), and also the expression pattern of drug transporters is, although only
qualitatively, similar (Englund et al., 2006; Hilgendorf et al., 2007). On the other hand,
the paracellular space is tighter (Artursson et al., 2001; Avdeef and Tam, 2010) and the
expression levels of drug metabolizing CYP enzymes are lower in wild type Caco-2
than in the human enterocytes in vivo (Crespi et al., 2000; Engman et al., 2001; Ungell,
2004). Compared to Caco-2, an advantage of MDCK and LLC-PK1 cell  lines  is  their
faster growth and differentiation in culture. The expression levels of endogenous
transporters  in  these  cell  lines  is  considered  to  be  low,  but  not  completely  absent
16
(Braun et al., 2000; Goh et al., 2002). Thus, these cell lines are considered to be suitable
and are widely used, after transfection with transporter encoding genes, for studying
the function of selected transporters (Balimane and Chong, 2005).
Most of the cellular permeation experiments used to model intestinal absorption are
performed using the Transwell system where the cell monolayers are cultured on
porous membranes. Typically, the drug is applied to the apical liquid compartment
(representing the luminal side of the enterocytes). Then, the appearance of the drug to
the basal liquid compartment (representing the circulation within the capillaries
embedded in the lamina propria) is monitored as a function of time and the apparent
permeability (Papp) through the cells is determined by relating the observed transport
rate to the concentration gradient driving the transport (Hubatsch et al., 2007).
Additionally, the involvement of active transporters may readily be probed by
performing the experiments also in the opposite, i.e. basal to apical, direction. Also the
possible concentration and pH dependencies of the drug transfer can be easily tested
(Neuhoff et al., 2003; Polli et al., 2001). Furthermore, in more detailed mechanistic
studies, both the disappearance from the donor and the appearance into the receiver
compartment as well as retention within the cell monolayer may be determined
(Bartholome et al., 2007). However, one of the restrictions for multiple measurements in
a single experiment is the limited liquid compartment volume and consequent
inevitable depletion of the compound into samples as well as the end point nature of
the cellular sampling. Furthermore, the experimental data from the cellular
compartment is at most a single value of the total cellular amount and, thus, does not
provide any direct information about the intracellular localization.
2.5 MATHEMATICAL MODELS OF DRUG DISPOSITION KINETICS IN
CELL PERMEATION EXPERIMENTS
Several mathematical and computational models to describe and predict the drug
disposition during permeation experiments have been proposed. Most often the
analysis of permeation experiment data involves the determination of Papp and,  thus,
utilization  of  a  single  barrier  model.  However,  considering  the  cell  monolayer  as  a
single  barrier  is  in  some  cases  a  major  oversimplification.  Thus,  also  several  more
mechanistic models describing the drug disposition with more thorough spatial detail
have been proposed.
2.5.1 Single barrier models
Although there are several individual barriers and transfer routes involved in the drug
disposition in cell permeation studies (Figure 2.2), the data analysis is often based on
the assumption of a single permeation barrier separating the donor and receiver
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compartments. These models are derived from Fick’s first law of diffusion, assuming a
linear concentration gradient across the barrier (Equation 2.2). In practice, these models
describe the flux through the whole barrier (?M/?t) with a single parameter, usually
referred to as the apparent (Papp) or effective (Peff) permeability to acknowledge the fact
that this parameter is not reflecting only the intrinsic permeability coefficient but,
rather, it represents a composite value reflecting all the permeation barriers and routes
involved.
Equation 2.2
Cd and Cr refer to concentration in the donor and receiver compartments, respectively,
and A is the area available for transport.
Figure 2.5. Box-model representation of single barrier (A,B) and compartmental (C,D) models
to describe the drug disposition kinetics in the cell monolayer permeation experiments. (A)
Drug disposition is modeled as a unidirectional process (one headed arrow) from donor to
receiver compartment through a single barrier (dashed line). (B) Drug disposition is modeled as
a bidirectional process (double headed arrow) through a single barrier between donor and
receiver compartments. (C) The cell monolayer is described as a single kinetic compartment
between the donor and receiver compartments. Drug disposition through the barriers at the
donor and receiver sides of the cellular compartment may be described as a combination of
unidirectional and bidirectional processes referring to passive diffusion and active transport,
respectively. (D) The detail embedded in the compartmental models may be increased by
including additional intracellular compartments and independent transport processes between
different compartments.
Schematically the single barrier models can be categorized into unidirectional and
bidirectional models (Figure 2.5 A,B). The former group approximates the flux to be
)CA(CP
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unidirectional  from the  donor  to  the  receiver  compartment  without  being affected by
the receiver concentration. The latter models take into account the increase of the
receiver concentration as well as the decrease of the donor concentration, thus allowing
for the determination of permeability also when the concentration gradient decreases
significantly during the experiment.
2.5.1.1 Unidirectional single barrier models
The most often used model to analyze permeation experiment data is given in Equation
2.3.
Equation 2.3
In this model, the Equation 2.2 is simplified by assuming the concentration gradient
driving the flux to be constant over the experiment and equal to the donor
concentration at the beginning of the experiment (Cd0). This assumption is bound to be
violated to some extent by the flux of the compound. However, the consequent error is
generally considered insignificant if the concentration at the receiver compartment is
less than 10% of the donor concentration, i.e. so called sink conditions are maintained
(Hubatsch et al., 2007). Thus, this permeability estimate will be referred to as Papp,sink in
this thesis. The sink conditions in the receiver compartment will be maintained if the
flux of the compound through the barrier is sufficiently slow. Furthermore, the
sampling protocol often includes replacement of the withdrawn sample with fresh
buffer,  thus  enabling  prolonged  sink  conditions  also  with  high  permeability
compounds. In such cases, the concentration gradient may be diminished considerably
due to reduction of the donor concentration. Therefore, it has been recommended that
the donor concentration should be recalculated after every sampling by subtracting the
cumulative amount transported to the receiver compartment at each time interval in
order to obtain the Papp value that describes correctly the disposition of the compound
(Hubatsch et al., 2007). Additionally, the amount of the compound withdrawn from the
system  and  the  possible  changes  in  the  liquid  volumes  due  to  sampling  have  to  be
taken into account in the calculations.
In addition to the sink condition assumption, the compound is assumed to be fully
recoverable from the liquid compartments, i.e. there should not be ‘loss’ of drug due to
any mechanism, such as degradation, metabolism or binding to the apparatus or the
cell structures. Significant violations of 100% recovery assumption as well as violation
of sink conditions are known to cause a bias in estimated Papp values (Hubatsch et al.,
2007). However, there is no consensus about what represents adequate recovery (Polli
d0sinkapp, ACP?t
?M ?
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et al., 2004), partly because the tolerable error in Papp estimates depends on the purpose
of the study.
2.5.1.2 Bidirectional single barrier models
Since the sink conditions may not be maintained with high permeability compounds,
models have been proposed to estimate Papp under nonsink conditions.
Assuming the total amount of the compound in the system (M) is constant within a
sampling interval and is fully recoverable from the liquid compartments, a model that
does not require sink conditions to be maintained can be derived from Equation 2.2
(Palm et al., 1999). In this bidirectional single barrier model, the single parameter
describing  the  drug  disposition  can  be  determined  by  fitting  Equation  2.4  to  the
measured receiver concentrations. This permeability estimate will be referred to as
Papp,Palm in this thesis.
Equation 2.4
VR and  VD are the volumes of the receiver and the donor compartment, respectively.
CR(0) is the concentration in the receiver compartment at the beginning of the sampling
interval and CR(t) is the concentration in the receiver compartment at time t from the
beginning of the sampling interval.  In practice, depending on the experimental
protocol, the sampling necessitates recalculation of, CR(0) (Palm et al., 1999) or VD and
VR (Korjamo et al., 2008), and M at each sampling interval.  This model assumes 100%
recovery and, thus, it is likely to show errors in the Papp determination if mass balance
problems are present (Hubatsch et al., 2007).
Another proposed bidirectional single barrier model, i.e. applicable to nonsink
conditions, to describe the drug disposition in cell permeation experiments requires the
measurement of the concentration in both donor and receiver compartments at each
sampling time (Tran et al., 2004). In this model, the permeability estimate, referred to as
Papp,Tran in this thesis, is calculated for each sampling interval separately according to
Equation 2.5.
Equation 2.5
This model uses the difference between the receiver concentration and the ‘average
system concentration’ (<C>, Equation 2.6), which is calculated at each sampling time, as
the thermodynamic force term. This model describes the rate of change in the apparent
mass balance as a first order process and takes into account the reduced concentration
gradient.  Consequently,  it  was  originally  proposed  that  this  model  would  provide
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exact permeability estimates even when the sink conditions and 100 % mass balance
were not maintained (Tran et al., 2004).
Equation 2.6
Both of the above mentioned bidirectional models describe the drug disposition with a
single parameter, namely Papp, and take into account the decrease in the concentration
gradient  assuming  that  the  donor  and  receiver  concentrations  will  be  equal  at
equilibrium,  i.e.  the  concentration  gradient  across  the  cell  monolayer  is  predicted  to
approach zero. However, in cases where the transport through the cell monolayer is
polarized, such as when active transport is involved, or in cases where weak acids or
bases are studied in the presence of a pH gradient, the concentrations in the donor and
receiver compartments will not be equal at equilibrium, i.e. the concentration gradient
will approach some non-zero value, which is dependent upon the direction and extent
of the polarization of the transport. Thus, these models do not adequately take into
account the change in the concentration gradient when the transport is significantly
polarized; ultimately leading errors in the permeability estimates in such cases.
Nonetheless, both of these models have been utilized in studies reported in the
literature where symmetric bidirectional transport does not apply, namely for weak
acids and bases in the presence of a pH gradient across the cell monolayer (Palm et al.,
1999; Thiel-Demby et al., 2009).
2.5.1.3 Applications of the single barrier models
The use of single in vitro determined  Papp value for the prediction of intestinal
absorption in vivo is based on several assumptions, i.e. 1) the cell model applied is able
to adequately mimic the permeation characteristics of the in vivo intestinal epithelia for
the whole length of the absorptive area, 2) the gastrointestinal transit time is similar for
all compounds and 3) the in vivo absorption is limited only by the permeation through
epithelia.  Indeed,  when  solubility  and  stability  issues  do  not  limit  absorption,  and
absorption through the epithelia is mainly governed by passive diffusion, a correlation
between in vitro Papp through in vitro cultured cell monolayers and fraction absorbed
(FA) in human can be obtained (Artursson et al., 2001; Fagerholm, 2007b). However,
these predictions generally tend to be less reliable for low permeability compounds
than for high permeability compounds (Fagerholm, 2007b; Matsson et al., 2005).
Furthermore, there may be substantial inter-laboratory variation in the observed Papp
values due to different cell culture and experimental conditions may be substantial
(Hayeshi et al., 2008a). Thus, in vitro data  from  various  sources  cannot  be  used  in  a
single correlation, but rather, independent correlations need to be developed for each
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cell system and experimental setup. Additionally, it has been recently suggested that
equally  reliable  predictions  of  FA of  passively  absorbed  drugs  could  be  simply
calculated from the physicochemical properties of the molecule (Linnankoski et al.,
2008).
Although the FA of passively absorbed drugs may be predicted fairly well from in vitro
cell permeation derived Papp, the correlation between in vitro and in vivo permeation
rates is qualitative rather than quantitative because the relative contribution of different
transfer routes, such as paracellular space and active transporters, tend to differ
between the in vitro and  the in vivo situations (Artursson et al., 2001; Matsson et al.,
2005). Additionally, the effective area for absorption may differ in the in vitro and in
vivo settings and the spatial variation in several factors, such as pH, paracellular space
and the expression levels of transporters and metabolizing enzymes along the intestine
(Figure 2.1) will undoubetly affect the permeation in vivo. Therefore, a single in vitro
determined Papp value cannot totally predict the in vivo intestinal absorption, especially
when complex concentration dependent phenomena, such as metabolism or active
transport,  are involved. Therefore, a rigorous in vitro - in vivo extrapolation (IVIVE) of
intestinal absorption requires a more complex mechanistic approach.
Although a simple single barrier analysis of absorptive direction permeability assay at
a single concentration gives an estimate of the overall absorption potential of the
molecule from intestinal lumen into portal vein, the problem is that it usually does not
reveal any details about the mechanism of drug disposition. However, the single
barrier analysis has been applied for mechanistic investigation of drug disposition.
Adson and co-workers (Adson et al.,  1995) were able to uncouple the contributions of
hydrodynamic barriers from the cellular barriers and, furthermore, to distinguish the
paracellular transfer route from the transcellular route. In practice, these studies derive
their  conclusions  from  the  Papp estimates determined under various experimental
conditions. Similar experimental approaches have been applied by several others to
quantify the role and the distribution of the unstirred layers (Karlsson and Artursson,
1991; Korjamo et al., 2008) and to explore the transfer route of the ionized species of
weak electrolytes (Avdeef et al., 2005; Palm et al., 1999) as well as elucidating the active
transport mechanisms from the passive transcellular diffusion (Korjamo et al., 2007;
Polli et al., 2001; Troutman and Thakker, 2003b). Theoretically, any of the above
mentioned single barrier models could be used for determination of Papp in mechanistic
studies as long as the assumptions of the model applied are adequately met. However,
often these assumptions are violated, at least to some extent. The extent of these
violations and, thus, also the consequent errors may vary between different
experimental conditions (e.g. concentration, pH etc). Therefore, the effects of the
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experimental conditions of interest on the Papp may  be  biased  and,  consequently,  the
interpretation of the data and conclusions may be confounded. Thus, critical
examination of the applicability of the assumptions involved in the Papp estimation
should not be overlooked. This is further examined in chapters 6 and 8.
One of the most often applied approaches to probe the transfer mechanisms in cell
permeation studies is to conduct the permeation experiments in both absorptive (apical
to basal) and secretory (basal to apical) directions (sometimes referred as bidirectional
permeation experiments in the literature (Neuhoff et al., 2003), which should not be
confused with the term ‘bidirectional single barrier model’ used in this text) to reveal
the apparent polarization of the transport (Polli et al., 2001). Usually clear polarization
of the transport, i.e. >2 fold difference in Papp in opposite directions, is interpreted as
involvement of active transport (FDA, 2006) if there is no pH gradient present in the
experiments. However, more detailed investigation (concentration dependency, use of
specific inhibitors, transfected cell lines etc) is often required to confirm this conclusion
and to identify the transporter(s) involved. Moreover, because of the saturable nature
of transporter function, the substrate concentration used is of importance in these
experiments. Consequently, performing these kinds of studies with only a single
concentration provides qualitative or, at best, ‘semi-quantitative’ information about the
active transport involved (Del Amo et al., 2009; Kalvass and Pollack, 2007).
After intestinal administration, the intestinal drug concentrations in vivo may  be
relatively high and thus the saturation of transporters and metabolic enzymes in the
enterocytes is a distinct possibility. Thus, a general approach to predict the
involvement of saturable processes in vivo should be able to predict the concentration
dependency of these processes. One often applied approach to study the saturation of
transporter function in in vitro cell permeation experiments is based on unidirectional
single barrier model and on the assumption of additive passive diffusion and active
transporter mediated transport (Equation 2.7) (Kalvass and Pollack, 2007; Korjamo et
al., 2007; Sun and Pang, 2008; Troutman and Thakker, 2003a).
Equation 2.7
Where Ppass is the passive diffusion driven apparent permeability, Vmax,app  is the
maximal achievable effective transporter mediated flux rate and Km,app is the initial
donor concentration that will yield an effective transporter mediated flux rate which is
50 % of Vmax,app. The sign of the active component of Equation 2.7 indicates the direction
of active transport relative to the total flux. Often in the literature the parameters
describing the kinetics of active transport are referred to as Vmax and Km, which infers to
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interpretation of these parameters according to the original Michaelis-Menten enzyme
kinetics. However, in this model, the concentration dependency of the transporter
function is directly related to the initial concentration at the bulk phase of the donor
compartment whereas the binding site of transporters lie at the surface of the cells
(uptake) or within the cells (efflux). Therefore, although the Michaelis-Menten theory
might adequately describe the transporter function per se, the donor concentration
derived Vmax,app and  Km,app parameters do not reflect only the transporter function.
Rather, they are composite parameters, describing the concentration dependency of the
interplay between passive and active transport mechanisms. Indeed, Vmax,app and Km,app
values have been observed to be biased by passive permeability, unstirred water layers
as well as the transporter expression level (Balakrishnan et al., 2007; Bentz et al., 2005;
Korjamo et al., 2007; Sun and Pang, 2008) and also to show direction dependency
(Troutman and Thakker, 2003a). Consequently, these parameters are not readily
applicable for the prediction of transporter saturation in vivo (Bolger et al., 2009; Del
Amo et al., 2009). Similarly, simulation studies have revealed that concentration
dependence of intracellular metabolic enzymes cannot be adequately incorporated into
single barrier models (Sun and Pang, 2008). Thus, more sophisticated models are
needed. The effects of the experimental setup, and of the consequent changes in the
passive drug disposition, on the apparent transporter kinetics are further discussed in
chapter 8.
2.5.2 Compartmental models
The  determination  of  Papp using a single barrier model is the cornerstone of the
permeation experiment data analysis. However, it is clear that single barrier models
cannot fully describe the drug disposition and the mechanisms involved in permeation
experiments. Therefore, several more mechanistic compartmental models have been
developed to explain and predict the experimental data. In general, compartmental
models describe the transfer of a compound between several kinetic compartments
(Figure 2.5). The degree of complexity of the proposed compartmental models varies
from fairly simple three-compartment models, which describe the transfer as a one-
dimensional process with a set of differential equations and the cell layer as a single
kinetic compartment in between donor and receiver compartments (Gonzalez-Alvarez
et al., 2005; Kalvass and Pollack, 2007; Kapitza et al., 2007; Korjamo et al., 2007), to
multi-compartment models which describe the cell layer as several compartments and
may incorporate a more complex spatial dependency of molecule movement as well as
formation and movement of the metabolites within the system modeled (Bentz et al.,
2005; Tam et al., 2003; Tran et al., 2005; Zhang et al., 2006).
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Compartmental models are usually composed of a group of ordinary differential
equations defining the rates of compound movement between kinetic compartments.
Additionally, it is important to account for possible discontinuation in functions due to
the mass and volume removed in the sampling (Sun et al., 2008). In some cases, these
differential equation groups can be solved analytically with certain approximations
(Kalvass and Pollack, 2007; Komin and Toral, 2009). However, often these differential
equation groups are not analytically solvable and, thus, numerical methods need to be
employed to simulate the time course of drug disposition. Therefore, utilization of
these kinds of models requires a considerable amount of computing power though this
should not pose a problem with modern computers.
2.5.2.1 Applications of compartmental models
One of the first published compartmental models of the drug disposition in in vitro cell
permeation was applied for the quantitative analysis of the interplay of passive
diffusion through the cell membranes and the efflux transporter P-gp mediated
transport through the apical cell  membrane (Ito et al.,  1999).  In that study, Ito and co-
workers showed that a rather simple, but still mechanistically feasible, three
compartment model was better able to describe the experimental drug disposition than
a single barrier model. Additionally, this study suggested that the permeability
through the apical cell membrane of two low permeability compounds, digoxin and
vinblastine, was significantly lower than through the basolateral cell membrane,
consistent with the low fluidity of the exofacial leaflet of the apical cell membrane
(Lande et al., 1995).
In the above mentioned study by Ito et al (1999) the experimental data was only
available from a single concentration and, consequently, the P-gp mediated transport
was described as linear, concentration independent process. This model has been
further  refined  by  several  investigators  to  further  justify  the  biochemically  feasible
location and binding site of the P-gp in the model (Gonzalez-Alvarez et al., 2005) and to
include Michaelis-Menten type concentration dependent P-gp function to explain
unexpected experimental observations and to gain insights into the dynamics of
concentration dependent efflux transport (Kalvass and Pollack, 2007; Korjamo et al.,
2007; Tran et al., 2005). Furthermore, the same three compartment base structure of the
model has been further developed to describe a more complex interplay between
several concentration dependent processes, such as different transporters, metabolism
and the putative concentration dependent paracellular transfer to simulate the possible
outcomes of the interplay as well as to determine parameters describing the individual
processes involved (Bourdet et al., 2006; Sun and Pang, 2008; Sun et al., 2008; Tam et al.,
2003).
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In the above mentioned models, the cell monolayer was modeled as a single kinetic
compartment without any intracellular concentration gradients. However, also more
detailed models describing intracellular kinetics have been suggested; such as models
accounting for the distribution of the compound between cell membranes and cytosol,
the distribution into the intracellular lipid and mitochondrial and lysosomal
accumulations driven by electrostatic and pH gradients (Zhang et al., 2006; Zhang et
al., 2010). These models may be able to mimic the time course of observed drug
disposition in the liquid compartments as well as the total cellular retention during the
experiments. However, in practice, the parameter values cannot be rigorously
estimated by fitting these models into the experimental data from cell permeation
experiments because the experimental data does not contain detailed enough
information about the cellular localization of the compound. Therefore, utilization of
these models is based on a priori estimates of the input parameter values.
When the parameter values of a model are to be determined by fitting the model to the
experimental data, the model complexity is in practice limited by the resolution of the
experimental data. Consequently, such models are likely to ignore some of functionally
minor mechanisms and to describe some of the mechanisms under composite
parameters. Thus, compartmental models could often be considered as ‘semi-
mechanistic’ (Dahl et al., 2009). Nonetheless, the compartmental models enable the
mathematical description of complex systems with parameters bearing some
mechanistic significance, as well as estimation of these parameters and also the
determination of the statistical uncertainty of the estimates (Ito et al., 1999).
2.6 PHYSIOLOGICALLY BASED MODELS OF IN VIVO INTESTINAL
ABSORPTION
Several physiologically based pharmacokinetic (PBPK) models have been applied for
predicting the in vivo pharmacokinetics (Pelkonen et al., 2008). Such models allow
simulation and prediction of the effects of variation of several mechanistic details, such
as in the expression levels and population variability of transporters and metabolic
enzymes. Furthermore, it has been proposed that PBPK models could be exploited for
simulation of pharmacokinetic studies in populations in which in vivo clinical studies
could not feasibly be performed (Jamei et al., 2009b). However, the details of the
mechanisms involved in the pharmacokinetics are often unreachable when approached
from ‘top-down’ from the clinical data (Jamei et al., 2009a). Therefore, several in vitro
approaches have to be applied and the data obtained have to be combined elaborately
in order to construct a feasible prediction from ‘bottom-up’ that accounts for all the
clinically significant phenomena involved. Building such a model is a challenging and
ambitious task. However, in the recent years, marked advances in the field of
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physiologically based IVIVE have been achieved (Agoram et al., 2001; Badhan et al.,
2009; De Buck and Mackie, 2007; Jamei et al., 2009a; Rostami-Hodjegan and Tucker,
2007). Furthermore, computer software, such as GastroPlus™ (Simulations Plus Inc,
Lancaster,  CA,  USA),  Simcyp®  Population-based  ADME  Simulator  (Simcyp  Ltd,
Sheffield, UK) and PK-Sim® (Bayer Technology Services GmbH, Leverkusen,
Germany), utilizing these models have become commercially available. Various
approaches to incorporate the intestinal absorption with varying degrees of
mechanistic detail in the PBPK models have been published (Huang et al., 2009). The
first intestinal absorption models ignored the structure of the gastrointestinal tract and,
thus, lacked mechanistic detail. However, an increased insight into absorption
mechanisms has led to incorporation of a more physiological description of the factors
involved in absorption (reviewed by Boobis et al., 2002). An early version of this kind
of physiologically based intestinal absorption model (Compartmental Absorption and
Transit, CAT) proposed by Yu and Amidon (1999) described the gut wall as a single
barrier and the permeability parameters were originally derived from in situ absorption
studies  in  human.  However,  as  in  the in vitro situation,  also  in  the in vivo setting, the
single barrier model of the gut wall cannot adequately describe the dynamics of the
involvement of efflux transporters and intestinal metabolism. Consequently, recent
models have included the enterocytes as an additional compartment between intestinal
lumen and circulation and these models now contain several transporters and
metabolic enzymes in mechanistically and biochemically reasonable locations (Agoram
et al., 2001; Badhan et al., 2009; Jamei et al., 2009b; Tubic et al., 2006). Despite the
evident advances in the physiologically based IVIVE, several issues still remain and
more and more reliable and useful predictions are still being sought for. A practical
and reliable approach for IVIVE of concentration dependent active transport of
molecules through the cell membranes in the relevant tissues is one of aspects still
lacking from the current predictions, partly because of the lack of suitable in vitro input
data (Badhan et al., 2009). Such a lack of data possibly results in imprecise predictions
for compounds whose pharmacokinetics are significantly affected by transporters. One
of the requirements for successful exploitation of in vitro data in in vivo predictions is a
thorough understanding of the in vitro method being applied. Therefore, the studies in
this thesis were conducted in order to gain insights into selected in vitro methods used
to study the permeation and transporter kinetics. Furthermore, a rational approach was
sought for handling the in vitro component of IVIVE of transporter mediated transport.
A major emphasis was placed upon intestinal absorption and P-gp mediated transport.
However, the general principles are applicable for other barrier tissues and also for
other transporters.
27
3 Aims of the study
The general objective of the studies conducted in this thesis was to gain further insights
into the dynamics of active and passive disposition processes in in vitro models for
drug permeation and active transport in order to improve the predictive value of in
vitro methods. The specific aims were:
1. To assess the effects of the experimental setup on the observed concentration
dependent function of P-gp (I, IV)
2. To assess the validity of single barrier assumption based analysis of cell
permeation data under various experimental conditions (II, IV)
3. To establish a rational approach to describe and determine the active and passive
drug disposition kinetics in in vitro  permeation experiments (II, III, IV)
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4 General experimental procedures
4.1 CHEMICALS
(+/-)Verapamil hydrochloride was from ICN Biomedicals (Aurora, OH), (+/-) ibuprofen,
(+/-) propranolol hydrocloride and quinidine from Sigma (St. Louis, MO), testosterone
from Fluka (Buchs, Switzerland), bafilomycin A1 was from LC Laboratories (Woburn,
MA) and the P-gp inhibitor GF120918 (Hyafil et al., 1993) was a kind gift from
GlaxoSmithKline (Research Triangle Park, NC). 3H-ibuprofen (5 Ci/mmol), 3H-
testosterone (76 Ci/mmol) and 3H-quinidine (20 Ci/mmol) were from American
Radiolabeled Chemicals (St. Louis, MO) and 3H-propranolol (20.6 Ci/mmol) from
Perkin Elmer (Boston, MA, USA). The cell culture reagents were from BioWhittaker
(Cambrex Bio Science, Verviers, Belgium) and EuroClone (UK). All the chemicals were
of analytical grade or better.
Some properties of the model compounds are summarized in Table 4.1.
Table 4.1. Properties of model compounds used
Compound pKa Daqc MW
Monensin acid 4.26 a 5.1 693
Quinidine base 4.32, 8.51 b 7.2 324
Verapamil base 9.07 b 5.9 491
Testosterone NA 7.5 288
Propranolol base 9.53 b 7.9 259
Metoprolol base 9.56 b 7.8 268
Ibuprofen acid 4.45 b 7.9 260
a Calculated by the ACDLABSACD/pKa program (Version 6.00)
b Experimental values taken from (Avdeef and Box, 1995; Avdeef, 2003)
c Aqueous diffusion coefficient at 37 °C was calculated with equations presented
in (Avdeef et al., 2005)
NA, Not applicable
4.2 CELL CULTURE
MDCKII-MDR1 (The Netherlands Cancer Institute, Amsterdam, The Netherlands) and
Caco-2 (ATCC HTB-37, Manassas, VA) cells were cultured and prepared for
permeation experiments as described earlier (Korjamo et al., 2005; Korjamo et al., 2007).
For permeability experiments, the cells were seeded onto uncoated polycarbonate
filters (Catalog number 3401, pore size 0.4 µm, diameter 12 mm; Corning Life Sciences,
Corning, NY). MDCKII-MDR1 (passages 34-43) and Caco-2 (passages 42-55) were used
for permeation experiments at 4 and 21-24 days post-seeding, respectively.
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Before the experiments, the cell monolayers were washed and preincubated for 30
minutes at 37 °C in a humidified incubator in the appropriate transport buffer. The
integrity of the monolayers was checked by a transepithelial electrical resistance
measurement, only data from inserts with resistance higher than 150 ?cm2 (MDCKII-
MDR1) or higher than 300 ?cm2 (Caco-2) were included in the analysis.
4.3 SAMPLE ANALYSIS
In the analysis, the 3H-labelled samples were mixed with OptiPhase HiSafe 3
scintillation cocktail (PerkinElmer Wallac) and the radioactivity was quantified using a
MicroBeta liquid scintillation counter (PerkinElmer Wallac, Turku, Finland).
4.4 COMPARTMENTAL MODELS
Several compartmental models were constructed and applied in this thesis. Schematic
box-model figures of these models are presented in Figure 4.1 and the differential
equations describing the mass transfer are shown below.
4.4.1 Model 1a: Three-compartment model
Model 1a describes the passive permeation through the permeation barriers at the
apical and basal sides of the cell monolayer as well as instantaneous intracellular
distribution.
The time profile of free concentration at the apical (Capi) and basal (Cbaso) chambers and
in the cell monolayer (Ccell,free) are defined as
Equation 4.1
Equation 4.2
Equation 4.3
Papi and  Pbaso are the composite permeability coefficients across the ABL and cell
membrane at the apical and basal sides, respectively. Vapi and Vbaso refer to volumes of
apical and basal chambers, respectively. The stepwise decline in chamber volumes due
to sampling was accounted for when applicable. The cellular volume (Vcell) for
modeling was calculated from the nominal filter area and the height of the cell
monolayer estimated from cross sectional microscopy of cells which were cultured
with the same protocol as the cells used for permeation experiments (10 µm for
MDCKII-MDR1 and 20 µm for Caco-2).
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Figure 4.1. Box model representation of models 1a, 1b and 2. In models 1a and 1b, the aqueous
boundary  layer  (ABL)  and cell  membrane  on  both  sides  of  the  cell  monolayer  are  described  as
single barriers (a,b). In model 1b, the cytosol to lysosome and lysosome to cytosol distribution
rates are described with rate coefficients Q12 and  Q21, respectively. Model 2 accounts for the
ABLs and cell membranes individually (1-4) and allows the inclusion of P-gp mediated efflux
through the apical cell membrane (5) into a mechanistically feasible location. The experiments
were conducted at various extracellular pHs and the ionization of the compounds was accounted
for in the model 2. The dashed lines show schematically the approximation of the concentration
gradient from the donor to the receiver compartment in the apical to basal direction experiments
at pH 7.4.
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The instant cellular distribution was described with cellular distribution coefficient K,
which is defined as the ratio of total to the free cellular concentration.
Equation 4.4
Cellular retention was found to be saturable (see the results in capters 6 and 8) and the
concentration dependence of the cellular distribution coefficient K was approximated
using a simple sigmoidal function assuming a non-saturable component and a single
saturable binding site.
Equation 4.5
EC50,K refers  to  the  intracellular  free  concentration  resulting  in  the  K  of  average  of
upper (Kmax) and lower (Kmin) limits.
4.4.2 Model 1b: Four-compartment model
The lysosomal sequestration of basic compounds may affect also the rate of cellular
retention in addition to the extent. In model 1b, the distribution between the ‘cytosolic’
and ‘lysosomal’ compartments was described with first order rate coefficients Q12 and
Q21.
Mass transfer in apical and basal compartments was described identically in models 1a
and 1b. Thus, Equation 4.1 and Equation 4.3 describe the concentration profile in apical
and basal compartments, respectively, also in model 1b.
The mass transfer in the cellular ‘cytosolic’ compartment:
Equation 4.6
Cellular ‘lysosomal’ compartment:
Equation 4.7
M refers to the amount of the compound in apical (api), basal (baso), cytosolic (cyto) and
lysosomal (lyso) compartments.
4.4.3 Model 2: Five-compartment model
Model 2 accounts separately for ABLs and cell membranes, as well as for the
concentration dependent P-gp mediated transport when applicable. The total
permeation  barrier  in  the  cell  permeation  experiments  was  differentiated  into  four
distinct barriers between the compartments; apical ABL, apical cell membrane, basal
cell  membrane  and  basal  ABL  (including  both  porous  support  filter  and  the  basal
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UWL). Although the basal ABL consists of UWL and the support filter, the contribution
of  ABL  on  both  sides  of  the  cell  monolayer  was  handled  similarly  in  the  five
compartment model. Thus, the contributions of the filter support and UWL within the
basal ABL are not distinguished in the model.
The time profile of average free concentration at apical (Cbulk,api,  CABL,api) and basal
(Cbulk,baso, CABL,baso) bulk and ABL compartments, respectively, and in the cell monolayer
(Ccell,free) are defined as
Equation 4.8
Equation 4.9
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Equation 4.11
Equation 4.12
P-gp mediated transport rate ‘in situ‘, is defined as
Equation 4.13
or in the presence of the P-gp inhibitor GF120918 and for the passively transported
compounds
Equation 4.14
PABL,api and PABL,baso are the permeabilities across the apical and basal ABLs, respectively.
Current data did not allow for the determination of separate permeability values in
apical and basal cell membranes. Thus, in the final model fitting, separate values for Pu
and Pi were obtained but equal values in both cell membranes were used. fu, fi,, fu,cell and
fi,cell refer to unionized and ionized fraction in the extracellular and in the intracellular
compartments, respectively, calculated assuming constant intracellular pH of 7.4,
which is in the range of the measured intracellular pH values both in Caco-2 (Liang et
? ?? ?apisurf,apibulk,apiABL,
apibulk,
apibulk, CCP-
V
A
dt
dC ??
? ? ? ? ? ?? ?gpPfreecell,icelli,ucellu,apisurf,iiuuapisurf,apibulk,apiABL,
apiABL,
apiABL,
JCPfPfCPfPfCCP
V
A
dt
dC
???????
? *
? ?? ?basobulk,basosurf,basoABL,
basobulk,
basobulk, CCP
V
A
dt
dC ??
freecell,m
freecell,
maxgp-P CK
C
VJ ??
33
al., 2007; Nielsen et al., 2003) and MDCK (Bogner et al., 1992), whereas transport buffer
pH (5.8 – 7.4) of a given experiment was used for the extracellular compartments.
The model structure would allow for the addition of paracellular flux between the ABL
compartments bypassing the cell membranes and the intracellular space. However,
attempts to fit both the membrane permeability of ionized species and the paracellular
permeability simultaneously resulted in obscure parameter estimates (data not shown).
Furthermore, addition of paracellular permeability of 2 *10-6 cm/s into the model, based
on the mannitol permeability, did not significantly affect the parameter estimation
(results not shown). Thus, for simplicity, paracellular flux was neglected.
The operational ABL volumes separately on both sides are
Equation 4.15
Daq is the estimated aqueous diffusion coefficient at 37°C (Table 4.1).
Consequently bulk phase volumes are
Equation 4.16
Vtot refers to the total volume of the corresponding chamber (Vapi or  Vbaso).  When  the
sample volumes are not replaced to the chambers the volumes decline stepwise during
the experiments. This was accounted for in the modeling when applicable.
The concentrations at the cell surfaces (Csurf,api and  Csurf,baso) were estimated from the
bulk concentration (Cbulk) and the average concentration in ABL compartment (CABL) on
the  respective  side  of  the  cell  monolayer  assuming  a  linear  concentration  gradient
within the ABLs (Figure 4.1)
Equation 4.17
The initial conditions for the differential equations in apical to basal direction
experiments are
Equation 4.18
Equation 4.19
Whereas in the experiments in the basal to apical direction, the initial conditions are
Equation 4.20
Equation 4.21
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5 Protein concentration and pH
affect the apparent P-glycoprotein
ATPase activation kinetics1
Abstract. Reliable predictions of the role of P-glycoprotein in the pharmacokinetics are
needed already at the early stage of drug development. In order to obtain meaningful
in vitro–in vivo scaling factors, it is essential to know the factors affecting the in vitro
results. In this study, the apparent P-glycoprotein–ATPase activation kinetics was
determined using the cell membrane fraction of human MDR1-transfected insect cells.
The apparent affinities to P-glycoprotein of basic verapamil and quinidine were higher
at pH 7.4 than at pH 6.8. However, this shift in pH did not have a significant effect on
the apparent affinity of acidic monensin. The protein concentration used in the assay
did not affect the apparent activator affinities, but was inversely related to the
maximum activation achieved. Thus, pH and protein concentration should be taken
into account when interpreting the Pgp–ATPase data.
1  Adapted with permission of Elsevier B.V. from: Heikkinen A.T., Mönkkönen J.: Protein
concentration and pH affect the apparent P-glycoprotein ATPase activation kinetics, Int J
Pharm 346: 169-172, 2008. © 2007 Elsevier B.V. All Rights Reserved.
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5.1 INTRODUCTION
The P-gp-ATPase activation method has been used for determining kinetic parameters
describing the concentration dependent P-gp function (Adachi et al., 2001; Xia et al.,
2006). However, the kinetic parameters obtained with the P-gp-ATPase method vary
between laboratories. In this study the effect of pH and protein concentration to the P-
gp-ATPase activation assay were examined. The results show that these factors result
in variation in P-gp-ATPase activity measurements and thus may partly explain the
variation in the parameters that has been reported.
5.2 MATERIALS AND METHODS
The P-gp-ATPase assay was performed using the cell membrane fraction from High
Five cells expressing human P-gp (GENTEST/BD Biosciences, Woburn, MA, USA). The
assay was performed according to the manufacturer's protocol with modifications in
protein concentration and in buffer pH. 50 µl of membrane suspension (20, 40 or 60 µg
of protein/well) in ATPase buffer containing 50 mM Tris, 50 mM MES, 2 mM EGTA, 2
mM dithiothretiol,  50 mM potassium chloride and 5 mM sodium azide, pH 6.8 or pH
7.4 as indicated, was preincubated with or without test compound for 5 min at 37 ?C. 10
µl  of  30  mM  ATP  magnesium  salt  in  ATPase  buffer  was  added  (final  ATP
concentration was 5 mM). After 20 min of incubation at 37 ?C, 30 µl 10 % of SDS
solution supplemented with Antifoam A was added to stop the reaction. Subsequently,
150 µl of detection solution containing 8 % of ascorbic acid, 3 mM of zinc acetate and 7
mM of ammonium molybdate was added and these mixtures were incubated at 37 ?C
for 20 min. The absorbance of each mixture was measured at 660 nm using Victor2
(Perkin Elmer/Wallac, Turku, Finland).
The P-gp-ATPase activity (APgp) was calculated according to the equation
Equation 5.1
where iP(t) and iP(0) are the amount of liberated phosphate at time t and 0, respectively,
and iP(t)bg and iP(0)bg are the amount of liberated phosphate in the presence of 100 µM
sodium orthovanadate at time t and 0, respectively. The activities were normalized to
the protein amount n. iP(t)bg was not affected by any of the studied molecules (data not
shown) indicating that studied molecules did not interfere with the background (bg)
ATP hydrolysis or with the detection of liberated phosphate.
To estimate the maximum activation with particular activator (APgp,max) and the
activator concentration resulting in half-maximum activation (EC50,Pgp), the data were
fitted to the Equation 5.2
n*t
)P-P(-)P-P(
A (0)bgi(t)bgi(0)i(t)iPgp ?
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Equation 5.2
where A0 is the P-gp-ATPase activity at activator concentration C = 0. GraphPad Prism,
version 4.03 (GraphPad Software Inc., San Diego, CA) was used for data fitting.
All the experiments were performed using the same membrane lot to avoid the
possible effect of membrane lot to lot variation.
5.3 RESULTS AND DISCUSSION
The apparent EC50,Pgp of the basic compounds verapamil and quinidine were lower at
pH 7.4 than at pH 6.8 with all protein concentrations used (Figure 5.1). Most of the
known P-gp substrates are weak bases and their distribution between aqueous and
lipid phases varies according to pH at the physiological pH range. As the binding site
of P-gp lies inside the lipid bilayer (Figure 2.4), it is expected that basic substrates reach
the binding site more readily at higher pH, resulting in lower EC50,Pgp values. However,
the reversed effect was not clearly seen with the acidic monensin. This is probably due
to the fact that the pH area used was too far away from the pKa of monensin (Table
4.1), thus the concentration at the binding site of P-gp was not significantly affected.
Further, pH shift did not affect the P-gp-ATPase activation of the neutral compounds
digoxin and testosterone (data not shown), suggesting that the pH shift did not affect
on the P-gp function per se.
In  addition  to  EC50,Pgp,  the  pH  shift  slightly  affected  Amax values of verapamil and
monensin. According to the Sigma product information sheet of MgATP, the pKa of
ATP is 6.5. Thus, also the ionization state of ATP is affected when pH in changed from
6.8 to 7.4. The affinity to P-gp of different forms of ATP may vary and could cause the
observed shift in APgp,max parameters. However, if this was the reason the effect would
be seen independent of the activator used. With quinidine, digoxin and testosterone
there  was  no  sign  of  pH  effect  on  APgp,max (digoxin and testosterone data not shown).
Thus, the reason for the variable APgp,max values of verapamil and monensin in different
pH environments remains unclear.
The protein concentration used in the assay did not significantly affect EC50,Pgp,
suggesting that the concentration of activators at the binding site was not significantly
affected by the variation in the protein concentration used.
Pgp50,
Pgp,0maxPgp,Pgp,0Pgp ECC
C*)A(AAA ????
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Figure 5.1. Apparent EC50,Pgp (A,C,E)  and  Amax (B,D,F) values of verapamil (A,B), quinidine
(C,D) and monensin (E,F) at pH 6.8 (open symbols) and at pH 7.4 (closed symbols) when
assays were performed using 20, 40 or 60 µg of protein/well. Symbols represent the parameters
fitted on data from 4 measurements at 5 to 7 concentrations per compound ± SE of fitted
parameters.
Surprisingly, the Amax and the protein concentration were inversely related (Figure 5.1).
However, the basal P-gp-ATPase activity (3.7 ± 1.5 nmol/min/mg protein) was not
detectably affected by the protein concentration. The ATP concentration remained
above  3  mM  during  all  incubations.  3  mM  initial  ATP  concentration  was  enough  to
give practically maximum P-gp-ATPase activity (Figure 5.2), suggesting that
apparently lower P-gp-ATPase activity with higher protein concentrations is not due to
ATP depletion. P-gp-ATPase activity has been shown to be inhibited by ADP, and also
substrate inhibition of P-gp-ATPase by high ATP concentrations has been suggested
38
(Sharom et  al.,  1995).  End product  inhibition due to  ADP accumulation could explain
the apparently lower P-gp-ATPase activities when higher protein concentrations are
used.
Figure 5.2. Kinetics of the P-gp-ATPase
activity at pH 7.4 in the presence of 500
µM verapamil. P-gp-ATPase activity was
measured at various ATP concentrations
using 20 (closed symbols) and 60 (open
symbols) µg protein/well. Symbols
represent the average of two measurements.
5.4 CONCLUSIONS
In P-gp-ATPase assay, the possible effect of pH on activators lipid distribution should
be taken into account when analyzing ionizable compounds.
Apparent P-gp-ATPase activity is lower when high protein concentrations are used,
possibly due to ADP accumulation during the incubation.
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6 Kinetics of cellular retention
during permeation experiments2
Abstract. The permeability estimation from cell monolayer permeation data is usually
based on 100 % recovery assumption. However, poor recovery is often seen in such
experiments in practice, but often neglected in data interpretation. In the present study,
the cellular retention kinetics during Caco-2 permeation experiments of three passively
transported compounds (basic propranolol, acidic ibuprofen and neutral testosterone)
were determined. Further, the effects of cellular retention kinetics on apparent
permeability were evaluated and the role of lysosomal sequestration in cellular
retention of propranolol was explored. The cellular retention profiles were observed to
be direction and concentration dependent, which may cause erroneous directionality
and concentration dependence in permeability estimates. Further, the lysosomal
sequestration was demonstrated to contribute to the extent and kinetics of the cellular
retention of propranolol.
2  Adapted  with  permission  of  the  American  Society  for  Pharmacology  and  Experimental
Therapeutics from: Heikkinen A.T., Mönkkönen J., Korjamo T.: Kinetics of cellular retention
during Caco-2 permeation experiments: Role of lysosomal sequestration and impact on
permeability estimates, J Pharmacol Exp Ther 328:882-892, 2009. ©2009 the American Society for
Pharmacology and Experimental Therapeutics. All rights reserved.
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6.1 INTRODUCTION
Typically, in in vitro permeation experiments the permeability estimates are based on
the appearance kinetics of the test compound to the receiver compartment.
Additionally, samples from both donor and receiver sides are often collected at the
final time point of the experiment to determine the recovery of the test compound. The
analysis and interpretation of permeation data are often based on the assumption that
the cell monolayer behaves as a single barrier for the solute transfer and that the whole
mass of the studied compound is in donor and receiver compartments, i.e. the recovery
is 100 %. However, physiologically the permeation barrier in cell monolayer
experiments consists of various serial and parallel barriers (Figure 2.2) and, further,
reduced recovery is often observed in permeability experiments (Polli et al., 2001).
Incomplete recovery is attributed to metabolism, drug binding to the plastic surfaces
and/or to cellular retention of drug (Fisher et al., 1999; Palmgren et al., 2006; Östh et al.,
2002). The possible bias in permeability estimates caused by poor recovery is generally
acknowledged but still often neglected in the data interpretation.
The mechanisms causing poor recovery and, consequently, the kinetics of apparent loss
of test compound in permeation experiments may be specific to compound,
experimental apparatus and permeation barrier (Tran et al., 2004; Östh et al., 2002).
Thus, accurate universal correction terms for poor recovery in permeation experiments
cannot be applied. However, in some reported studies the poor recovery have been
taken into account by correcting the calculations with experimental recovery at a single
time point, practically either at the end of the experiment (Youdim et al., 2003) or after
initial 'cell loading' period in the beginning of the experiment (Korjamo et al., 2008;
Tran et al., 2004).
In Caco-2 cells,  drug metabolism is limited due to low expression levels of cytocrome
P450 metabolizing enzymes (Engman et al., 2001; Korjamo et al., 2006; Prueksaritanont
et al., 1996). Further, an earlier study in our lab have suggested that in the presence of
buffer the loss of various drugs to cell  culture plastics is minimal whereas the cellular
retention may be substantial (Palmgren et al., 2006). Therefore, retention into the
cellular structures is likely to be the primary cause of poor recovery for many
compounds in cell-based permeation experiments.
Cellular  retention  may  be  caused  by  partitioning  into  the  cellular  lipids  due  to  high
lipophilicity (Sawada et al., 1999), specific or nonspecific binding to the cellular protein
or due to electrostatic binding to the charged structures of the cell (Duvvuri and Krise,
2005a). Furthermore, one major mechanism causing the compound sequestration into
the intracellular organelles is ion trapping of weak bases into the organelles with acidic
interior (Kaufmann and Krise, 2007). Several intracellular organelles possess acidic
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interior and intraorganelle pH may be as low as 4.5 in lysosomes, whereas cytosolic pH
lies near neutrality (Asokan and Cho, 2002). It has been shown that basic compounds
with suitable pKa are sequestered into the acidic organelles, provided that the
membrane permeability of the ionized and unionized forms differ substantially
(Duvvuri et al., 2004). Further, lysosomes are the most acidic organelles in the cells and,
therefore, most of the pH-partitioning based sequestration of basic compounds is likely
to be due to lysosomal sequestration. In addition, it is challenging to experimentally
distinguish the true lysosomal sequestration from the possible sequestration into the
other  acidic  vesicles,  such  as  endosomes,  in  the  cells.  Therefore,  for  simplicity  in  this
text term 'lysosome' is used to cover also the other acidic vesicles than lysosomes.
In this study, the cellular retention kinetics of basic propranolol,  acidic ibuprofen and
neutral testosterone during Caco-2 permeation experiments were explored and
modelled. Further, the role of lysosomal sequestration in cellular retention of
propranolol was demonstrated. Finally, the effects of cellular retention kinetics on
estimates of apparent permeability through the Caco-2 cell monolayer were evaluated.
6.2 METHODS
6.2.1 Permeability and cellular retention experiments.
The physicochemical properties of the model compounds are given in Table 4.1. One
basic (propranolol), acidic (ibuprofen) and neutral (testosterone) compound were
selected for the experiments. All the model compounds are known to be transported
symmetrically  through  Caco-2  monolayers  when  no  pH  gradient  is  present.
Consequently, the permeation is assumed to be primarily governed by passive
diffusion. Furthermore, these compounds are not significantly metabolized during
Caco-2 permeation experiments (Engman et al., 2001; Korjamo et al., 2008).
HBSS buffered with 25 mM Hepes, pH 7.4, with or without 100 nM bafilomycin A1, a
specific  inhibitor  of  vacuolar  type H+ -ATPase (Bowman et al., 1988), that inhibits the
acidification of lysosomes (Yoshimori et al., 1991), was used as the transport buffer. The
donor solutions were prepared in transport buffer and spiked with the respective 3H-
labelled compound (1 µCi/ml). The initial donor concentrations were 1 µM, 50 µM and
300 µM for propranolol and ibuprofen and ~10 nM (blank transport buffer spiked with
3H-testosterone), 1 µM and 50 µM for testosterone. The stock solutions of unlabeled
compounds were prepared in dimethylsulfoxide (DMSO) and the DMSO concentration
did not exceed 1 % in final donor solutions.
The permeability and cellular retention experiments were conducted in both apical to
basal and basal to apical directions on an orbital shaker with orbit diameter of 3 mm at
320 rpm (Titramax 101, Heidolph, Schwabach, Germany) at 37 °C in a humidified
incubator. The experiments were started by replacing the preincubation buffer with
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fresh transport buffer into the receiver compartment and donor solution into the donor
compartment (500 µl in apical and 1500 µl in basal compartment), both with or without
100 nM bafilomycin A1 as indicated. Due to the end point nature of the cellular
retention measurements separate cell monolayers were used for each time point. At
each time point (5, 15, 30, 60 and 90 minutes) 100µl samples were withdrawn from both
chambers from three inserts. Promptly, these three inserts were washed with ice cold
transport buffer and the cells were lysed with 300 µl transport buffer supplemented
with 1 % Triton X 100 at least for 30 minutes at 37 °C in a humidified incubator. The cell
lysates were carefully mixed and 100 µl samples were withdrawn for liquid
scintillation counting.
6.2.2 Kinetic modelling.
The compartmental models were constructed, and data fitting and simulations were
done with WinNonlin software (version 5.0.1, Pharsight Corporation, CA, USA).
In data fitting, 6 data sets (apical, basal and cellular amounts at every sampled
timepoint) of corresponding test compound were simultaneously used; 3
concentrations (1, 50 and 300 µM for ibuprofen and propranolol and 0.01, 1 and 50 µM
for testosterone) in both directions. All the experiments were conducted twice in
triplicate. Thus, 6 individual experimental values for each time point were used in data
fitting. In the fitting procedure, various weighting schemes were tested (no weighting,
1/predicted and 1/predicted2). The weighting scheme of 1/predicted2 was selected
based on residual blots and estimated standard errors of parameter estimates. Other
settings for minimization of the error were the default WinNonlin settings.
6.2.2.1 Model 1a: Modeling the permeation and rapid cellular binding
The compartmental model published earlier (Korjamo et al., 2007) was used as the basis
of the compartmental models (Figure 4.1).
All  the  test  compounds  included  in  this  study  have  relatively  high  transcellular
permeability. Therefore, the contribution of paracellular flux of these compounds to the
total transport is insignificant. Thus, paracellular space was omitted from the models.
The diffusion barriers at both sides of the cell monolayer consist of ABL and the cell
membrane. However, at the basal side the ABL includes also support filter in addition
to  UWL.  Furthermore,  the  UWL  is  not  likely  to  be  evenly  distributed  to  apical  and
basal sides because of the differences in compartment geometries (Ho et al., 1999;
Korjamo et al., 2008). Additionally, the apical and basolateral membranes of epithelial
cells have distinct lipid composition (Simons and van Meer, 1988) and, consequently,
they may also have distinct permeation characteristics. Thus, it would be purely
coincidental if the permeabilities through the apical and basal barriers of the cell
monolayer (Papi and Pbaso, respectively) would be equal. Therefore, it was assumed that
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permeabilities are direction and concentration independent, but not necessarily equal
for apical and basal barriers. Thus, Papi and Pbaso were fitted separately.
The cellular retention was concentration dependent (Figure 6.1). Therefore, a simple
sigmoid equation (Equation 4.5) was employed to model the concentration dependence
of the cellular distribution coefficient (K). The differential equations for mass transfer
are presented in the Chapter 4.4.
6.2.2.2 Model 1b: Modeling the lysosomal sequestration kinetics
It was assumed that bafilomycin A1 affects the propranolol kinetics only by decreasing
the pH gradient between cytosol and lysosomes. This is almost impossible to show
experimentally, but the assumption is reasonable because the presence of bafilomycin
A1 did not detectably affect the behaviour of ibuprofen or testosterone (data not
shown). Therefore, bafilomycin A1 was assumed not to affect the cytosolic
compartment.  Further,  fitting  of  too  many  parameters  simultaneously  results  in
obscure parameter estimates. Thus, the fitted permeability and cell-buffer distribution
parameters (Papi, Pbaso, Kmax, Kmin and EC50,K) were fixed to the values obtained from the
data fitting of model 1 in the presence of bafilomycin A1.
Subsequently, the distribution between cytosolic and lysosomal compartments was
described with Q12 and Q21, first order rate coefficients from cytosolic to lysosomal and
lysosomal to cytosolic compartments, respectively. However, because of the possible
concentration dependence of distribution kinetics, both, Q12 and  Q21, were fitted
separately for each concentration and direction. Schematic presentation of model 1b is
shown in Figure 4.1 and the differential equations for mass transfer in model 1b are
presented in the Chapter 4.4.
6.2.2.3 Simulations.
Model 1 was used to simulate the transfer and cellular retention of virtual test
compound in permeability experiment. In the simulations, Papi and Pbaso were set to be
500*10-6 cm/s and 200*10-6 cm/s, respectively. The cell-buffer distribution coefficient was
set to 4, 100 or 400. These values are in the range of the fitted parameter values (Table
6.1).
6.2.3 Estimation of permeability coefficients.
The apparent permeability through Caco-2 cell monolayer was estimated using three
different single barrier models described in chapters 2.5.1.1 (Equation 2.3/Papp,sink) and
2.5.1.2 (Equation 2.4/Papp,Palm and Equation 2.5/Papp,Tran). In addition to the experimental
data, simulated data at the same ‘sampling’ times than experimental data were used in
permeability estimations. Because the simulated data does not include experimental
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variation, the variation in the permeability estimates of the simulated data is neither
caused nor masked by experimental variation.
Theoretically, the permeability is the reciprocal of the permeation resistance and the
total permeation resistance of serial barriers is the sum of the individual resistances of
barriers (Flynn et al., 1974). Thus, the apparent permeability was also calculated from
permeabilities through apical and basal barriers.
Equation 6.1
6.3 RESULTS
6.3.1 Cellular retention during permeation experiments.
Ibuprofen was not significantly retained in the cell monolayer whereas cellular
retention of testosterone and propranolol was substantial (Figure 6.1 and Figure 6.2).
Further, in the presence of bafilomycin A1 the cellular retention of propranolol was
significantly reduced, whereas bafilomycin A1 did not affect the cellular retention of
ibuprofen and testosterone (data not shown).
Although, the fraction of the test compound retained in the cell monolayer varied
significantly between the test compounds, some similarities in cellular retention
profiles were observed (Figure 6.1 and Figure 6.2). Firstly, the fraction of the test
compound retained in the cell monolayer was lower with the higher concentrations,
resulting in apparently saturable cellular retention. Secondly, in apical to basal
direction the test compounds accumulated into the cells fairly rapidly and after initial
accumulation phase the amount retained in cells started to decline, whereas in basal to
apical direction experiments the test compounds gradually accumulated into the cells
for the whole duration of the experiments (90 minutes).
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Figure 6.1. The fraction of initial donor amount of (A) propranolol, (B) propranolol in the
presence of 100 nM bafilomycin A1, (C) ibuprofen and (D) testosterone retained in the cell
monolayer during Caco-2 permeation experiments (note the different scales of the vertical axes).
Closed and open symbols represent the apical to basal and basal to apical direction experiments,
respectively. Triangles, diamonds and squares denotes to low, intermediate and high
concentration, respectively. The symbols represent the average of six measurements. The error
bars are omitted for clarity, but the coefficient of variation was generally 10 % or less.
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Figure 6.2.  The time course of  1 µM (A, B) propranolol,  (C, D) propranolol  in the presence of
100 nM bafilomycin A1, (E, F) ibuprofen and (G, H) testosterone transfer in Caco-2 permeation
experiments. The symbols (solid squares and triangles for apical and basal compartments,
respectively, and open squares for cell monolayer) represent the average of 6 measurements and
the solid and dashed lines represent the fitted results of model 1 (C to H) and model 2 (A and B).
The error bars are omitted for clarity, but the coefficient of variation was generally 10 % or less.
The fitted curves mimic the observed data equally well also with the other concentrations used
(data not shown).
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6.3.2 Kinetic modelling of the solute transfer and cellular retention.
The transfer and cellular retention data were fitted to model 1a and, additionally,
propranolol data were fitted to model 1b. The fitted parameters are presented in Table
6.1 and Table 6.2.
Model 1a (cellular compartment modelled as a single kinetic compartment) was found
to mimic the transfer and the cellular retention of ibuprofen and testosterone, and also
of  propranolol  when  bafilomycin  A1  was  present.  However,  the  predicted  cellular
retention profile of propranolol without bafilomycin A1 did not follow the same profile
than the observed data (Figure 6.3). Especially in apical to basal direction at 50 µM and
300 µM the amount retained into the cells did not decline as fast as model 1 predicted.
Thus, the propranolol data were fitted also to model 1b which includes lysosomes as a
distinct kinetic compartment. In the model 1b the cytosol-to-lysosome distribution rate
coefficients were fitted individually for each experiment and the precision of rate
coefficient estimates was fairly poor, especially for basal to apical direction experiments
(Table 6.2). However, the Q12 to  Q21 ratios (estimated as secondary parameters in
WinNonlin) could be estimated more precisely and they showed clear concentration
dependency (Figure 6.4). Further, the model 1b was better to mimic the cellular
retention profile (Figure 6.3) as well as disappearance from donor and appearance to
receiver than model 1.  In addition, the fitted values for Papi were consistently higher
than the respective fitted values for Pbaso.
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Table 6.1. The fitted parameters (± SE) for propranolol in the presence of 100 nM bafilomycin
A1, ibuprofen and testosterone in model 1a
Compound
Propranolol
+ bafilomycin A1 Ibuprofen Testosterone
Papi (cm/s*10-6) 530 ±8 406 ±16 523 ±12
Pbaso (cm/s*10-6) 200 ±2 183 ±4 241 ±3
Papp (cm/s*10-6) a 145 ±1 126 ±2 165 ±1
Kmax (dimensionless) 100 ±1 20 ±1 109 ±1
Kmin (dimensionless) 44 ±1 6.2 ±0.2 30 ±1
EC50 (µM) 11 ±1 2.4 ±0.5 0.8 ±0.1
aApparent  permeability  was  estimated  as  a  secondary  parameter  in  WinNonlin,
Papp=1/(1/Papi+1/Pbaso)
Table 6.2. The fitted parameters (± SE) for propranolol in model 1a and model 1b.
Model 1a Model 1b
Papi (cm/s*10-6) 598 ± 18 530
b
Pbaso (cm/s*10-6) 200 ± 3 200
 b
Papp (cm/s*10-6) a 150 ± 2 145
 b
Kmax (dimensionless) 414 ± 14 100
 b
Kmin (dimensionless) 70 ± 2 44
b
EC50 (µM) 1.8 ± 0.2 11
 b
Q12, 1 µM AB (1/s*10-2) NA 300 ± 40
Q21, 1 µM AB (1/s*10-2) NA 1.0 ± 0.2
Q12, 50 µM AB (1/s*10-2) NA 140 ± 70
Q21, 50 µM AB (1/s*10-2) NA 2.6 ± 1.4
Q12, 300 µM AB (1/s*10-2) NA 2.1 ± 0.3
Q21, 300 µM AB (1/s*10-2) NA 0.06 ± 0.01
Q12, 1 µM BA (1/s*10-2) NA 300 ± 30
Q21, 1 µM BA (1/s*10-2) NA 0.8 ± 0.1
Q12, 50 µM BA (1/s*10-2) NA 320 ± 390
Q21, 50 µM BA (1/s*10-2) NA 6 ± 7
Q12, 300 µM BA (1/s*10-2) NA 50 ± 30
Q21, 300 µM BA (1/s*10-2) NA 2 ± 1
AIC c  1307 1056
aApparent  permeability  was  estimated  as  a  secondary  parameter  in  WinNonlin,
Papp=1/(1/Papi+1/Pbaso).
bValues taken from Model 1a in the precence of 100 nM bafilomycin A1 (Table 6.1).
cAkaike information criterion. NA, not applicable.
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Figure 6.3. The time course of cellular retention of (A, B) 1 µM, (C, D) 50 µM and (E, F) 300
µM propranolol in Caco-2 permeation experiments (note the different scales of the vertical axes).
The symbols represent the average of 6 measurements (± standard deviation). The thin and thick
lines represent the fitted results of model 1a and model 1b, respectively. The dashed and dotted
lines represent the predicted time course of propranolol in cytosolic and lysosomal
compartments in model 1b, respectively.
Figure 6.4. The concentration dependence of
lysosomal sequestration of propranolol. The
closed and open symbols refer to the estimated
ratio of flux rates between cytosolic and
lysosomal compartments (± standard error) in
apical to basal and basal to apical direction
experiments, respectively.
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6.3.3 Estimation of permeability coefficients.
Model 1a was used to simulate data for permeability estimation. The permeabilities
estimated from simulated data using Equation 2.3 (Papp,sink) increased initially and
started to decline in the later phases (Figure 6.5 A). Further, the Papp,sink values were
lower with higher K, i.e. with higher cellular retention. However, the Papp,sink values in
apical to basal and basal to apical directions at same cellular retention level were
identical. Further, Papp,sink was constantly lower than the theoretical Papp (calculated
using Equation 6.1) and also lower than the permeabilities estimated using Equation
2.4 (Papp,Palm) or Equation 2.5. (Papp,Tran).
Figure 6.5. The apparent permeabilities estimated from the simulated data using model 1 in
apical to basal direction (closed symbols, solid line) and basal to apical direction (open symbols,
dash line). Papp,sink, Papp,Palm and Papp,Tran are presented in panels A, B and C, respectively. Grey
dash line refers to the theoretical Papp calculated from Papi and  Pbaso using equation
Papp=1/(1/Papi+1/Pbaso). In the simulation Papi and  Pbaso were set to 500 and 200 cm/s*10-6,
respectively and K was set to 4 (squares), 100 (diamonds) or 400 (triangles). There were no
direction difference in Papp,sink at the same cellular retention, thus, only apical to basal direction is
shown.
Papp,Palm and Papp,Tran showed similar trends. They both take the decreased concentration
gradient into account and render accurate permeability estimates when there is no
significant cellular retention. However, cellular retention affects both Papp,Palm and
Papp,Tran. They both increased initially and reached eventually a stable level and the time
to reach the stable level was longer with higher cellular retention (Figure 6.5). Both
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Papp,Palm and Papp,Tran were consistently higher in A to B direction than in B to A direction
(Figure 6.5 B,C). These discrepancies were higher with higher cellular retention.
Further,  at  stable  level  Papp,Palm in A to B direction was always higher, and in B to A
direction always lower, than the theoretical Papp, whereas  Papp,Tran remained generally
below or at the level of Papp in both directions.
Similar trends in permeability estimates were seen when data were simulated using
model  1b.  However,  the  times  to  Papp,sink reach the maximum value and Papp,Palm and
Papp,Tran to reach the stable level were delayed when the sequestration to lysosomal
compartment was slow (data not shown).
The permeability estimates using experimental data showed similar trends than
permeability estimates of simulated data (Figure 6.6).
Figure 6.6. The apparent permeabilities of (A) 50 µM propranolol, (B) 50 µM propranolol in the
presence of 100 nM bafilomycin A1, (C) 50 µM ibuprofen and (D) 1 µM testosterone estimated
from the experimental data in apical to basal direction (closed symbols) and basal to apical
direction (open symbols). The symbols (triangles for Papp,sink, squares for Papp,Palm and diamonds
for  Papp,Tran) represent the average permeabilities and the error bars are omitted for clarity. At
late time points,  the testosterone (D) concentrations at the donor and receiver side are close to
equilibrium. Consequently, the experimental errors cause significant variation in Papp,Palm and in
Papp,Tran. Therefore, Papp,Palm and in Papp,Tran are presented only up to 60 minutes for testosterone.
Grey dashed line refers to the theoretical Papp calculated from the fitted values of Papi and  Pbaso
(Table 6.1).
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6.4 DISCUSSION
This study demonstrates the errors caused by cellular retention in permeability
estimates. Further, propranolol was observed to be significantly sequestered into the
lysosomes during Caco-2 permeation experiments. The inhibition of lysosomal
sequestration has recently been reported to increase the apparent Caco-2 permeability
(Papp,sink) of amodiaquine (Hayeshi et al., 2008b). These results suggest that the
lysosomal sequestration of basic compounds may significantly contribute to the cellular
retention of basic compounds and, thus, cause substantial errors in permeability
estimates. However, it has to be noted that all basic compounds may not be susceptible
to lysosomal sequestration (Duvvuri et al., 2004).
The fittings of model 1a suggest that cell monolayer behaves as a single kinetic
compartment for testosterone and ibuprofen, whereas for propranolol also a slow
intracellular compartment may be needed to describe the cellular retention. However,
in the presence of bafilomycin A1 a single intracellular compartment was adequate to
describe also the cellular retention profile of propranolol, although it is possible that
bafilomycin A1 does not neutralize the lysosomes completely (Yoshimori et al., 1991).
The principal driving force to lysosomal sequestration of weak bases is pH gradient
between cytosol and lysosomes (Kaufmann and Krise, 2007). However, lysosomal
sequestration of bases has been reported to cause concentration dependent elevation of
lysosomal pH (Poole and Ohkuma, 1981). Further, extensive accumulation of weak
bases, including propranolol, causes osmotic swelling of lysosomes (Ohkuma and
Poole, 1981), which may affect the surface area of the lysosomes. Thus, both the driving
force and the area available for flux between cytosolic and lysosomal compartments are
likely to be dynamic. Consequently, the distribution kinetics of weak bases between
cytosolic and lysosomal compartments is variable, depending, among other factors, on
the amount of the base in the system. Because of the complexity of the factors involved,
it is not a simple task to rigorously model the lysosomal sequestration kinetics.
Model 1b is an attempt to model the lysosomal sequestration kinetics during Caco-2
permeation experiments. Describing the flux rates between the cytosolic and lysosomal
compartments  with  first  order  rate  coefficients  is  a  rough  simplification  of  the
underlying phenomena. The cellular data in this study was based on measurements of
total cell lysates and, thus, we have no direct experimental knowledge of the test
compounds intracellular localization, which would be needed to develop a more
rigorous mechanistic model of the lysosomal sequestration kinetics. The methods to
measure the intracellular localization are reviewed elsewhere (Kaufmann and Krise,
2007). However, with the currently available methodology it would be very
challenging (if not impossible) to obtain rigorous intracellular localization data in
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permeation setting. Anyhow, two conclusions can be drawn from the current analysis.
Firstly, the clear concentration dependence seen in Q12 to  Q21 ratio (Figure 6.4), which
describes the extent of lysosomal sequestration, suggests that the capacity of lysosomes
to sequester propranolol is saturating within the concentration range used. Secondly,
although the problems in identifying the lysosomal distribution rate coefficients, the
model 2 was able to successfully mimic the total cellular retention profile of
propranolol better than model 1. Also the AIC values (Table 6.2) favour the model 1a in
describing the propranolol kinetics, suggesting that lysosomes may act as a kinetically
slow intracellular compartment and the lysosomal distribution rate may be
concentration dependent. Thus, the lysosomal sequestration of weak bases affects not
only the extent but also the rate of cellular retention.
The cellular retention profile of test compound is dependent of the direction from
where the compound enters the cell monolayer. Compartmental modeling was
employed to clarify the factors causing this behaviour. The results suggest that the
barrier at the basal side of the cell monolayer resist the flux of compounds more that
the barrier at the apical side. This seems reasonable because the barrier at the apical
side  consists  only  of  cell  membrane and unstirred water  layer,  whereas  the  barrier  at
the basal side contains additionally the filter support. Further, it has been suggested
that the resistance of unstirred water layer would lie predominantly at the basal side
because of the differential hydrodynamics (Ho et al., 1999). However, it has been
difficult to obtain experimental evidence in favor of this suggestion (Korjamo et al.,
2008).
As  expected,  using  Papp,sink, the approach that requires sink conditions to be fulfilled
constantly underestimates the permeability because the concentrations in both
compartments changes significantly during the experiments. Moreover, the estimated
permeabilities lower with lower concentration due to higher cellular retention. Further,
it is important to note that as the appearance kinetics to the receiver is irrespective of
experimental direction and because Papp,sink neglects the decline of donor concentration,
there are no direction differences in Papp,sink estimates at the same cellular retention
level.
For high permeability compounds it is expected that Papp,Palm would be a better estimate
of the permeability than  Papp,sink, since the loss of sink conditions does not cause the
Papp,Palm estimates to decline in the late phases. Also the actual concentration gradient at
the onset of the sampling interval is taken into account. However, Papp,Palm
underestimated the permeability in B to A direction for the whole time course whereas
in A to B direction permeability is underestimated only in the very early stage and
overestimated at the late stages. The errors made are higher when high amount of test
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compound is retained in the cells (Figure 6.5 and Figure 6.6) The appearance kinetics to
the receiver is irrespective of experimental direction. Thus, this discrepancy must be
caused by the difference in disappearance kinetics from the donor. The permeabilities
through apical barrier are estimated to be 2 to 3 times higher than the permeabilities
through basal barrier (Table 6.1), for the compounds used in this study. Consequently,
at the apparent steady state permeation (when the Papp,Palm has reached the stable level),
the free cellular concentration as well as amount retained in the cell monolayer follows
the concentration of the apical compartment irrespective of the direction of the
experiment. Therefore, at the apparent steady state permeation in A to B experiments
the test compound appears to the receiver side faster than disappears from the donor
side, whereas the opposite is seen in B to A experiments, ultimately causing the errors
seen in Papp,Palm. Further, it has to be noted that with compounds which are significantly
retained in the cell monolayer the time to reach the apparent steady state permeation
may be delayed significantly. Therefore, at the steady state permeation the
concentrations at the donor and receiver may already be near to equilibrium and, thus,
the concentration change within a sampling interval is small. Consequently, already
minor experimental variation causes significant variation in Papp,Palm causing the
behaviour of estimated permeabilities to be erratic.
Usually in cell permeation experiments only the appearance rate is measured whereas
disappearance rate is not observed in detail. Such data does not contain information
about the cellular retention kinetics and, thus, it is impossible to take the cellular
retention rigorously into account in permeability estimates. Anyhow, it has been
suggested that poor recovery could be taken into account in Papp,sink estimate based on
recovery calculation at a single time point, in practice at the end of the experiment
(Youdim et al., 2003). However, because the cellular retention time profiles are
concentration and directions dependent (Figure 6.1), correcting the permeability
estimates with a single time point recovery may lead into apparent concentration
dependency and directionality although the transfer of the test compound were solely
due to passive diffusion.
Sampling of both receiver and donor compartments has been suggested for more
rigorous correction for poor recovery (Tran et al., 2004). When there is no significant
cellular  retention involved (ibuprofen and simulation K=4),  Papp,Tran works perfectly in
estimating the passive permeability although sink conditions are nor maintained.
However, when significant cellular retention is involved (propranolol, testosterone and
simulations K=100 and K=400), this approach encounters similar type of errors than
another single barrier approach Papp,Palm (Figure 6.5 and Figure 6.6). More the
compound is retained in the cells larger is the apparent direction dependence of
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permeability. Papp,Tran is based on assumption of a single barrier and the amount of
compound lost (due to any mechanism) from the solutions is assumed to 'vanish' from
the system and, thus, assumed not to contribute to the transfer by any means. If this
assumption would strictly hold true, it would mean that if the solution at the both
apical and basal compartments would be replaced with fresh buffer, none of the
compound retained in the cells would flux out from the cells. There are several
examples in the literature showing that this is not usually true if  metabolism or other
degradation of the compound is not involved (Ho et al., 1999). When the amount of
compound retained in the cells is affecting the transfer, the cellular 'volume of
distribution' and the amount of compound in the cell  monolayer should be taken into
account to obtain correct ‘average system concentration’ <C>. However, taking the
cellular compartment into account in <C> calculation would not be applicable to single
barrier model the rest of the calculations are based on.
The data shown in this report suggests that considering the cell monolayer as a single
barrier is in some cases an over simplified view even when studying passive transfer of
the  solutes  through the  cell  monolayer.  Further,  flaws of  applying single  barrier  view
in mechanistic studies, such as studies to elucidate active transporter function, have
recently been reported (Bentz et al., 2005; Korjamo et al., 2007; Sun and Pang, 2008).
Thus, it seems evident that more sophisticated data analysis and interpretation
approaches than traditional single barrier view should be employed when detailed
insight into solute transfer is to be obtained.
Often in cell monolayer permeation studies the conclusions are drawn based on the
assumption that the cell monolayer is a single barrier which does not significantly
retain the compound studied. This approach has been shown to be applicable for
screening for transporter interactions (Polli et al., 2001) and prediction of intestinal
absorption of passively absorbed compounds (Artursson et al., 2001). However, it has
been suggested that as good predictions of intestinal absorption of passively absorbed
compounds can be obtained even by computational methods (Linnankoski et al., 2008).
The use of the cell monolayer permeability studies to predict the in vivo absorption
have been justified with the presence of relevant transfer routes, which are absent in
artificial membranes and are not necessarily taken into account in computational
approaches, such as paracellular space and active transporters (Artursson et al., 2001).
However, the relative role of different transfer routes in in vitro cell models tend to
differ from the in vivo setting. Therefore, successful scaling from in vitro data to in vivo
setting is likely to require detailed mechanistic insight.
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7 Distribution of permeation
resistance in in vitro cell
permeation experiments3
Abstract. The results of cell monolayer permeation experiments are often affected by
concentration dependent cellular processes, such as active transport and metabolism.
The rigorous analysis of the concentration dependence of these processes is often
limited by the lack of knowledge of the actual concentration at the site of action
because the measurement of the local concentration is seldom feasible. However, the
local concentrations can be estimated if the rates into and out of a particular location
are known. Thus, an insight into the distribution of the permeation resistance in the in
vitro cell monolayer permeation experiments would enable the estimation of local
concentrations during the permeation experiments and, consequently, a more thorough
analysis of the concentration dependent processes involved in the transepithelial
transfer of compounds. In this study, a compartmental model was constructed
applicable for dissecting the roles of apical and basal side aqueous boundary layers and
the cell membranes in the total permeation barrier for weakly acidic and basic
compounds. The model was applied for the analysis of the Caco-2 permeation data of
three high permeability compounds, propranolol, metoprolol and ibuprofen.
Furthermore, the effects of extracellular pH and the agitation conditions on the local
concentrations of these compounds were evaluated.
3 Adapted from: Heikkinen A.T., Mönkkönen J., Korjamo T.: Determination of permeation
resistance distribution in in vitro cell monolayer permeation experiments. Eur J Pharm Sci 40:
132-142, 2010. © 2010 Elsevier B.V. All rights reserved.
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7.1 INTRODUCTION
Mechanistic cell permeation studies are often focused on some concentration
dependent  mechanism(s)  involved  in  the  transfer  of  the  studied  compound,  such  as
active transport and/or metabolism. The site of action is rarely ever in the bulk phase of
the donor or receiver compartment in such studies. Rather, the site of action lies at
some specific cellular substructure, such as on the cell surface for uptake transporters
(Balakrishnan et al., 2007), within the inner leaflet of the cell membrane for efflux
transporters (Ambudkar et al., 2006) or at the endoplasmic reticulum for cytochrome
P450 enzymes (Szczesna-Skorupa and Kemper, 2008). Although the location of the site
of action is often known, the local substrate concentration is usually not readily
measurable from intact cells. Consequently, the initial donor concentration is often
used as a surrogate for the true local concentration (Maier-Salamon et al., 2006;
Troutman and Thakker, 2003a). In the permeation setting, there is a concentration
gradient from the donor to the receiver chamber and the cellular structures are
downstream from the donor compartment. Furthermore, in practice the donor
concentration always declines during the permeation experiment to some extent. Thus,
the use of initial donor concentration in kinetic analyses biases the results because
intracellular and extracellular concentrations are neither constant nor in constant
proportion to each other during the whole experiment. On the other hand, the
concentration of the compound studied at any location during the experiments is
dictated by the ‘rate in’ to and the ‘rate out’ from the particular site. Consequently,
theoretically the local concentration can be estimated without direct measurements if
the above mentioned rates are known.
The permeation barrier in the cell monolayer permeation experiments consists of
several individual barriers; the ABLs and the cell membranes at both apical and basal
sides of the cell cytosol (Figure 2.2). Consistent to the low fluidity of the exofacial leaflet
of the apical cell membrane (Lande et al., 1995; Simons and van Meer, 1988), early
reports suggest that for low permeability compounds digoxin and vinblastine (Ito et al.,
1999) and the ciprofloxacin derivative, CNV 97100 (Gonzalez-Alvarez et al., 2005) the
passive permeability across the permeation barrier at the apical side is less than that
across the barrier at the basal side. In contrast, the results presented in the Chapter 6
suggested that the total passive permeation barrier at the basal side is two to three
times greater than the barrier at the apical side for high permeability compounds
propranolol, ibuprofen and testosterone. The ABL is a significant part of the
permeation barrier for the high permeability compounds (Korjamo et al., 2009).
Therefore, the distribution of permeation resistance for high permeability compounds
into apical and basal sides of the cell monolayer is more likely to reflect the distribution
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of ABL than the differential permeabilities through the apical and basolateral cell
membranes. Thus, it seems that the distribution of the permeation barrier to the apical
and basal sides depends both on the compound, apparatus used for the experiments
and on the experimental conditions.
Several experimental approaches have been proposed to distinguish the permeation
resistance of ABL from the resistance of the biological or artificial barrier of interest
(reviewed in Korjamo et al., 2009). However, generally these methods are not able to
distinguish the distribution of the ABL and cell monolayer into the apical and basal
components.  Thus, often some simplified assumption of the distribution of permeation
barrier is applied. For example, ABL can be totally neglected and the permeability
through both apical and basal cell membranes is assumed to be equal (Sun et al., 2008)
or ABL may be postulated either to be negligible on the basal side because there is an
extensive sink in the basal compartment or to be equally distributed into apical and
basal sides (Nielsen and Avdeef, 2004). Furthermore, there is only one study reported
in which the dissection of the distribution of UWL into apical and basal components
has been attempted experimentally (Korjamo et al., 2008). However, in that study the
cell monolayer was modeled as a single barrier. Thus, the analysis did not enable direct
estimation of the intracellular concentrations or the local concentrations at the surfaces
of the cell monolayer. Consequently, the results cannot be directly used for mechanistic
analysis of concentration dependent processes, such as metabolism or active transport.
Compartmental model based analysis, without discrimination of ABLs from cell
membranes, has been applied for estimating the distribution of the permeation barrier
into the apical and basal components (Gonzalez-Alvarez et al., 2005; Ito et al., 1999). On
the other hand, the so called pH shift method exploiting the different cell monolayer
permeation, but similar ABL permeation characteristics of the ionized and unionized
species has been applied for estimation of the distribution of the permeation barrier
into the ABL and cell monolayer (Avdeef et al., 2005; Korjamo et al., 2009). However,
apical and basal components were not discriminated. In this study these two
approaches were combined in order to estimate the distribution of the permeation
resistance into four components; apical and basal side ABLs and cell membranes. A
compartmental model accounting for the cell membranes and apical and basal ABLs
individually was constructed and used to analyze our earlier in vitro Caco-2
permeation data (Korjamo et al., 2008). This modeling exercise was conducted in order
to assess the suitability and robustness of a compartmental modeling approach for
estimating the relative contributions of individual barriers in the total permeation
barrier. Additionally, the compartmental model constructed was further exploited to
explore the effects of extracellular pH and agitation conditions on the distribution of
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the permeation resistance in Caco-2 monolayer permeation experiments and the
consequent effects on the estimated intracellular and cell surface concentrations.
7.2 MATERIALS AND METHODS
7.2.1 Experimental data
The experimental data were taken from (Korjamo et al., 2008). Briefly, the permeation
experiments to both directions at four different pH values (5.8, 6.5, 7.0 and 7.4) and at
four different shaking rates (250 rpm, 320 rpm, 370 rpm and 420 rpm) with and without
vigorous magnetic stirring at the basal chamber were conducted using Caco-2
monolayers on an orbital shaker with orbit diameter of 1.5 mm (Titramax 1000,
Heidolph, Germany). For clarification, in this text the terms shaking and stirring refer
to the planar orbital shaking of the Transwell plate and to the magnetic stirring at the
basal chamber, respectively, whereas the term agitation is used as a more general term
covering both shaking and stirring. The studied compounds (atenolol, antipyrine,
ibuprofen, metoprolol, propranolol and verapamil) were dosed as a mixture, each at 50
µM initial donor concentration. Atenolol was used as a cell monolayer integrity control
in the study and the concentrations at the receiver compartment in successful
experiments were partially below or at the detection limit. Thus, the atenolol data was
not included in the analysis. The method applied to estimate aqueous boundary layer
permeability is based on the change of ionization of the compound as a function of pH.
Since the charge state of antipyrine is virtually zero throughout the entire pH range
used, antipyrine data could not be used for this analysis.  Earlier analysis of verapamil
data pointed to apically directed active transport of verapamil (Korjamo et al., 2008).
The compartmental model applied in this study assumes only passive diffusion based
transfer of the compounds. Thus, the verapamil data was also omitted from the current
analysis.
7.2.2 Kinetic modeling
Model 2 was applied for the analysis of the data, i.e. the disposition of the compounds
in the cell monolayer permeation experiments was modeled as movement of the
compound between five consecutive compartments; apical bulk, apical ABL, cell, basal
ABL and basal bulk (Figure 4.1). The results reported in the Chapter 6 revealed that the
cellular  retention  may  be  saturable.  However,  current  data  was  only  from  single
concentration experiments. Therefore, the data did not allow for fitting the
concentration dependence of the cellular retention. Consequently, K was assumed to be
concentration independent.
Due to differences in the apical and basal cell membrane composition (Simons and van
Meer, 1988), the permeabilies through apical and basal cell membranes may differ from
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each other. However, current data did not allow rigorous fitting apical and basal of cell
membrane permeabilities separately (data not shown). Thus, for final model fitting
both Pi and Pu were constrained to be equal across the apical and basal cell membranes.
7.2.3 Simulations and estimation of model parameters
The permeability and cellular distribution parameters were estimated by fitting the
compartmental model individually to the data sets from different agitation schemes
(each dataset containing data from experiments at 4 different pH values in both
directions) using WinNonlin software, version 5.2.1 (Pharsight, Mountain View, CA) to
estimate the permeabilities through the cell membranes and cellular distribution
coefficients of propranolol, metoprolol and ibuprofen and the apical and basal ABL
thickness at the different agitation schemes. A weighting scheme 1/predicted2 was
chosen for all data fittings based on residual plots (Figure 7.1) and S.E. of the parameter
estimates. Otherwise, the default WinNonlin settings for minimization of error were
applied.
Simulated concentrations from the best fits to the data were used to explore the
estimated concentrations at the cell surfaces and within the cell cytosol during the
experiments at different experimental conditions.
Figure 7.1. Comparison of observed and
predicted concentrations. Results from model
fit to ibuprofen data at 250 rpm shaking rate
with the basal magnetic stirring are shown as
representative plots. A) Time profiles of
observed (average ± SD) and predicted
concentrations at pH 6.5 into both directions
are presented. Also data at other pH values
were used in the same model fit but were
omitted from this plot for clarity. B) Observed
vs. predicted concentrations. Dashed lines
depict the 1.5 fold error interval. C)
Distribution of weighted residuals.
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7.3 RESULTS
7.3.1 Estimation of the cell membrane permeabilities, cellular distribution
and the effects of agitation on the ABL thickness
The  five  compartment  model  constructed  was  able  to  mimic  the  observed
concentration profiles.  In total, more than 85% and 97% of the observed concentrations
were within 1.2 fold and 1.5 fold error intervals, respectively. Comparison of observed
and predicted concentrations of a typical model fit is visualized in Figure 7.1.
As expected, the estimated cell membrane permeability of unionized species of all
model compounds were significantly (2 to 4 orders of magnitude) higher than the cell
membrane permeability of the corresponding ionized species (Figure 7.2).
Furthermore, generally the best fit estimates of cell membrane permeability (Figure 7.2)
or the cellular distribution coefficients (Figure 7.3) remained unaffected by the agitation
applied. However, the estimates of cell membrane permeability ionized metoprolol as
well as the cellular distribution coefficient of ibuprofen showed substantial variations.
On the other hand, despite the considerable variation in the estimates the agitation
applied exerted clear effects on the operational ABL thickness on both sides of the cell
monolayer (Figure 7.4). Furthermore, the trends of ABL thickness were similar for all
compounds studied. However, the estimated ABL thickness was generally slightly
higher for metoprolol than for propranolol and ibuprofen. Without basal magnetic
stirring, the ABL thickness decreases with higher shaking rates at both apical and basal
sides. However, in the presence of basal magnetic stirring, the increase in shaking rate
did not decrease the basal ABL. In contrast, the estimated basal ABL thickness was
slightly higher at 420 rpm than with the lower shaking rates. Furthermore, the basal
magnetic stirring did not exert any clear effects on the apical ABL thickness, whereas
the basal ABL thickness was generally lower in the presence than in the absence of
basal magnetic stirring. Overall, the operational ABL thickness, and consequently the
ABL permeability, without basal magnetic stirring seem to be at an approximately
similar level on both sides of the cell  monolayer.  However, due to the presence of the
support filter, the ABL lies more at the basal side with higher than with lower shaking
rates.
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Figure 7.2. Permeabilities through the cell
membranes (± S.E. of the estimate) of
unionized (black) and ionized (grey) species of
propranolol (A), metoprolol (B) and ibuprofen
(C) estimated separately at each agitation
scheme. Solid symbols/solid lines and open
symbols/dashed lines refer to experiments
without and with basal magnetic stirring,
respectively.
Figure 7.3. Cellular distribution coefficients (± S.E. of the estimate) of propranolol (triangles),
metoprolol (squares) and ibuprofen (diamonds) estimated separately at each agitation scheme.
Solid symbols/solid lines and open symbols/dashed lines refer to experiments without and with
basal magnetic stirring, respectively.
Figure 7.4. The estimated operational ABL thicknesses  (± S.E. of the estimate) at apical (A) and
basal (B) sides at different agitation schemes for propranolol (triangles), metoprolol (squares)
and ibuprofen (diamonds). Solid symbols/solid lines and open symbols/dashed lines refer to
experiments without and with basal magnetic stirring, respectively.
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7.3.2 Effects of extracellular pH and shaking rate on the free cellular and cell
surface concentrations during the cell permeation experiments
The simulated free intracellular and cell surface concentrations at different extracellular
pH and shaking conditions were taken from the best fits of the model to the
corresponding experimental data.
According to the simulations the cellular free concentrations of all model compounds
reach approximately half of the initial donor concentration level at pH 7.4, when there
is no pH gradient across the cell membranes (Figure 7.5). In contrast at a lower
extracellular pH values, the basic metoprolol is rejected from the cytosol whereas acidic
compound, ibuprofen is sequestered into the cytosol, resulting in low free cellular
metoprolol concentrations and high free cellular ibuprofen concentrations at pH 5.8.
Consequently, at low extracellular pH the metoprolol concentration in receiver
compartment exceeds the intracellular free concentration during the late phases of the
experiment, whereas the intracellular free ibuprofen concentration exceeds both the
receiver and donor concentrations (Figure 7.5 and Figure 7.6). A change in the shaking
rate affects the time profile of cellular concentration, but exerts only minor effect on the
average cellular concentration level. Propranolol, the other basic model compound
used, displayed a similar trends as seen with metoprolol (not shown).
Figure  7.5.  Simulated  cellular  free  concentrations  of  metoprolol  (A)  and  ibuprofen  (B)  in  250
rpm (grey lines) and 420 rpm (black lines) apical to basal direction experiments at different
extracellular pH values. pH 5.8 thin solid line, pH 6.5 thin dashed line, pH 7.0 thick solid line
and pH 7.4 thick dashed line. The cellular free concentrations reach approximately half of the
initial donor concentration at pH 7.4, when there is no pH gradient across the cell membranes.
At lower extracellular pH values the pH gradient across the cell membranes rejects the basic
metoprolol from the cytosol and sequesters the acidic ibuprofen into the cytosol, resulting in low
and high cellular metoprolol and ibuprofen concentrations at pH 5.8, respectively. The change
in  stirring  rate  affects  the  time  profile  of  the  cellular  concentration  but  causes  only  a  minor
effect on the average cellular concentration level.
The effects of shaking rate and extracellular pH on the concentrations at the cell
surfaces are illustrated in Figure 7.6. The concentration gradient across the cell
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monolayer (from the cell surface to another) becomes smaller with a higher
permeability through the cell monolayer, i.e. at high pH values for basic metoprolol
and propranolol and at low pH for ibuprofen. Consequently, also the concentration
difference between the bulk phase and the corresponding cell surface is more
pronounced when the permeability through the cell monolayer is high. On the other
hand,  the  concentration  difference  between  bulk  phase  and  the  corresponding  cell
surface decreases as the shaking rate increases, whereas the concentration gradient
across  the  cell  monolayer  increases  slightly.  Similar  trends  were  observed  also  in  the
simulations of the propranolol and ibuprofen concentrations and also in the basal to
apical direction experiments (not shown).
Figure 7.6. Simulated metoprolol concentrations at different locations during 250 rpm (A,B)
and 420 rpm (C,D) apical to basal direction experiments at pH 5.8 (A,C) and pH 7.4 (B,D).
Black and grey lines refer to bulk phases and cell surfaces, respectively. Solid and dashed lines
represent the concentrations at the apical and basal sides of the cell monolayer, respectively. The
thin line is the simulated cellular free concentration. The concentration gradient across the cell
monolayer (from apical to basal cell surface) becomes smaller as the permeability through the cell
monolayer becomes higher, i.e. at high pH values for the basic compound, metoprolol. The
concentration gradient between the bulk phase and the corresponding cell surface becomes
smaller with a higher stirring rate.
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7.4 DISCUSSION
The present study evaluated the feasibility and robustness of compartmental model
based data analysis to determine the distribution of the permeation resistance in in vitro
cell permeation experiments. The five compartment model developed was further
exploited to estimate the local concentrations at the cell surfaces as well as in the
intracellular compartment during the time course of the experiments.
Theoretically, the cellular permeation and distribution should be independent of the
agitation applied whereas the thickness and distribution of ABL are expected to be
dependent on the agitation applied. On the other hand, ABL thickness and distribution
should be similar for these similar sized molecules (Table 4.1) (Yu and Sinko, 1997),
whereas the cellular permeation and distribution characteristics would be expected to
be compound specific. Consequently, more accurate estimates of different parameters
would be expected if all the available data were utilized in a single model fit, i.e. by
fitting the model simultaneously to all data sets and estimating only one value for cell
related parameters (Pu,  Pi and K) for each compound and single values for apical and
basal ABL thickness for each agitation scheme. Also, utilization of non-linear mixed-
effects modeling approach could enable inclusion of covariate factors, such as shaking
rate or molecule properties into the model and quantitative analysis of the effects of
these covariates. However, there were two reasons why the parameter estimation was
conducted individually for each compound at each agitation scheme rather than
estimating the ‘global’ best fit values based on all the data sets: 1) For practical reasons,
further applications of the approach used for the parameter estimation should not
require such an extensive amount of experimental data as was conducted in this study.
Consequently, one of the main goals of this study was to assess the robustness of the
compartmental model based data analysis in the determination of the distribution of
permeation resistance into apical and basal ABL and cell membranes in in vitro cell
permeation experiments. 2) The amount of differential equations and data points
handled  simultaneously  is  limited  in  WinNonlin  software  thus  creating  a  practical
limitation for the model complexity and the amount of data used for simultaneous
fitting when this software is used.
In general, the parameter estimates followed the above mentioned expectations: the
parameters describing the cellular permeation and distribution (Pu, Pi and K) remained
generally fairly stable and were not affected by the agitation applied (Figure 7.2 and
Figure 7.3) whereas the ABLs were clearly dependent on the agitation. This suggests
that the current five compartment model is able to distinguish the ABL and cell
monolayer related processes from each other. The estimated distribution of ABL and
UWL into apical and basal sides of the cell monolayer follows the same general trends
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than obtained in the earlier analysis of these data (Korjamo et al., 2008). The ABL
resistance  is  at  an  approximately  similar  level  on  both  sides,  but  the  contribution  of
UWL decreases with high shaking rates whereas the filter permeability is unaffected.
Thus, an increase in orbital shaking rate of Transwell plate will decrease more
efficiently the apical than the basolateral ABL. Furthermore, the operational ABL
thickness at the basal side in the presence of basal magnetic stirring is generally in the
level of <100µm. This is in accordance with the calculated permeability through the
filter support (Korjamo et al., 2008), which would respond to approximately 80µm of
operational ABL thickness. Additionally, this result also confirms the ability of our five
compartment model to estimate the magnitude and distribution of ABL. However,
there was considerable variation in some of the parameter estimates, which is probably
partly a consequence of the fact that the experimental data used was obtained from an
earlier  study  and,  thus,  the  experimental  setup  was  not  designed  for  the  purposes  of
the current analysis approach. In the compartmental model based analysis, the
experimental data needs to contain information about the time profile of the compound
transfer in each compartment included in the model; i.e., when there are no direct
measurements of cellular retention available, the information about the concentration
time  profile  in  cellular  compartment  is  based  on  the  recovery  of  the  drug  from  the
aqueous compartments. Therefore, it would be advantageous if the cellular retention
time profile would be readily observable from the recovery. However, the original data
analysis and interpretation of this data set was based on the determination of apparent
permeability (Papp)  through  the  whole  barrier  at  several  experimental  conditions
(Korjamo et al., 2008). Poor recovery and variation in the recovery may disturb the Papp
estimates (Hubatsch et al., 2007; Youdim et al., 2003). Therefore, the effects of cellular
retention on the permeability estimates were minimized in the current experimental
setting with a 5 minute initial accumulation phase into the cells before application of
the receiver buffer (Korjamo et al., 2008). Consequently, there were no major changes in
the recovery after the initial accumulation phase, which makes the compartmental
model based analysis more vulnerable to experimental variation.
Although the current model was able, to some extent, to estimate the distribution of
ABL into apical and basal sides of the cell monolayer, it was not able to distinguish the
permeability coefficients through apical and basal cell membranes. The attempts to fit
separate permeability values for apical and basal cell membranes resulted in similar
permeability coefficients  through both membranes accompanied by increased
uncertainty and greated variation in the parameter estimates (data not shown).
Consequently, in model fitting the permeabilities through apical and basal cell
membranes were constrained to be equal. This contrasts to the generally accepted
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assumption that the apical cell membrane is the primary barrier for transcellular
permeation (Lennernäs, 2007), which is supported by the lower fluidity of the exofacial
leaflet of the apical cell membrane (Lande et al., 1995) as well as the compartmental
model based analysis of cell monolayer permeation kinetics of the low permeability
compounds digoxin, vinblastine and CNV 97100 (Gonzalez-Alvarez et al., 2005; Ito et
al., 1999). The failure to distinguish apical and basal cell membrane permeabilities may
partly be related to the above discussed suboptimal experimental design for current
analysis. However, similar results were obtained also for another high permeability
compound, quinidine (Chapter 8), indicating that more thorough sampling from
aqueous compartments does not solve this problem. Furthermore, analysis of the
passive efflux rate of the highly permeable lipid antioxidant, U-78517F from MDCK
cells suggested that the permeabilities through the apical and basal cell membranes are
equivalent (Raub et al., 1993). Thus, a more plausible explanation for indistinguishable
apparent permeability of high permeability compounds through the apical and basal
cell membranes may be traced to the intracellular permeation and distribution kinetics.
The current model assumes that the space between the cell membranes is well stirred
without any resistance to compound transfer. For low permeability compounds, the
relative permeation resistance of cytosol is likely to be negligible whereas for high
permeability compounds, such as the molecules used in this study, the cytosol may
represent a more significant part of the permeation barrier. If one assumes that the
permeation barrier of cytosol is equal to a 20 µm thick water layer in between the cell
membranes (equal to thickness of Caco-2 cell monolayer) it can be approximated that
the proportion of cytosol in the total permeation resistance of the cell monolayer is 5-
25% for the compounds used in this study (see sub-chapter 7.5 for the calculations).
However, the viscosity of the cell cytosol is likely to be higher than that of bulk water
(Luby-Phelps, 2000) and, thus, the role of cytosol in the cellular permeation barrier may
be even more prominent. Nonetheless, it should be noted that effectively the overall in
vitro permeation for such rapidly transported compounds is primarily controlled by
ABL. Additionally, analysis of propranolol and metoprolol data may be confounded by
lysosomal  sequestration  of  these  compounds.  The  previous  analysis  of  the  cellular
retention kinetics of propranolol indicated that acidic cellular compartments such as
lysosomes may behave as a ‘slow’ kinetic cellular compartment (Chapter 6). However,
the current data do not include direct measurements of cellular retention and, thus, do
not provide sufficient information about the cellular retention profile to allow inclusion
of an additional cellular compartment into the model. Consequently, the possible
effects of lysosomal sequestration on the cellular distribution kinetics are neglected.
Thus, in the case of high permeability compounds, the Pu and Pi estimates may reflect
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not only the permeability through the cell  membranes but may also be limited by the
permeation and distribution kinetics within the cells.
Although intracellular kinetics may limit the cell membrane permeability estimates, the
Pi estimates, especially of ibuprofen and propranolol, were much higher than the
paracellular permeability of mannitol suggesting that the ionized species of these
molecules are able to permeate the cell membranes. The pH partition hypothesis
suggests that only unionized molecules are able to diffuse through the cell membranes.
Thus, our results do not agree with the pH partition hypothesis. The apparent
transcellular permeability of ionized species in Caco-2 experiments has also been
reported by others (Avdeef et al., 2005), though the exact mechanism underlying these
findings remains to be clarified. The ionized species of lipophilic compounds have been
shown to be able to distribute into artificial lipids and, thus, it has been suggested that
passive diffusion based permeation of ionized molecules could contribute to membrane
permeability (Austin et al., 1995; Duvvuri et al., 2004). Furthermore, there are also
experimental results suggesting lipid bilayer permeability of anionic forms of weak
acids has been reported (Thomae et al., 2005). However, these results are controversial
and it has been suggested that they arise from an experimental artifact (Saparov et al.,
2006). On the other hand, although there were no signs of polarization of transport
through the whole cell monolayer, the possible involvement of transporters in the
current study cannot be ruled out. It has been suggested that cell membrane
permeation of ionized forms of metoprolol and propranolol is mediated by the organic
cation transporter OCT2 rather than passive diffusion (Dudley et al., 2000).
Furthermore, uptake experiments with Xenopus laevis oocytes have suggested that
ibuprofen can inhibit the monocarboxylic acid transporter 1 (MCT1) mediated
transport of lactic acid and OAT1 mediated transport of para-aminohippurate and,
thus, it was proposed that ibuprofen might be transported by these proteins
(Apiwattanakul et al., 1999; Tamai et al., 1995). Since there is some evidence for
expression of these transporters in Caco-2 (Ahlin et al., 2009; Hilgendorf et al., 2007), it
is possible that their involvement has interfered with the current results.
The  five  compartment  model  based  data  analysis  allows  estimation  of  the  free
concentration inside the  cell  monolayer  as  well  as  at  both cell  surfaces  when only  the
bulk phase concentrations are measured (Figure 7.5 and Figure 7.6). However, due to
above discussed limitations and uncertainties in estimating the contributions of
different permeation barriers the estimates of local concentrations should be considered
only as approximations. Nonetheless, these estimates are believed to follow the trends
of the actual local concentrations and, thus, are likely to represent a better basis for
analysis of concentration dependent cellular processes than the traditionally applied
69
initial donor concentration approach. Furthermore, the simulations highlight
significant difference in the free intracellular concentrations of weak bases compared to
weak acids when there is a pH gradient across the cell membranes (Figure 7.5). Since
there is a pH gradient across the apical cell membrane in the intestine in vivo (acidic
intestinal lumen vs. approximately neutral enterocyte interior) (Avdeef, 2003), this may
have significant implications on the interpretation of concentration dependent
intracellular processes observed in in vitro permeation experiments as well as on the
extrapolation of these processes to the in vivo situation.
To conclude, this study demonstrated the applicability of compartmental models for
the analysis of the permeation resistance distribution and as a way to estimate the local
concentrations in in vitro cell permeation experiments. Furthermore, the compartmental
model used can be further developed to incorporate other drug disposition
mechanisms, such as active transport and metabolism. However, current analysis
underlines the importance of high quality data and good experimental design when
compartmental models are applied for data analysis. In addition, the limitations of
using the experimental data to justify and estimate the parameters describing the
mechanistic detail embedded in the model were demonstrated. Compartmental models
will invariably represent simplifications of the system being modeled and, thus,
dynamically  minor  mechanisms  are  not  described  in  detail.  Consequently,  critical
inspection  of  the  underlying  mechanisms  is  crucial  for  rigorous  interpretation  and
application of the results obtained.
7.5 APPENDIX: APPROXIMATION OF THE PROPORTION OF CYTOSOL
IN THE PERMEATION RESISTANCE OF CELL MONOLAYER
In the five compartment model used for analysis of the experimental data, the
permeation through the cell monolayer was modeled as the passive permeation of
ionized and unionized species through the cell membranes. The permeation barrier of
the cell monolayer was assumed to consist of only apical and basal cell membranes,
whereas the possible permeation barrier caused by the space in between the apical and
basal cell membranes (i.e. cytosol) was neglected. Although the space in between the
apical and basal cell membranes contains several other structures and is not only
cytosol,  for simplicity,  in this text,  the word cytosol refers to the space in between the
apical and basal cell membranes unless indicated otherwise. However, when
membrane permeability is high, it is possible that the cytosol constitutes a significant
part of the cellular permeation barrier. The calculations to estimate the proportion of
the cytosol in the permeation resistance of the cell monolayer are derived in this
supplement. First, the total pH dependent cellular permeation resistance (Rcell) of each
compound is calculated from the cell membrane permeability values of the ionized (Pi)
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and unionized (Pu) species estimated by the five compartment model based analysis
presented in the actual research report. Second, the permeation resistance of the cytosol
(Rcyto) is estimated assuming that the cytosol is an aqueous space with the thickness
equal to cell monolayer height. Finally, the proportion of the permeation barrier
attributed to the cytosol (Rcyto%) is calculated from the estimated Rcell and Rcyto.
7.5.1 Calculation of Rcell from experimental data
The effective permeability for each compound through the whole cell monolayer (Pcell)
is calculated from the average of the best fit values Pi and Pu from the fitting of the five
compartment model.
First, let C1,  C2,  C3 and C4 be the concentrations at the donor side cell surface, cytosol
facing donor side cell membrane, cytosol facing the receiver side cell membrane and
receiver side cell surface, respectively (Figure 7.7). Pi and  Pu values used for
calculations are estimated using the five compartment model neglecting the cytosolic
concentration gradient. Thus, C2 is  assumed to equal C3. Subsequently let J1 and J2 be
the flux rate of the compound from the donor to the cellular and from the cellular to the
receiver compartments, respectively (Figure 7.7).
Equation 7.1
Equation 7.2
At steady state, the flux rate across each individual barrier equals the flux rate across
the whole cell monolayer; therefore,
Equation 7.3
By combining Equation 7.1, Equation 7.2 and Equation 7.3 and setting Ccell=C2=C3, we
obtain
Equation 7.4
Subsequently, the cellular concentration can be solved
Equation 7.5
Thus, the flux rate through the whole cell monolayer is
Equation 7.6
Thus, the effective permeability through the cell monolayer is
Equation 7.7
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The Pcell estimates at different extracellular pH ( Table 7.1) are generally at similar level
with the values reported earlier in the literature (Korjamo et al., 2008).
Figure 7.7. Schematic representation of the concentration gradient within the cell monolayer.
The dotted line represents the approximated concentration profile based on the assumptions of
the five compartment model used to analyze the experimental data; the cytosol is assumed to be a
well stirred space and, thus, the cytosolic concentration facing the donor side cell membrane (C2)
is assumed to equal the cytosolic concentration facing the receiver side cell membrane (C3). The
cell membrane permeability values for ionized and unionized species estimated using this model
were used for estimation of the total cellular permeation resistance (Rcell). The dashed line
represents the approximated concentration profile when the cytosolic permeation resistance is
accounted for, i.e. there is a concentration gradient in between the C2 and C3. This approach was
used in order to estimate the cytosolic permeation resistance (Rcyto).
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 Table 7.1. The estimated permeabilities across the Caco-2 monolayer
Metoprolol Propranolol Ibuprofen
Pu (cm/s * 10-6) a 110000 260000 110000
Pi (cm/s * 10-6) a 11 100 320
pKa 9.56 9.53 4.45
Daq (cm2/s *10-6) 7.91 7.80 7.90
Rcyto% b 10 % 26 % 6 %
pH  5.8  fu 0.017 % 0.019 % 4.276 %
Pcell (cm/s * 10-6) c 15 74 2500
pH  6.5  fu 0.087 % 0.093 % 0.883 %
Pcell (cm/s * 10-6) c 53 170 640
pH  7.0  fu 0.275 % 0.294 % 0.281 %
Pcell (cm/s * 10-6) c 160 430 310
pH  7.4  fu (= fu,cell) 0.687 % 0.736 % 0.112 %
Pcell (cm/s * 10-6) c 380 1000 220
a The average of best fit estimates of the permeabilities of unionized and ionized species
across the cell membrane
b The estimated proportion of the cytosol in the cellular permeation barrier is independent
of extracellular pH. Calculated according to Equation 7.17
c The apparent permeability across the cell monolayer. Calculated according to
Equation 7.7
The permeation resistance is defined as the reciprocal of permeability (Flynn et al.,
1974), consequently the permeation resistance of the cell monolayer is
Equation 7.8
7.5.2 Calculation of Rcyto from theoretical considerations
The permeation resistance of the jth barrier in the series of barriers is
Equation 7.9
where hj is the thickness of the of the jth barrier, Dj is the diffusion coefficient within the
jth barrier and Kj represent the distribution coefficient to the jth barrier in respect to the
external phase (Flynn et al., 1974). For the approximation of cytosolic permeation
resistance, it is assumed that the diffusion rate in the cytosol equals the diffusion rate in
water and the thickness of the cytosol is equal to the height of the Caco-2 cell
monolayer (20 µm). The effective distribution coefficient between the cytosol and the
extracellular aqueous phase at donor or receiver (Kcell,1 or Kcell,2, respectively) is assumed
to be constant throughout the experiment and, thus, equal to the distribution at
equilibrium. At equilibrium, the effective flux rate J equals zero, i.e.
Equation 7.10
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Equation 7.11
where uP  and iP are the permeabilities of unionized and ionized species through the
donor side cell membrane when the cytosolic concentration gradient is accounted for
whereas uP
~ and iP
~  refer to permeabilities through the receiver side cell membrane,
respectively. Consequently,
Equation 7.12
Equation 7.13
The ratio of cell membrane permeabilities of ionized and unionized species is assumed
to equal the ratio of Pi and Pu estimated using five compartment model, i.e.
Equation 7.14
This is a reasonable approximation, because if ui PP  would be significantly different
than ui PP
~~  it would result in polarization of the transcellular flux in the presence of a
pH gradient across the cell membranes,  whereas there were no indications of this kind
of polarization of the transcellular flux in the experimental data.
By combining Equation 7.12, Equation 7.13 and Equation 7.14 we obtain
Equation 7.15
Thus, the effective distribution coefficient between the extracellular aqueous phase and
the cytosol is dictated by the ionization states of the compound in the extracellular and
cytosolic compartments and the ratio of cell membrane permeabilities of ionized and
unionized species.
By combining Equation 7.9 and Equation 7.15, the permeation resistance of the cytosol
is estimated to be
Equation 7.16
7.5.3 Calculation of Rcyto%
When the permeation resistances of the whole cell monolayer as well as of the cytosol
are estimated, the proportion of cytosol in the permeation resistance of cell monolayer
can be approximated to be
Equation 7.17
From Equation 7.17, we can see that the proportion of the cytosol in the permeation
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resistance of cytosol is not affected by the extracellular pH conditions. Based on the
average of the best fit values of Pi and Pu, the relative contribution of the cytosol in the
cellular permeation barrier was approximated to be 10%, 26% and 6% for metoprolol,
propranolol and ibuprofen, respectively ( Table 7.1). However, the cytosol is not pure
water and it has been estimated that the cytosol viscosity may be significantly higher
than that of bulk water (Luby-Phelps, 2000). Consequently, the diffusion rate in the
cytosol could be significantly less than diffusion rate in water. Furthermore, our
approximation of cytosol permeability completely neglects the possible diffusion via
the lateral cell membrane and the existence of cellular organelles. Thus, the
contribution of space between the apical and basal cell membranes in the permeation
barrier may be more significant than approximated above. However, because of this
relatively crude estimation of the cytosolic permeation barrier, it was considered that
these approximations would be too arbitrary to be included into the compartmental
model. Thus, these estimates are used only as suggestive values to illustrate that the
space in between the cell membranes may indeed play a role in the cellular permeation
barrier and interfere with the determination of Pi and Pu.
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8 Concentration dependency of
active efflux transport in in vitro
cell permeation experiments4
Abstract. P-gp mediated efflux is one of the barriers limiting drug absorption from the
intestine. Predictions of the intestinal P-gp function need to take into account the
concentration dependency because high intestinal drug concentrations may saturate P-
gp.  However,  the  substrate  binding  site  of  P-gp  lies  inside  the  cells  and  the  drug
concentration at the binding site cannot be measured directly. Therefore, rigorous
determination of concentration dependent P-gp kinetics is challenging. In this study,
the effects of the aqueous boundary layers, extracellular pH and cellular retention on
the apparent saturation kinetics of P-glycoprotein mediated transport of quinidine in
an in vitro cell permeation setting were explored. The changes in the experimental
conditions caused one order of magnitude variation in the apparent affinity to P-gp
(Km,app) and a five-fold difference in the maximum effective P-gp mediated transport
rate  of  quinidine  (Vmax,app). However, fitting the concentration data into a
compartmental model which accounted for the aqueous boundary layers, cell
membranes and cellular retention suggested that the P-gp function per se was not
altered, it was the differences in the passive transfer of quinidine which changed the
apparent transport kinetics. These results provide further insight into the dynamics of
the P-gp mediated transport and on the roles of several confounding factors involved
in in vitro experimental setting.
4 Adapted with permission of the American Chemical Society from: Heikkinen A.T., Korjamo T.,
Lepikkö V., Mönkkönen J.: Effects of experimental setup on the apparent concentration
dependency of active efflux transport in in vitro cell permeation experiments. Mol
Pharmaceutics 7: 605-617, 2010. © 2010 American Chemical Society, All rights Reserved.
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8.1 INTRODUCTION
One  of  the  key  characteristics  of  P-gp  mediated  transport  is  its  saturability;  this  is
especially the case in the intestine where the drug concentrations are relatively high (Li
et al., 2008; Saitoh et al., 2007; Tubic et al., 2006). Thus, reasonable predictions of P-gp
function in vivo must include the possibility of P-gp saturation. Usually the
concentration dependency of P-gp mediated transport in in vitro cell permeation
experiments is described via Michaelis-Menten type kinetics, i.e. with Vmax,app and
Km,app parameters. In cell monolayer permeability experiments, these parameters have
traditionally been estimated based on the observed apparent permeability (Papp) or the
flux rate through the cell monolayer as a function of initial donor concentration (Cd0).
However, the Vmax,app and  Km,app parameters reported in the literature tend to vary
significantly. This variability can partly be attributed to the fact that the binding site of
P-gp lies within the cell monolayer (Ambudkar et al., 2006), whereas the concentration
dependency is estimated on the basis of the initial donor concentration. Several factors
in the experimental setup, in addition to initial donor concentration, can affect the local
intracellular concentrations in the permeation experiments. Thus, it is reasonable to
predict that these factors may affect also the apparent P-gp mediated transport.
Indeed, the effects of several factors on apparent P-gp mediated transport in
permeation experiments have been discussed in the recent literature:
A)  In  contrast  to  Michaelis-Menten  theory,  the  Km,app values  in  the  cell  monolayer
permeability assays have been reported to correlate with the Vmax,app value and, thus,
also with the P-gp expression levels of the cells used (Korjamo et al., 2007; Shirasaka et
al., 2008b). This has been attributed to decreased substrate concentration at the binding
site of P-gp due to the transporter function. Thus, the extracellular substrate
concentration needed to saturate the pump will be higher if more functional P-gp is
being expressed in the cell monolayer used (Bentz et al., 2005; Korjamo et al., 2007; Sun
and Pang, 2008).
B) The pH of extracellular buffer has been shown to affect the apparent P-gp mediated
transport of basic P-gp substrate quinidine in the rat in situ intestinal permeability
assay (Varma and Panchagnula, 2005). As the pH of extracellular buffer decreases, the
apparent Vmax,app and  Km,app increases because quinidine is more ionized at lower pH
and consequently the ability to traverse the cell membrane to the binding site of P-gp is
decreased.
C) In addition to the cell  monolayer,  the aqueous boundary layer (ABL) on both sides
of the cell monolayer may play a prominent role in the permeability barrier for high
permeability compounds (Avdeef et al., 2005; Korjamo et al., 2009). The effects of ABL
on the apparent human apical sodium-dependent bile acid transporter (hASBT)
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kinetics have been examined recently (Balakrishnan et al., 2007). Thus, it is likely that
also apparent P-gp mediated efflux kinetics of high permeability substrates are affected
by ABL (Korjamo et al., 2007). However, no definitive data detailing this effect have
been published.
D) The majority of the P-gp substrates drugs are weak bases and thus, it is possible that
they are sequestered into the acidic intracellular compartments such as lysosomes
(Asokan and Cho, 2002; Duvvuri and Krise, 2005b). Recently, it has been shown that
lysosomal sequestration may significantly affect the apparent permeability of
amodiaquine (Hayeshi et al., 2008b) Furthermore, lysosomal sequestration may affect
the substrate concentration at the interaction site of P-gp. Thus, lysosomal
sequestration is likely to affect the apparent P-gp mediated transport. Indeed, it has
been reported that some lysosomotrophic agents can affect the apparent P-gp mediated
transport in in vitro permeability experiments (Lacave et al., 1999). However, no
definitive conclusions about the mechanism(s) underlying this finding can be drawn
based on the data reported.
Although several factors affecting the apparent permeability of P-gp substrates and the
apparent P-gp mediated transport are known, the relative contributions of these
various factors are not fully understood. Consequently, it is not known how these
factors should be taken into account when determining the concentration dependent P-
gp function in vitro so that the parameters obtained could be used for valid prediction
of saturation of intestinal P-gp in vivo (Bolger et al., 2009; Del Amo et al., 2009).
However, a detailed dissection of the concentration dependent P-gp mediated
transport  would  play  a  vital  role  in  the  successful  IVIVE  of  intestinal  P-gp  function
(Badhan et al., 2009; Bolger et al., 2009; Tachibana et al., 2010).
In this study, the effects of aqueous boundary layer, extracellular pH and lysosomal
sequestration on the apparent P-gp mediated transport of quinidine were examined.
All these factors were demonstrated to affect the apparent P-gp mediated transport.
Thereafter, a compartmental model was exploited to determine the concentration
dependent P-gp mediated transport ‘in situ’.  This  model  takes  into  account  the  apical
and basal cell membranes and aqueous boundary layers (ABL) separately and allows
the discrimination of P-gp mediated transport from passive disposition processes. The
current analysis provides further insight into the dynamics of the interplay of active
transport and passive disposition through several barriers in cell monolayer
permeation experiments. Furthermore, the implications on the IVIVE of active
transport, especially in the context of intestinal absorption, are discussed.
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8.2 EXPERIMENTAL SECTION
8.2.1 Permeation experiments and sample analysis
The donor solutions with unlabeled quinidine at the concentrations indicated were
prepared  in  the  corresponding  transport  buffer,  HBSS  buffered  either  with  25  mM
Hepes (pH ? 7.0) or MES (pH < 7.0) with or without 5 µM GF120918, P-gp inhibitor,
and/or 100 nM bafilomycin A1, a specific inhibitor of vacuolar type H+ -ATPase
(Bowman et al., 1988), that inhibits the acidification of lysosomes (Yoshimori et al.,
1991) and, thus, reduces the cellular retention of lysosomotrophic compounds. The
donor solutions were spiked with 3H-quinidine. The stock solutions were prepared in
DMSO but the DMSO concentration did not exceed 1 % in final donor solutions.
The experiments were started by replacing the preincubation buffer with fresh
transport buffer into the receiver chamber and donor solution into the donor chamber.
At each sampling time point (5, 15, 30, 45, 60, 90 and 120 minutes), 25 µl samples were
withdrawn from both chambers simultaneously. Additionally, the amount of quinidine
retained in the cell monolayers was sampled at 120 minutes according to the procedure
presented in Chapter 6.2.1.
The permeation experiments were conducted at 37 °C in a humidified incubator on an
orbital shaker with an orbit diameter of 3 mm or 1.5 mm (small) as indicated (Titramax
101 or Titramax 1000, respectively; Heidolph, Schwabach, Germany). The shaking rate
was 320 rpm in all experiments.
8.2.2 Selection of compounds
Quinidine was chosen as the model compound for these studies because it is a well
known P-gp substrate that is stable in the cell monolayer permeation setting and it can
readily be used in such experiments in the concentration range where a full saturation
curve of the apparent P-gp mediated transport is observed. GF120918 is an effective
inhibitor of both P-gp and breast cancer resistance protein BCRP. However, the
evidence available in the literature suggests that quinidine does not interact with BCRP
or MRP2 (Matsson et al., 2009), the other major ABC transporters expressed in the
Caco-2 cells as well as in the intestinal epithelia. Moreover, in the presence of GF120918
the polarization of quinidine disposition through the cell monolayer is abolished in
both cell lines used (Korjamo et al., 2007). Thus, although several other transporters are
expressed in the cell lines used (Ahlin et al., 2009; Goh et al., 2002) and quinidine has
been suggested to be transported by OCTN2 transporter (Ohashi et al., 1999), the data
in this study is not expected to be significantly confounded by the involvement of other
transporters than P-gp. However, a minor contribution of additional transporters
cannot be ruled out totally.
79
8.2.3 Determination of the apparent permeability and apparent P-gp
function
To study the effects of different factors on the apparent P-gp mediated transport as
well as on the apparent passive permeability of quinidine, the permeation experiments
were conducted with six different donor concentrations ranging from 1 to 300 µM in
MDCKII-MDR1 or from 0.3 to 100 µM in Caco-2 in the absorptive direction (apical to
basal) with and without the P-gp inhibitor, GF120918 (5 µM) at eight different
experimental conditions. The experimental approaches to probe the effects of aqueous
boundary layer, cell membrane permeability and cellular retention are summarized in
Table 8.1.
Table 8.1. Summary of permeation experiments conducted to experimentally dissect the roles of
different factors affecting the apparent P-gp mediated transport of quinidine. The experiments
were conducted only in the absorptive direction (apical to basal).
Factor probed
Experimental
approach used
Extracellular
pHa
Orbit
diameterb Cell line Treatment
None 7.4 3 mm MDCKII-MDR1 None
Aqueous
boundary layer
Change of
agitation scheme 7.4 1.5 mm MDCKII-MDR1 None
Cell membrane
permeability
Change of
extracellular pH
6.4 3 mm MDCKII-MDR1 None
6.4 1.5 mm MDCKII-MDR1 None
Cellular
retention
Inhibition of
lysosomal
sequestration
7.4 3 mm MDCKII-MDR1 BAFc
6.4 3 mm MDCKII-MDR1 BAFc
Expression level
of P-gp
Use of cell lines
with different P-gp
expression levels
7.4 3 mm Caco-2d None
6.4 3 mm Caco-2d None
a Same pH was used in both apical and basal compartments.
b Orbital shaking rate in all experiments was 320 rpm.
c Lysosomal acidification and consequent lysosomal sequestration of quinidine was inhibited
by treating the cells with 100 nM bafilomycin A1.
d The P-gp expression level in Caco-2 cells is significantly lower than in MDCKII-MDR1 cells
(Korjamo et al 2007).
The concentration dependency of the effective P-gp mediated transport in permeation
setting has often been described with Equation 2.7. To solve the concentration
dependency of Papp (in absorptive direction), the Equation 2.7 is modified to
Equation 8.1d0appm,
appmax,
passapp CK
V
PP
?
??
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When P-gp is involved in the permeation kinetics the transcellular transport is
polarized. Thus, Papp,Palm (Equation 2.4) or Papp,Tran (Equation 2.5) would not be
applicable. Therefore, Papp,sink (Equation 2.3) was used for determination of Papp.
Subsequently, Equation 8.1 was fitted to the Papp at six quinidine concentrations
without P-gp inhibitor to estimate Ppass,  Vmax,app and Km,app parameters under different
experimental conditions using GraphPad Prism software, version 4.03 (GraphPad
Software Inc., San Diego, CA). In order to avoid unreasonably high Ppass estimates in
data fitting, Ppass was constrained not to be higher than the highest apparent
permeability observed at the corresponding experimental conditions (with or without
P-gp inhibitor GF120918). Extra sum-of squares F test was used for comparison of
Vmax,app and  Km,app at different experimental conditions and P values lower than 0.05
were considered to signify statistically significant difference.
8.2.4 Parameter estimation
The estimation of parameters describing the quinidine disposition in cell permeation
experiments was done by sequential fitting the compartmental models to apical and
basal chamber concentration data of several permeation experiments using WinNonlin
software, version 5.2.1 (Pharsight, Mountain View, CA). A weighting scheme
1/predicted2 was chosen based on residual plots and S.E. of the parameter estimates.
Otherwise, the default WinNonlin settings for minimization of error were applied.
In the first fitting step, the parameters describing the concentration dependency of
cellular binding of quinidine (Kmax,  Kmin and EC50) to MDCKII-MDR1 and Caco-2, and
to MDCKII-MDR1 in the presence of 100 nM bafilomycin A1 were estimated by fitting
the three compartment model (Figure 4.1) to the data from corresponding experiments
with six different quinidine concentrations in the presence of 5 µM GF120918 at pH 7.4.
When the disposition through individual permeation barriers is symmetric (i.e. when
pH gradient across membranes or active transporters are not involved) the apical and
basal permeation barriers (including ABL and cell membrane each) can be described as
single barriers. Furthermore, at this step there were no separate estimates of ABL and
cell membrane permeabilities available. Therefore, the three compartment model was
exploited in this parameter estimation step.
In the second fitting step, the cellular binding parameters were fixed to the best fit
values of the first fitting step. Subsequently, the parameters describing the passive
permeation through the cell membranes (Pu and Pi) and ABLs (PABL,api and PABL,baso) were
estimated by fitting the five compartment model (Figure 1B) into the concentration data
from permeation experiments through MDCKII-MDR1 conducted with 30 µM
quinidine into both directions at five different pH (5.6, 6.0. 6.4, 7.0 and 7.4). The initial
donor quinidine concentration was 30 µM and 5 µM GF120918 was present in both
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donor and receiver compartments. Equal permeability values were assumed for apical
and basal cell membranes, because determination of separate was not possible with the
current data. Pu and  Pi were constrained to be independent of agitation, whereas
separate values for PABL,api and  PABL,baso were estimated for experiments conducted
under different agitation conditions. Quinidine is a diprotic base with pKa values of
4.32 and 8.51 (Table 4.1), i.e. there are two ionized species of quinidine present at the
pH conditions applied. However, current data does not allow determination of
permeation characteristics of these two ionized species separately (not shown). Thus,
the membrane permeability of both ionized species were approximated to be equal and
only the pKa value of 8.51 was used to calculate the unionized and ionized fractions (fu,
fi and fu,cell, fi,cell in extra- and intracellular spaces, respectively).
In the final, third, fitting step, the passive permeability parameters were fixed to the
best fit values of the second fitting step and the cellular binding parameters remained
fixed to the corresponding best fit values of the first fitting step. Subsequently, the
parameters describing the concentration dependent P-gp mediated transport in situ
(Vmax and  Km) were estimated by fitting the five compartment model to data from
experiments with six different quinidine concentrations in the absence of GF120918 at
each experimental condition (Table 8.1).
8.3 RESULTS
8.3.1 Effects of passive permeability on the apparent P-gp mediated
transport
Figure  8.1  illustrates  the  effects  of  extracellular  pH  and  ABL  on  the  concentration
dependence of the apparent permeability of quinidine. Quinidine is more ionized at
pH 6.4 than at pH 7.4 and, consequently, the permeability through the cell monolayer
was lower at pH 6.4 than at pH 7.4, whereas the permeability through ABLs is assumed
to be  unaffected.  Additionally,  the  change of  pH from 7.4  to  6.4  also  shifted the  P-gp
saturation curve to the right (i.e. to higher concentrations). This shift was manifested as
the higher apparent Km,app. In addition, the apparent Vmax,app was higher at pH 6.4 than
in pH 7.4 (Table 8.2). Similar pH effects in Km,app and  Vmax,app were observed at both
shaking orbits (3 mm and 1.5 mm) and with both cell lines.
Reduced agitation (change of shaking orbit diameter from 3 mm to 1.5 mm) reduced
the permeability through ABLs, whereas the permeability through the cell monolayer
was assumed to be unaffected. Additionally, the P-gp saturation curve shifted slightly
to the right. However, although the apparent passive permeability through the whole
system was reduced virtually to the same extent by the change in the cell monolayer
permeability (the pH effect at 3 mm shaker) and by the change in ABL permeability
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(the agitation effect at pH 7.4), the shift in the P-gp saturation curve was less
pronounced in the latter case (Figure 8.1). Consequently, Vmax,app remained virtually
unaffected by the agitation and there was a tendency towards the higher Km,app values
at reduced agitation. Similar effects in Km,app and Vmax,app due to agitation applied were
observed at both pH conditions (6.4 and 7.4). However, the effect on Km,app reached
statistical significance only at pH 6.4 (Table 8.2).
Figure 8.1. Effect of extracellular pH, aqueous boundary layer and cellular retention on the
apparent P-gp mediated transport of quinidine through MDCKII-MDR1 cell monolayers. The
symbols refer to the average of three to six measurements (± standard deviation) and the
predicted curves are simulated with the best fit  values of  Equation 8.1.  Squares are for pH 7.4
and triangles for pH 6.4. Solid and open symbols represent the experiments on the shakers with
3 mm and 1.5 mm (small) orbit diameter, respectively. Grey color refers to experiments with
inhibition of lysosomal sequestration (100 nM bafilomycin A). The results of the experiments in
the presence of bafilomycin A at pH 6.4 are omitted for clarity.
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8.3.2 Effects of lysosomal sequestration on the apparent P-gp mediated
transport
Weak bases, such as quinidine, are susceptible to lysosomal sequestration during
permeation experiments. Consequently, the inhibition of the acidification of lysosomes
by bafilomycin A1 reduced the extent of cellular retention of quinidine at pH 7.4
(Figure 8.2).
Figure 8.2. The effects of P-gp mediated efflux, lysosomal sequestration and extracellular pH on
the extent of cellular retention of quinidine in permeation experiments. The symbols refer to the
amount  of  quinidine  recovered  from  the  MDCKII-MDR1  cell  monolayer  at  the  end  of  the
permeation experiments (at 120 min) at pH 7.4 (A) and at pH 6.4 (B) (average of  three to six
measurements ± standard deviation). Solid symbols/thick lines refer to experiments with 5 µM
GF120918 (P-gp inhibitor) and open symbols/thin lines refer to experiments without
GF120918. Triangles/dashed lines refer to experiments with 100 nM bafilomycin A (inhibition
of lysosomal sequestration) and squares/solid lines refer to experiments without bafilomycin A.
At low quinidine concentrations P-gp efficiently reduced the cellular retention of
quinidine. At intermediate quinidine concentrations, the P-gp starts to saturate and the
cellular retention increased, whereas at high quinidine concentrations, the cellular
retention again decreased probably because of the saturation of cellular binding and
saturation of lysosomal sequestration of quinidine (Figure 8.2). A similar bell shape
trend in cellular retention as a function of quinidine concentrations was observed with
each experimental setup. However, this trend was less pronounced in the presence of
bafilomycin A and in the pH 6.4 experiments because of the lower cellular retention
(Figure 8.2B). Consequently, quinidine was retained in the cells to a greater extent at
intermediate concentrations than at low or high concentrations and the effect of
bafilomycin A on cellular retention was most pronounced at intermediate
concentrations. Cellular retention decreases the appearance rate into the receiver
compartment and, thus, decreases the apparent permeability. Consequently, the
inhibition of lysosomal sequestration caused an increase in Papp at the intermediate
quinidine concentrations whereas the Papp at high and low quinidine was affected to a
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significantly lesser extent. Consequently, at pH 7.4 the apparent P-gp saturation curve
shifted to the left in the presence of bafilomycin A1 (Figure 8.1). This was reflected as
significantly lower apparent Km,app and Vmax,app values (Table 8.2).
At pH 6.4, the extent of cellular retention was significantly lower than at pH 7.4 (Figure
8.2). Therefore, the cellular retention and the effect on the cellular retention by
bafilomycin A1 did not significantly affect the apparent permeability of quinidine.
Consequently, the Km,app and  Vmax,app values were not significantly affected by
bafilomycin A1 at pH 6.4 (Table 2). This suggests that bafilomycin A1 did not have any
direct effect on P-gp function but, rather, the effect seen at pH 7.4 was caused by the
changes in the cellular retention.
8.3.3 Effects of P-gp expression level on the apparent P-gp mediated
transport
Comparison of the concentration dependent apparent permeability through MDCKII-
MDR1 and Caco-2 monolayers is shown in Figure 8.3. Caco-2 cells have a lower P-gp
expression level than MDCKII-MDR1 cells, whereas the passive permeability of
quinidine is apparently rather similar in both of these cell lines (Korjamo et al., 2007)
(Figure 8.3, Table 8.2). The effect of P-gp mediated transport on the apparent
permeability of quinidine was more pronounced in MDCKII-MDR1 cells than in Caco-
2 cells as expected based on P-gp expression levels. This was reflected as higher Vmax,app
and Km,app values in MDCKII-MDR1 cells compared to Caco-2 cells (Table 8.2).
Figure 8.3. Effect of P-gp expression level on the apparent P-gp mediated transport of quinidine.
The symbols refer to average of three to six measurements (±standard deviation) and the
predicted curves are simulated with the best fit  values of  Equation 8.1.  Squares/solid lines and
triangles/dashed lines refer to MDCKII-MDR1 and Caco-2, respectively. Black and grey color
refer to pH 7.4 and 6.4, respectively.
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Figure  8.4.  The  apparent  (A,  B)  and  in  situ  (C,  D)  parameters  describing  the  concentration
dependent P-gp mediated transport of quinidine at different experimental conditions.
8.3.4 Compartmental modeling and determination of Km and Vmax of P-gp
mediated transport in situ
The estimated parameters from sequential compartmental model fitting are
summarized in Table 8.2. Additionally, comparison of Km,app and Vmax,app and in situ Km
and  Vmax values of P-gp mediated transport of quinidine at different experimental
setups are visualized in Figure 8.4. The Km values at different setups were all at a
similar level, the average being 0.3 µM with 1.6 fold difference between the lowest and
highest estimates, whereas the Km,app values  varied  by  more  than  one  order  of
magnitude.  The  relative  variation  in  Vmax estimates between different experimental
settings was larger than in Km estimates and, thus, partly masking the presumed
difference in Vmax between Caco-2 and MDCKII-MDR1. However, on average, the Vmax
estimates in MDCKII-MDR1 (5800 fmol/s/cm2)  were  almost  3  fold  higher  than  those
obtained with Caco-2 (2100 fmol/s/cm2). Furthermore, the Km,app estimates were
significantly higher than in situ Km values whereas Vmax,app values were significantly
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lower than their in situ Vmax couterparts. The difference between Km,app and Km values
was more pronounced at pH 6.4 than at pH 7.4 and also slightly more pronounced in
experiments with the 1.5 mm shaker than in experiments with the 3 mm shaker,
whereas the difference between Vmax,app and Vmax was more pronounced at pH 7.4 than
at pH 6.4 and at a similar level with both agitation conditions.
8.4 DISCUSSION
The apparent active transporter kinetics in in vitro permeation experiments are usually
biased by the experimental setup and the combination of both active and passive
permeation. This study examined the effects of the experimental setup on the apparent
kinetic parameters of the P-gp mediated transport. The expression level of P-gp and,
consequently, the P-gp mediated transport rate has been reported to be higher in
MDCKII-MDR1 cells than in Caco-2 cells (Korjamo et al., 2007; Shirasaka et al., 2008b).
Furthermore, the P-gp mediated transport decreases the substrate concentration at the
intracellular binding site of P-gp and, thus, the higher the level of expression is the
higher an initial donor concentration is needed to saturate the pump, i.e. a higher Km,app
(Korjamo et al., 2007; Sun and Pang, 2008). The values of both Vmax,app and  Km,app
observed in this study under similar experimental conditions were higher in MDCKII-
MDR1 cells than their counterparts in Caco-2, thus supporting the results reported
earlier. Furthermore, both Vmax,app and  Km,app observed  in  this  study  were  higher  at
extracellular pH 6.4 than at pH 7.4. Thus, the effects of the extracellular pH on the
apparent concentration dependent P-gp mediated transport of quinidine are also in line
with the results reported earlier in the literature (Varma and Panchagnula, 2005).
Additionally, the permeation resistance of ABL and the cellular retention were
demonstrated to play a role in the apparent concentration dependent P-gp mediated
transport of quinidine. However, the compartmental modeling results indicate that the
P-gp function per se was not affected by the experimental conditions but, rather, the
changes seen in the apparent P-gp kinetics were due to the modulation of the access of
the substrate to the binding site of the transporter protein.
P-gp transports the substrate molecules out of the cell across the apical cell membrane.
Thus, P-gp mediated transport reduces the permeation rate through the cell monolayer
in absorptive direction permeation experiments by maintaining the concentration
gradient across the apical cell membrane. In contrast, the permeabilities across the
other permeation barriers (i.e. ABL at both sides of the cell monolayer and the basal cell
membrane) are not affected by P-gp. The magnitude of the concentration gradient
across the apical cell membrane maintained by P-gp and, consequently, the effective P-
gp mediated transport rate is dictated by the actual P-gp mediated transport rate and
the passive permeation rate from the apical cell surface to the intracellular binding site
88
of P-gp. Thus, the maximum effective transport rate (Vmax,app)  is  increased  by  the
increase in maximum actual transport rate (i.e. Vmax) and decreased by the increase in
passive permeability through the apical cell membrane from the cell surface into the
cell (i.e.  fiPi+fuPu). Consequently, Vmax,app is bound to be lower than Vmax. Lowering the
extracellular pH decreases the passive permeability of quinidine from the cell surface
into the cell whereas the P-gp function per se is believed not to be affected by the pH
conditions (Altenberg et al., 1993; Neuhoff et al., 2003). This is seen as higher Vmax,app
at 6.4 compared to the situation at 7.4 (Table 8.2, Figure 8.4). In contrast, decreasing the
permeability through the whole cell monolayer by decreasing the agitation (i.e.
decreasing the ABL permeability) does not affect the passive permeability from the cell
surface into the cell nor the P-gp function. Consequently, the Vmax,app is not significantly
affected by the agitation applied (Table 8.2, Figure 8.4).
Km,app represents the initial donor concentration resulting in 50% of Vmax,app. Thus, Km,app
is a composite parameter representing the actual Km as  well  as  the  relationship of  the
initial donor concentration and the concentration at the intracellular binding site of P-
gp. Km,app is bound to be higher than Km because the intracellular binding site of P-gp is
downstream from the donor compartment in the concentration gradient. The changes
applied in the experimental setup are assumed not to affect the actual Km. Thus, all the
variation  in  Km,app can be attributed to the changes in the access to the intracellular
binding site of P-gp. The decrease in the permeability from the donor bulk phase into
the intracellular binding site of P-gp by either lowering the extracellular pH or by
decreasing the agitation reduces the access rate of the substrate to the binding site of P-
gp. Consequently, the initial donor concentration needed to saturate the pump is
increased, i.e. the Km,app is increased. However, the decrease in the extracellular pH also
increases the effective P-gp mediated transport rate from the binding site. Thus, the
concentration gradient  in  between the  donor  bulk  phase  and the  intracellular  binding
site of P-gp is more increased by the decrease in the extracellular pH than by the
decrease in the agitation. Consequently, the effect of extracellular pH on the Km,app
value is more pronounced than the effect of agitation.
The estimation of Vmax,app and  Km,app is  based  on  Papp determined at several substrate
concentrations. Since the determination of Papp is based on the assumption of 100%
recovery,  the  Papp estimates are affected by the recovery. Low recovery (due to e.g.
cellular retention) leads to the underestimation of the actual permeability.
Consequently,  the  changes  in  the  recovery  as  a  function  of  concentration  result  in
concentration  dependency  of  Papp.  At  pH  7.4,  the  changes  in  the  cellular  retention  of
quinidine, caused by the saturation of P-gp followed by the saturation of apparent
cellular binding, were sufficient to cause a shift in the concentration dependence of
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quinidine Papp (Figure 8.1 and Figure 8.2). The inhibition of the lysosomal sequestration
decreases significantly the cellular retention of quinidine, thus virtually abolishing the
concentration dependence of cellular retention and consequently the bias in the
apparent saturation of the effective P-gp mediated transport. Although the effects of
poor recovery on the Papp estimates are generally acknowledged, there are no universal
correction terms available for accounting for poor recovery in the determination of Papp
(Hubatsch et al., 2007). If there is no evidence of major recovery problems, the effects of
recovery are often neglected in the data analysis. However, the results of this study
demonstrate that neglecting the role of recovery may bias the interpretation of the
apparent concentration dependent transporter function.
It is evident that the single-barrier view based analysis of the apparent concentration
dependency of P-gp mediated transport is biased by the passive disposition of the
compound. Therefore, compartmental modeling was applied to account for the passive
disposition and to estimate the P-gp kinetics in situ. The estimation of the parameter
values embedded in the compartmental model was conducted by sequential fitting of
the models to the experimental data. One major drawback of this approach is the fact
that the possible misspecifications of the model in the early fitting steps may be
reflected in the later fitting steps. On the other hand, the possible misspecifications of
the model in the late fitting steps will not confound the early fitting steps. More
importantly, for the further application of compartmental models to quantify the
concentration dependent transporter function, it would not be feasible to perform all
the experiments performed in this study. For instance, the estimates of ABL
permeabilities can theoretically be derived from the results of calibrator molecule(s)
(Yu and Sinko, 1997) or the parameters describing the distribution/binding into cellular
structures could be derived from separate, simpler experiments (Sun et al., 2008; Tran
et al., 2005). This kind of approach would be essentially similar to the current
sequential fitting approach. However, determining the optimal study design will
require further research.
The in situ Vmax and  Km are considered to reflect the actual P-gp mediated transport
kinetics through the apical cell membrane from the intracellular aqueous phase to the
cell  surface.  Thus,  Vmax would be expected to correlate with the expression level of
functional P-gp in the cell line used, whereas Km should  be  independent  of  the  P-gp
expression level. Furthermore, it is assumed that the experimental conditions will not
affect the P-gp function per se, i.e. Km and  Vmax should  be  independent  of  the
experimental conditions. However, the determination of in situ Km is based on the
estimated intracellular free concentration of the substrate, i.e unbound concentration in
the cellular aqueous phase, whereas the binding site(s) of P-gp are generally considered
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to lie within the inner leaflet of the cell membrane (Ambudkar et al., 2006). Assuming
the association and dissociation rates between the lipid and aqueous phases are much
faster than the rate of transmembrane transfer (Tran et al., 2005), the consentration at
the binding site of P-gp is at constant proportion to the unbound aqueous
concentration. Consequently, the current model is consistent with the substrate binding
from the lipid phase. However, the Km determined actually represents the product of
the cytosol – cell membrane distribution coefficient and the actual ‘lipid-phase Km’.
There are differences in the cell membrane lipid composition between cells from
different tissues (Avdeef, 2003). Thus, it can be hypothesized that Km values might be
cell type specific if there are significant differences in the cytosol-cell membrane
distribution of the P-gp substrate in different cell types. However, there were no signs
of this kind of difference between MDCKII-MDR1 and Caco-2 cell lines.
The Km estimates were at the same level regardless of the experimental conditions or
the cell line utilized (Figure 8.4, Table 8.2), thus fulfilling the above mentioned
expectations and providing further confidence on the interpretation of this parameter.
In  addition,  the  Vmax estimates within both cell lines were approximately at the same
level irrespective of the experimental conditions. However, there was a substantial
variation  in  Vmax estimates probably partly masking the expected difference between
Vmax in MDCKII-MDR1 and Caco-2. Earlier western blot results in our lab suggest that
the P-gp expression level in MDCKII-MDR1 is about one order of magnitude higher
than in Caco-2 (Korjamo et al., 2007) whereas the difference was on average only about
3 fold in Vmax estimated in this study. The reason(s) for this discrepancy are not known
but several possible explanations can be hypothesized. A) The P-gp expression levels
were not quantified from the cell batches used in this study. Furthermore, for practical
reasons, the serum batch used in the cell culture during this study was not the same as
utilized in our earlier study. Consequently, the P-gp expression levels reported earlier
may not exactly reflect the expression levels in the cells used here. The difference in
Km,app and  Vmax,app between MDCKII-MDR1 and Caco-2 in this study was not as
significant  as  in  our  previous  study  (Korjamo  et  al.,  2007),  thus  favoring  this
explanation. B) The expression levels quantified by western blot measures the total
expression  level  of  P-gp  protein  whereas  some  of  the  P-gp  expressed  may  not  be
localized on the cell membrane (Porcelli et al., 2009). Thus, the difference in the P-gp
expression levels detected by western blot may not directly reflect the difference in the
expression of active P-gp. C) There are indications that the permeability is lower across
the apical than the basal cell membrane (Gonzalez-Alvarez et al., 2005; Ito et al., 1999).
However, the passive permeability coefficients through the apical and basal cell
membranes were assumed to be equivalent because the experimental data did not
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allow for fitting of separate permeability coefficients for the apical and basal cell
membranes. Thus, the interplay of passive permeation and P-gp mediated transport
through the apical cell membrane may be inaccurately described in the current
analysis. D) The analysis in the current compartmental model was based on the
assumption that the passive permeability parameters determined using MDCKII-
MDR1 data describe the passive permeation also in Caco-2. This is a reasonable
approximation because there were no significant differences between these cell lines in
the apparent passive permeabilities at different pH conditions (Figure 8.3, Table 8.2).
Similar permeation characteristics of Caco-2 and MDCK cell lines have also been
reported by others (Crespi et al., 2000; Irvine et al., 1999). However, the composition of
cell membranes as well as other cellular structures is different in these cell lines.
Consequently, the assumption of exactly same permeability coefficients may not be
totally correct and this inaccuracy may be translated into the estimated parameters
describing the P-gp function.
The  pharmacokinetics  is  a  result  of  the  interplay  of  several  mechanisms,  such  as
passive permeability, active transport by several transporters and metabolism in the
enterocytes in the case of intestinal absorption. Consequently, successful prediction of
the in vivo pharmacokinetics based on in vitro data,  i.e.  IVIVE, requires inclusion of all
the clinically significant mechanisms and their interplay into a single prediction in both
physiological and mechanistically reasonable way. In practice, several studies aiming
for physiologically based IVIVE with varying levels of mechanistic detail have been
published in the recent literature (Badhan et al., 2009; Bolger et al., 2009; De Buck and
Mackie, 2007; Yang et al., 2007). Some of these studies have utilized commercial
software designed for this purpose, such as GastroPlus™ (Simulations Plus Inc,
Lancaster, CA, USA) and Simcyp® Population-based ADME Simulator (Simcyp Ltd,
Sheffield, UK). Physiologically based IVIVE of hepatic metabolism have resulted in
predictions with sufficient reliability to have practical utility in the drug development
(Fagerholm, 2007a; Rostami-Hodjegan and Tucker, 2007), whereas there are still no
success stories published of the IVIVE of concentration dependent efflux transporter
kinetics.
The virtually linear correlation between P-gp expression level and both Vmax,app and
Km,app, in constant experimental conditions, has been reported recently (Korjamo et al.,
2007; Shirasaka et al., 2008b). Consequently, it was suggested that the Vmax,app and Km,app
determined using at least three cell lines with different P-gp expression levels in
combination with a scaling factor derived from the apparent passive permeabilities in
vitro and in vivo could be exploited for predicting in vivo Vmax,app and  Km,app.
Subsequently, these estimates could be used for prediction of concentration dependent
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intestinal wall permeability in vivo (Shirasaka et al., 2008a). However, the results shown
in the current study suggest that when the data analysis is based on the apparent
permeability as a function of the initial donor concentration, the interpretation of the
relationship between passive permeation and P-gp mediated transport is not always
straightforward, thus making the extrapolation less reliable. Secondly, and more
importantly, there are often more than one saturable process affecting the overall
permeation through the intestinal wall, such as different transporters and metabolic
enzymes. The local concentration at the binding site of an individual transporter may
be significantly affected by the interplay with the other transporters and metabolic
enzymes. Thus, the applicability of this single-barrier view based scaling of Vmax,app and
Km,app values is limited. For more general applicability of IVIVE, the models used for
simulation of in vivo kinetics should enable prediction of the interplay of passive
diffusion, transporters, metabolic enzymes etc. in the intestinal absorption.
Consequently, many recent physiologically based intestinal absorption models have
included enterocytes as a distinct kinetic compartment in between the intestinal lumen
and the mesenteric circulation (Badhan et al., 2009; Huang et al., 2009; Jamei et al.,
2009b). However, one of the major challenges of using these models for IVIVE is
obtaining suitable input parameters which accurately describe the active transporter
kinetics (Badhan et al., 2009; Bolger et al., 2009; Tubic et al., 2006).
It  is clear that the in situ Km and Vmax values obtained in this study are to some extent
composite parameters that may partly reflect the passive disposition kinetics of the
substrate rather than exclusively P-gp mediated transport. However, the robustness
against the changes in the experimental conditions suggests that the in situ Km and Vmax
values are not significantly biased by the passive disposition of the substrate.
Therefore, compartmental model based quantification of active transporter kinetics
seems a promising approach for handling the in vitro component of physiologically
based IVIVE.
In addition to current compartmental model based approach, also another approach for
analyzing the concentration dependent permeability data in order to estimate in situ Km
and Vmax for P-gp mediated transport has been published just recently (Tachibana et al.,
2010). This model and the results obtained have some similarities with the current
compartmental model. Distingt permeation barriers at apical and basal sides of the cell
monolayer and concentration dependent P-gp mediated efflux through the apical
barrier with intracellular binding site are accounted for. Consequently, similar
correlation between Km,app and Vmax,app is  predicted and also the Km estimates obtained
are  consistently  lower  than  Km,app and at the same level with several cell lines with
different P-gp expression levels.  However, despite the similarities in the results,  there
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are also fundamental differences between these approaches. In the Tachibana
approach, compartmental model structure is used to derive steady state flux rates and,
consequently, Papp values  through  the  whole  cell  monolayer  at  different  donor
concentrations. Thereafter, the Km and Vmax values are estimated by fitting the model to
observed  Papp values. Thus, Tachibana approach is applicaple only for experimental
data where Papp (Papp,sink to be precise) can be reliably determined, i.e. concentration
gradient from donor to receiver compartment and recovery from aqueous chambers
should be virtually constant throughout the experiments. Consequently, the
applicability of the current compartmental model based approach to experiments
where these assumptions are violated provides a significant advantage over the
Tachibana approach. On the other hand, Tachibana approach does not involve fitting
complex model(s) consisting group of differential equations and may thus be more
easily implemented. Furthermore, the contribution of ABL in the permeation barrier is
neglected in Tachibana model, i.e. the model assumes that P-gp transports the substrate
from the intracellular binding site all the way to apical bulk compartment.
Consequently, when ABL is a significant part of the permeation barrier, Vmax estimates
using  Tachibana  model  are  bound  to  be  lower  than  Vmax estimates obtained with
current five compartment model, whereas Km estimates seems to end up at similar level
(average Km for quinidine in Tachibana paper was 0.25 µM). However, the Tachibana
approach should be possible to refine in order to take ABL into account provided that
there is a priori information of the contribution of ABL. However, further research is
needed in order to evaluate the practical value of both of these approaches in analysis
of concentration dependent transporter function for IVIVE.
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9 Summary and future perspectives
The rapid technological development of computer science during the past few decades
has provided enormous advancements in computing power generally available. One
field of pharmaceutical research that has effectively exploited this progress has been
PBPK modeling and physiologically based IVIVE. Successful utilization of in silico and
in vitro methods to predict drug behavior in vivo would  reduce  the  need  for in vivo
animal and clinical testing and, thus, be an advantage from both ethical and
economical point of views. Consequently, modeling and simulation has become an
integral part of the drug discovery – development process.
In  order  to  achieve  successful  IVIVE  the in vitro model  exploited  has  to  1)  be
biologically and mechanistically relevant for obtaining the desired information and 2)
thoroughly understood in order to adequately interpret the data obtained. The current
study aimed mainly at this latter aspect in the context of in vitro models for gut wall
permeation.
Membrane based assays, such as the ATPase activation assay, can be used to gain
insight into active transporter kinetics. However, it is currently not known in detail
how the observed ATPase activity translates into actual transport rates in living cells or
tissues (Giacomini et al., 2010). Therefore, in the drug development process the ATPase
activation assay should be considered primarily as a screening method for identifyig
transporter interacting compounds, whereas cell permeation experiments are more
suitable for detailed analysis of transport kinetics.
The total permeation barrier in cell monolayer permeation experiments is made up of
several individual barriers. However, the single barrier view based determination of
apparent permeability has been the cornerstone of permeation data analysis and still
remains suitable for classification of high and low permeability compounds according
to the Biopharmaceutical Classification System (Thiel-Demby et al., 2009; Volpe, 2004)
and also for the prediction of the extent of intestinal absorption of passively absorbed
compounds  (Artursson  et  al.,  2001).  On  the  other  hand,  the  single  barrier  view  in
permeation data analysis suffers some clear disadvantages; including the fact that the
assumptions about sink conditions and recovery may be experimentally impossible to
meet adequately. Moreover, there are no universal correction terms available for
violations of these assumptions (Chapter 6). Therefore, the results of single barrier
analysis of in vitro data are not always suitable for the quantitative uncoupling of the
different mechanisms involved or mechanism based in vitro – in vivo extrapolation
(Chapter 8). Consequently, more sophisticated data analysis approaches are required.
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Compared to single barrier models, compartmental models provide a possibility to
describe the transport phenomena during the in vitro permeation experiments in a
more mechanistic manner and, thus, to give additional insights into the mechanisms
involved  in  drug  disposition  (Chapters  6,  7  and  8).  The  rationale  in  using in vitro
experiments as a model for the in vivo situation is based on the assumption that the
drug behaviour in vitro is mechanistically similar to that occurring in vivo. Therefore, it
is reasonable to expect that mechanistic modeling of the in vitro experiments could
propose partial model structures feasible for simulating the in vivo situation.
Simultaneously, modeling of the in vitro experiments seems a promising approach for
determination of input parameters for in vivo simulations (Chapter 8). In addition to
the interplay of passive and active transport kinetics in the intestinal epithelia, the
focus of the current study, similar data analysis approaches have been applied for
gaining insights into ‘local kinetics’ comprising metabolism coupled with transport
kinetics in liver (Hallifax and Houston, 2006; Pelkonen et al., 2008; Poirier et al., 2008).
Although compartmental modeling seems a feasible and promising approach for
analysing in vitro data for IVIVE, the performance can and should still be improved
and also the validity of this approach still requires further verification. On the one
hand, more rigorous modeling of in vitro experiments would benefit from more
detailed experimental local and temporal concentration data within the system. On the
other hand, as a routine approach collecting all the possible experimental detail would
not be feasible in practice. Finding the balance between the extent of experimental
detail and practical feasibility however requires a thorough insight into the system, i.e.
what is crucial and what is trivial. In addition to the improvements in obtaining
meaningful data from in vitro systems, also high quality physiological data, such as
expression levels and population variation of transporters and enzymes in clinical
setting are of major importance in improving the performance of physiologically based
IVIVE (Sugano, 2009b).
In conclusion, the potential of physiologically based IVIVE is yet to be fully harnessed.
There have been some clear advances, but nonetheless, the models involved can and
should be further developed at both in vitro and in vivo ends  of  IVIVE so as  to  obtain
more accurate, precise and reliable predictions. Moreover, if and when successful,
physiologically based IVIVE should not be restricted to pharmacokinetics, but should
be extended also to the interplay between pharmacokinetics and pharmacodynamics.
At the end of the day, if pharmacokinetics is not coupled with pharmacodynamics it is
only ‘kinetics’ without ‘pharmaco’.
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10 Conclusions
The present studies were conducted in order to understand how passive disposition
kinetics affects the observed P-gp transporter kinetics in in vitro experiments.
Alterations which are expected to affect the passive disposition kinetics but not the P-
gp function per se, were experimentally tested in order to tease out the effects of the
passive disposition. Furthermore, because active transport cannot be studied in the
absence of passive disposition, a rigorous analysis of active transport must be based on
a thorough understanding of the interplay between these two. Thus, the main focus of
these studies was placed upon modeling initially of the kinetics of passive disposition
only and, subsequently on passive disposition accompanied with active transport
during cell permeation experiments. The modeling aimed also to determine kinetic
parameters that might be applicable for in vitro – in vivo extrapolation. Furthermore, the
pitfalls of the traditional in vitro permeation data analysis approaches were explored.
The main conclusions that can be drawn from these studes are:
1. Minor alterations in the experimental setup affecting the passive
disposition of the P-gp substrates may have a significant effect on the
apparent  concentration  dependency  of  P-gp  function  and  thus  may
hamper the correct interpretation of the data.
2. Single barrier assumption based data analysis is often an over-simplified
view in cell monolayer permeation data analysis, especially when a
detailed mechanistic insight is to be obtained.
3. Compartmental model based analysis of cell permeation data seems a
promising approach for determining the active and passive drug
disposition kinetics in vitro.
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In vitro models are often used for 
prediction of intestinal absorp-
tion during the drug development 
process. However, because of the 
complexity of the factors affecting 
permeation through the intestinal 
epithelia there still are gaps in our 
capabilities of translating the in vitro 
observed permeation characteristics 
to the in vivo situation. This thesis 
provides further insights into the 
dynamics of the drug disposition 
kinetics in epithelial permeation as 
well as on the confounding factors 
involved in in vitro experimental 
settings.
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